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Abstract
Functional analysis of the mouse CBP gene in the adult
central nervous system
Abstract
CBP (CREB-binding protein) was originally characterized as a transcriptional 
coactivator of CREB (cAMP response element-binding protein) which is implicated in 
many processes including the formation of long-term memory. CBP itself is regulated 
by nuclear Ca^  ^ and Ca^VCalmodulin kinase IV, suggesting a crucial role in synaptic 
plasticity. Mutations in human CBP gene are associated with the Rubinstein-Taybi 
syndrome (RTS) characterized by mental retardation and patterning abnormalities. 
These features suggest that CBP plays a central role in cAMP-mediated gene 
expression, which in turn is implicated in the formation of long-term memory.
The expression patterns of CBP and its homologue p300 were analyzed. Both are 
expressed in most of forebrain areas, with particularly high expression in the 
hippocampus. Parts of the mouse CBP gene were characterized. Six exons encode the 
CREB-binding domain (CBD). Two gene targeting experiments were performed to 
generate mouse lines with mutations in the CBP gene. The first was a deletion of the 
CBD exon 2, resulting in a frameshift and, thus, a truncated CBP protein (CBP®^ °^ ^^ )^. In 
the second experiment, a point mutation was aimed to be introduced in the CBD exon 5 
(CBP^^^^^^* )^. After germline transmission, three mouse lines were obtained from 
CBP®^op523 aiigig. CBD2^ ', a general deletion of the CBD exon 2; CBD2.floxed, which 
will be crossed with different Cre mouse lines for tissue-specific mutants; and 
CBD2.floxed.neo, which might be a hypomorphic allele due to the Neo cassette. For the 
construct cBpTyr658Aia^  none of the chimeras gave germline transmission, as apparently
Abstract
the splicing of the inverted allele was incorrect, possibly leading to strong reduction of 
vitality. Meantime, six CBP mutants were generated to elucidate functional domains of 
CBP in vitro: a deletion mutation CBPACBD2-5; CBPllOOaa, which was reported in 
mutant mice displaying RTS-like phenotypes; and a point mutation CBP658Ala, which 
was shown to be critical for interaction with phospho-CREB. The other three mutants 
retain different sizes of truncated N-terminal CBP and similar proteins were observed in 
RTS. Both CBP658Ala and CBPACBD2-5 interferred with the cAMP pathway, but not 
with nuclear receptor-mediated functions. RTS mutants showed strong inhibitory effects 
on the cAMP pathway.
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Chapter 1 Introduction
Chapter 1 
Introduction
1.1 cAMP pathway and memory
1.1.1 cAMP
Cyclic adenosine 3’,5’-monophosphate (cAMP) was first identified as an intracellular 
mediator of hormone action in 1959, and since then has been recognized to act as an 
intracellular second messenger in many prokaryotic and eukaryotic cells (Sutherland, 
1970). In response to extracellular stimuli, the concentration of cAMP (normally < 10'  ^
M at physiological level) will be changed up or down: cAMP levels can change five­
fold in seconds upon hormonal stimulation (Alberts et al., 1994). cAMP is synthesized 
from adenosine triphosphate (ATP) by plasma membrane-bound enzymes, adenylyl 
cyclases, and rapidly destroyed by cAMP phosphodiesterases which hydrolyze cAMP to 
adenosine 5’-monophosphate (5’-AMP). Many extracellular signaling molecules such 
as hormones, growth factors, and neurotransmitters may alter the activity of adenylyl 
cyclase, and thereby control cAMP level. Notably, the alteration of cAMP level mainly 
depends on the types of target cells (Antoni, 2000).
1.1.2 cAMP and CREB
Intracellular levels of cAMP are regulated primarily by adenylyl cyclase. This enzyme 
is in turn modulated by various extracellular stimuli mediated by receptors and their 
interaction with G-proteins (Gilman, 1987; McKnight et a l, 1988). The binding of a 
specific ligand to a receptor results in the activation or inhibition of the cAMP-
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dependent pathway. The neuropeptide gene somatostatin was one of the first genes 
shown to be regulated by cAMP (Montminy et al., 1986a). Deletion studies of the 5’- 
upstream region of the somatostatin gene identified the cis-acting element 
TGACGTCA, an 8 bp palindromic sequence, named a cAMP response element (CRE), 
which was later found in the promoter region of many other target genes (Montminy et 
al., 1986b). A comparison of the CRE sequences identified showed that the 5’-terminus 
of the palindromic sequence, TGACG, is more conserved, whereas the 3’-terminus, 
TCA motif, is less constant (Sassone-Corsi, 1995). The binding site specificity appears 
to require 18-20 bp, since 5 bases flanking the core consensus have been shown to 
dictate the permissivity of transcriptional activation (Deutsch et al., 1988). The search 
for CRE motif-recognizing factors led to the identification of CREB (cAMP response 
element-binding protein), a transcription factor belonging to the family of basic leucine 
zipper transcription factors (Gonzalez et al., 1989b).
cAMP is also a central molecule in synaptic plasticity and memory consolidation. 
During learning, extracellular stimuli such as neurotransmitters activate cell membrane 
receptors (G protein-coupled receptors), which in turn activate heterotrimeric GTP- 
binding proteins (G-proteins). Certain receptors activate adenylyl cyclase through 
stimulatory G protein (Gg), while others inhibit it through inhibitory G protein (Gi). In 
its inactive form, Gg exists as a trimer of Ga, Gp and Gy with G« bound to GDP. After 
receptor activation, Gg dissociates to G« and Gpy subunits. The G« activates adenylyl 
cyclase, while Gpy can stimulate other pathways. After Ga has hydrolyzed GTP, it no 
longer stimulates adenylyl cyclase, and binds again as a tight complex to Gpy.
The dissociated G-protein units influence the activity of various effector molecules 
including adenylyl cyclase. This enzyme then increases the intracellular cAMP 
concentration leading to the activation of cAMP-dependent protein kinase A (PKA) in
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the cytoplasm and to the modification of ion channels and synaptic proteins. The PKA 
holoenzyme, which consists of two catalytic subunits and two regulatory subunits, is 
localized in the cytoplasm, presumably by the interaction of the regulatory subunit R2 
with specific anchoring proteins called AKAPs (Faux and Scott, 1996). If the 
extracellular stimuli are persistent for a critical period of time, binding of cAMP to the 
regulatory subunits causes the release of the catalytic subunits of PKA, which are then 
free to translocate to the nucleus from cytoplasmic and Golgi complex anchoring sites 
to phosphorylate a number of substrates e.g., transcription factors on serines in the 
context X-Arg-Arg-X-Ser-X (Roesler et al., 1988; Meinkoth et al., 1990).
PKA has to phosphorylate the transcription factor CREB protein at serine-133 to 
achieve memory consolidation (Gonzalez and Montiminy, 1989a). Phospho-CREB then 
binds as a homodimer to CREs, thus, activates the transcription of immediate early 
genes (lEGs). The protein products of many lEGs are themselves transcription factors 
that can activate the transcription of late response genes, which are likely to encode 
proteins necessary for long-term modulation of synaptic function (Fig. 1.1). Nuclear 
localization of phosphatases, named PPl and PP2-A, are responsible for CREB 
dephosphorylation. PP-1 is present in the nucleus, while PP2-A is located mainly in the 
cytoplasm (Hagiwara et al., 1992; Wadzinski et al., 1993; Bito et al., 1996).
1.1.3 cAMP and LTP
It has been shown that CRE-mediated gene expression is stimulated by signals that 
induce long-term potentiation (LTP) (Impey et ah, 1996). LTP is defined as a long- 
lasting increase of synaptic efficacy following a brief high-frequency stimulation. LTP 
was discovered by Bliss and Lomo (1973) in the dentate gyrus and since then has been 
studied widely as a promising cellular mechanism for learning and memory. In the
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hippocampus, synaptic potentiation can be classified according to its responsive 
duration. Short-term potentiation (STP) presumably lasts for minutes, in contrast, LTP 
lasts at least 1 hour and may last up to several days.
cytoplasm
nucleus
cAMP
PKA
CRE
lEGs
B
cAMP
PKA
cytoplasm
nucleus
lEGs
CRE
CRE Late
Response
Genes
Fig. 1.1: Mechanisms of cAMP pathway and formation of long-term memory (LTM) (A). 
Short-term exposure to a neurotransmitter leads to the brief generation of cAMP that can 
activate PKA, and can lead to the modification of ion channels and synaptic proteins. (B). 
Long-term exposure to a neurotransmitter leads to continuous increase of cAMP, allowing the 
catalytic subunits of PKA to translocate to the nucleus to phosphorylate CREB, thereby to 
activate transcription of lEGs. Many lEG proteins are themselves transcription factors that 
activate the late response gene transcription. Those proteins are likely required for the formation 
of ETAL
A systematic study of the distribution of synapses that possesses the ability to undergo 
LTP in the limbie system was earried out. It was shown that the lateral olfactory tract
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shows no LTP, the pyriform cortex shows little LTP, followed by the amygdala, 
entorhinal cortex, perforant path, hippocampal CAl, septal area and fomix/fimbria 
(Racine et al., 1983). Note that hippocampal pathways show significantly larger LTP 
effects than do the non-hippocampal pathways. LTP has been observed in the three 
major excitatory synapses in the trisynaptic circuit of the hippocampus (Fig. 1.2).
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Fig. 1.2: Three major excitatory synapses in the trisynaptic circuit of the hippocampus:
perforant pathway, mossy fiber pathway and Schaffer collateral pathway.
The perforant pathway starts from the pyramidal cells of the entorhinal area to the 
granule cells of the dentate gyrus (dentate LTP); the mossy fiber pathway starts from 
the granule cells of the dentate gyrus to the CA3 pyramidal cells (mossy fiber LTP); and
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the Schaffer collateral pathway starts from the CA3 pyramidal cells to the CAl 
pyramidal cells (CAl LTP). Both dentate LTP and CAl LTP are initiated 
postsynaptically by the activation of N-methyl-D-aspartate (NMDA) receptors. In 
contrast, CA3 LTP is independent of NMDA receptors and is thought to be initiated 
presynaptically. It was shown that LTP of the hippocampal slice in either the dentate 
gyrus following perforant path stimulation or the hippocampal CAl area following 
Schaffer collateral stimulation, resulted in an increase in the incorporation of labelled 
valine into proteins destined for secretion into the extracellular medium from just those 
regions that had been stimulated (Bennett et al., 2000). Moreover, induction of LTP was 
also found following the increase in the size of dendritic spines (Fifkova et al., 1982) 
and the amount of neurotransmitters released (Malinow and Tsien, 1990).
The hippocampus is a major component of the medial temporal lobe, a brain system that 
plays an important role in declarative or relational memory (Eichenbaum et al., 1992; 
Squire 1992). Synaptic plasticity at the trisynaptic circuit of the hippocampus has been 
well defined anatomically and best studied in relation to learning and memory (see Fig. 
1.2). Lesion studies in rodents showed that two forms of declarative memory, spatial 
memory and contextual fear memory, depend on the intact hippocampus (Morris et al., 
1982; Kim and Fanselow 1992; Phillips and LeDoux 1992; Chen et al., 1996). 
Furthermore, both spatial memory and contextual fear memory have been shown to be 
disrupted by AP5, a specific antagonist for NMDA receptors. Mutant mice containing a 
CAl-specific inactivation of the NMDA receptor 1 showed a complete loss of LTP in 
hippocampal CAl region as well as a profound defect in spatial memory (Tsien et al., 
1996). These results support the notion that LTP in the Schaffer collateral pathways is 
important for memory formation, and that the formation of LTP requiring the activation 
of NMDA receptors is critical for those hippocampus-dependent learning and memory
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(Swanson et al., 1982; McNaughton et al., 1986). The initiating step for LTP in 
Schaffer collateral pathway involves the release of glutamate from the presynaptic 
terminals of the CA3 neurons, which leads to the activation of NMDA receptors on the 
postsynaptic CAl pyramidal cells, resulting in an influx of Ca^  ^ into the postsynaptic 
neuron. The Ca^  ^signal, in turn, activates many gene transcription through a number of 
second messenger kinases, including protein kinase A (PKA), calcium/calmodulin- 
dependent protein kinase II (CaMKII), protein kinase C (PKC) and many tyrosine 
kinases.
1.2 Transcription factor CREB
1.2.1 CREB family
CREB belongs to the large family of leucine zipper CREB/ATF transcription factors 
(Gonzalez et al., 1989b). The mammalian proteins show a high degree of homology 
throughout their C-terminal regions, which contain the bZip domain, but outside of this 
region, sequence homology between the family members is relatively poor. In rodents, 
the CREB/ATF family is comprised of at least ten genes (Brindle and Montminy, 1992), 
in addition to CREB, including CREM (CRE modulatory factor) and its variants, 
activating transcription factor (ATFl, ATF2, ATF3, and ATF4). All of these 
transcription factors can bind to the CRE sequence as homodimer or heterodimer, 
leading to extensive cross-interactions. Many of these genes are rapidly activated in 
response to the elevation of cytoplasmic cAMP or Ca^  ^levels. Furthermore, each of the 
genes is thought to encode many isoforms by different mechanisms, such as alternative 
splicing, use of alternative initiation codons and/or an alternative intronic promoter 
(Sassone-Corsi et al., 1995). Among the isoforms, some proteins activate gene
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transcription, and some repress. For example, partial or complete deletions of 
glutamine-rich regions give rise to repressors, e.g. CREB2b in Drosophila, and 
CREMa, CREMp and CREMy in mammals (Yin et al., 1995). JnAplysia, the insertion 
of premature stop codons in the CREB gene produces truncated proteins that lack the 
DNA-binding domain and the nuclear localization signal (Bartsch et al., 1998). 
Different members of the CREB/ATF superfamily also function differently on many 
signal transduction pathways. Within the brain, CREB subtype factors are the major 
CRE activator, while CREM factors may function primarily as negative modulator of 
CREB (Pham 1999).
1.2.2 Structure of CREB
CREB binds to CRE sites on target genes as a homodimer formed via the leucine zipper 
motif present at its C-terminus. In the last decade, numerous studies have contributed 
much to our understanding of CREB structure and function, and CREB-mediated gene 
transcription. CREB exists in three alternatively spliced isoforms (Ruppert et al., 1992; 
Blendy et al., 1996), CREBa, CREBp and CREB5, which have different developmental 
regulation (Walton and Dragunow, 2000). Most of CREB/ATF proteins consist of three 
functional domains (Montminy, 1997): the basic/leucine zipper (bZIP) domain which 
mediates dimerization and DNA-binding properties and is necessary for translocation of 
CREB into the nucleus (Johnson and McKnight, 1989; Waeber and Habener, 1991); the 
transactivation domain (glutamine-rich domain Q1 and Q2) are important for basal 
transcription (Ql) and interaction with the TATA-box-binding protein (TBP)-associated 
factor hTAFiso (Q2), a component of TFIID complex (Quinn, 1993; Xing and Quinn, 
1994; Ferreri et al., 1994); and the kinase-inducible domain (KID) contains the 
important phosphorylation sites, i.e., Ser-133 for PKA (Lamprecht, 1999), and sites for
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other kinases: Ser-115 and -129 for glycogen synthase kinase-3 GSK-3 (Fiol et al., 
1994); Ser-133 and -142 for Ca^^/calmodulin dependent kinase II and IV (CaMKII and 
IV) (Dash et al., 1991; Sun et al., 1994); and Ser-108, -111, -114 for casein kinase II 
(Saekigra/., 1999) (Fig. 1.3).
PKA
Phosphorylation site 
0
N H 2-g Ser-133
Ql KID Q2
■COOH
bZip
Transactivation DNA binding 
Dimerization
Fis. 1.3: Structure of CREB. The glutamine-rich domain Ql and Q2, kinase-inducible domain 
(KID) and basie domain and leucine zipper are shown. The amino acid Ser-133 phosphorylated 
by cAMP-dependent protein kinase A (PKA) is also indicated.
1.2.3 CREB and LTM
One of the hallmarks of memory consolidation in both vertebrates and invertebrates is 
the requirement for new protein synthesis. Duffy et al. (1981) found that two specific 
glial proteins are rapidly labelled and released into the extracellular fluid after the 
goldfish acquired a new pattern of behavior. Long-term but not short-term facilitation of 
the synaptic connections between neurons requires new mRNA expression and new 
protein synthesis, and such altered expression level of specific proteins is regulated 
through the cAMP second messenger pathway. The transcriptional activation of CREB 
is crucially dependent on phosphorylation of Ser-133 site by cAMP-dependent PKA and 
Ca^^-dependent calmodulin kinases. It has been suggested that this modification induces 
a conformational change that transforms CREB from an inactive to an active form (Bito
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et al., 1996). Interestingly, in its non-phosphorylated form, CREB can suppress 
activator protein 1 (API) activity by competing with Jun protein for the API site in 
target genes. As phosphorylated CREB lacks this ability, it acts as a regulator to 
facilitate transcriptional activation of immediate early genes (Lamph et al., 1990; 
Masquilier and Sassone-Corsi, 1992).
CREB is proposed to be a key factor that mediates memory consolidation, as both mice 
homozygous for a hypomorphic allele of the CREB gene (Bourtchuladze et ah, 1994; 
Blendy et al, 1996) and Drosophila overexpressing a dominant-negative form of CREB 
show a reduced ability to form long-term memory (Yin et al., 1994; 1995). Mice with a 
targeted disruption of the a  and A isoforms of CREB are profoundly deficient in long­
term memory based on the behaviour tests, fear conditioning and Morris water maze. In 
contrast, short-term memory, lasting between 30 and 60 minutes, remains normal. 
Electrophysiological studies in hippocampal slices from these mutants revealed that 
LTP in mutants is small and decays to baseline within 1.5 hours after induction 
(Bourtchuladze et al., 1994; Kogan et al., 1997). However, these results have recently 
been contradicted, as the homozygous mutants for CREBa and CREBA have showed no 
significant abnormalities observed in contextual or cued fear conditioning, or in 
hippocampal LTP (Gass et al., 1998). Meantime, the third isoform CREBp was strongly 
up-regulated. CREBp has nearly the same transactivation potential as the other CREB 
isoforms and is expressed ubiquitously; and transgenic mice expressing a dominant- 
negative form of CREB (CREBAi33) in the limbic system displayed normal LTP and 
depotentiation in basolateral amygdala (Rammes et al., 2000). These recent results 
suggest that CREB activity per se is dispensable and compensated by other CREB-like 
proteins.
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In Drosophila, a gene for CREB (dCREB2) was also cloned, and its two isoforms, 
activator dCREB2-a and repressor dCREB2-b, were analyzed for a functional role in 
memory consolidation. The dCREB2-a isoform is a PKA-responsive transcription 
activator, whereas the dCREB2-b product blocks PKA-responsive transcription induced 
by dCREB2-a in cell culture. To investigate the role of CREB in LTM formation in 
Drosophila, a transgene that expresses dominant-negative dCREB2-b under the control 
of a heat-shock promoter (hs-dCREB2-b) was generated. Induction of the transgene by 
heat shock prior to a massed training session did not affect short-term anesthesia- 
resistant memory. By contrast, induction prior to spaced training severely disrupted 
long-term memory. Heat shock alone had no effect on memory in wild-type flies or in 
flies containing a control transgene. They found that the expression of a dominant- 
negative CREB (dCREB2-b) completely and specifically blocked long-term memory, 
while the expression of dCREB2-a enhanced long-term memory formation. Mutating 
two amino acids in the leucine zipper dimerization domain of the CREB repressor was 
sufficient to prevent the dominant-negative effect on LTM. Thus, induction of LTM is 
not only protein synthesis-dependent but also CREB-dependent (Yin et al., 1994; 1995). 
Taken together, these findings suggest that CREB is necessary for the establishment of 
long-term but not short-term memory in Drosophila.
The switch from short- to long-term facilitation induced by behavioral sensitization in 
Aplysia involves CREB-like proteins, as the formation of long-term facilitation in 
Aplysia can be disrupted by drugs that interfere with transcription and translation, and it 
involves cAMP-dependent gene expression (Dash et al., 1996). Dendritic spines, the 
loci of excitatory interaction between central neurons, are prime candidates for long­
term synaptic modifications. In vitro studies with primary cultured rat hippocampal 
neurons have shown that estradiol induces two-fold the density of dendritic spines and
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increases concomitantly the levels of phosphorylated CREB and its major cofactor 
CREB-binding protein (CBP) (Murphy and Segal, 1997). Blockade of PKA eliminates 
estradiol-evoked spine formation, as well as the CREB and CBP responses. The 
dendritic outgrowth can also be inhibited by antisense oligonucleotides specific against 
CREB. These results indicate that CREB phosphorylation is a necessary step in the 
process leading to generation of new dendritic spines.
1.3 Transcriptional cofactor CREB-binding protein (CBP)
1.3.1 Characterization of CBP as a cofactor of CREB
As examined by affinity selection assay, phospho-CREB did not appear to associate 
directly with factors of the basal transcriptional machinery, i.e. TFIIA, B, D, E, F, H or 
RNA polymerase II. However, the glutamine-rich domain Q2 of CREB interacts with 
hTAFiso, a component of the TFIID complex. It was supposed that CREB needs 
cofactors to interact with the basal transcriptional machinery to further regulate gene 
transcription. Chrivia et al. (1993) screened a human thyroid Ig t l l  cDNA library using 
a recombinant CREB protein labeled at the PKA phosphorylation site with ^^ P. Through 
this binding assay, a portion of a 265 kDa protein was identified, named CREB-binding 
protein (CBP). Immunohistochemical studies in vertebrate cells demonstrated that CBP 
appears to be located exclusively in the nucleus. Far Western blot analysis of HeLa 
nuclear extracts with ^^P-labeled phospho-CREB probe also revealed a single band of 
265 kDa, which associated only with phospho-CREB (Arias et al., 1994). In vitro 
binding experiments showed that CBP specifically binds to the Ser-133 phosphorylated 
kinase-inducible domain (KID) of CREB through its CREB-binding domain (CBD) 
(amino acid 461-661), which is highly conserved in CBP homologs from
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Caenorhabditis elegans. Drosophila melanogaster to mammals. Hence, it is likely that 
a small region termed KIX (amino acid 591- 661) is actually sufficient for binding to 
phospho-CREB (Parker et al., 1996). a  helices formed in the CBD were shown to be 
crucial for the binding to phospho-CREB. Several hydrophobic residues were found in 
CBD, e.g., the phosphorylated Ser-133 was shown to form a hydrogen bond with the 
hydroxyl group of Tyr658 in CBD region. The KIDiKIX complex is disputed by low 
concentrations of non-ionic detergents, and mutation of hydrophobic residues in either 
KID or KIX severely affects the binding, suggesting that hydrophobic interactions play 
an important role in the complex formation (Radhakrishnan et al., 1997). In addition to 
CREB, the KIX domain of CBP also recognizes the transactivation domains of other 
nuclear factors, including c-Jun (Arias et a l, 1994), c-Myb (Dai et ah, 1996), Cubitus 
interruptus (Akimaru et al., 1997a), Gli-3 (Dai et ah, 1999), tumor suppressor gene 
product BRCAl (Pao et al., 2000), the E2 protein of human papillomavirus (HPV E2) 
(Lee et al., 2000), HTLV-1 virally encoded Tax protein (Kwok et al., 1996) and the 
mouse clock transcription factor Amt3 (mAmt3, also termed as BMALl or M0P3) 
(Takahata et al., 2000).
1.3.2 Domain structure of CBP
CBP, itself, is also directly regulated by nuclear Ca^  ^ and Ca^^/calmodulin kinase IV 
(CaMK rV) (Chawla et al., 1998). Moreover, CBP serves also as a coactivator for other 
transcription factors such as nuclear hormone receptors (Kamei et al, 1996; Hanstein et 
al, 1996; Chakravarti et al, 1996 and Torchia et al, 1997), p53 (Avantaggiati et al, 
1997; Gu et al, 1997; Lill et al, 1997), NF-kB (Perkins et al, 1997; Gerritsen et al, 
1997), c-Jun and c-Fos (Bannister et al, 1995a; 1995b), for transcriptional coactivators 
such as SRCl (Chen and Li, 1998; Sheppard et al., 2001), and for kinases such as
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pp90rsk (Nakajima et al., 1996) and CDK2 (for more details about interacting proteins 
of CBP see reviews by Janknecht and Hunter, 1996; Goodman and Smolik, 2000). Two 
small domains directly interacting with phosphorylated CREB range from amino acid 
residues 597 to 614 and from 647 to 662, which are located on two different exons 
(CBD exon 3 and exon 5) in the CREB-binding domain (CBD), and tyrosine 658 in 
CBD exon 5 is shown to be absolutely required for the interaction with phospho-CREB 
(Fig. 1.4), as a tyrosine to alanine mutation at position 658 hilly abolished in vitro 
binding of phospho-CREB with CBP (Radhakrishnan et al., 1997). By mutational 
analyses of CBP, the interaction domains in CBP with these various factors were 
characterized (Fig. 1.5).
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Fig. 1.4: Two small domains of mouse CBP encoded by CREB-binding domain (CBD) exon 3 
and 5 are known to bind to phosphorylated CREB. The amino acid residues 591-665 are listed 
under the corresponding helical structure of CBP; Amino acid residues involved in the binding 
to CREB are indicated in red.
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Fig. 1.5: Schematic representation of mouse CBP domains. Amino acid 1-101, 461-661, 1621- 
1891 and 2058-2163 containing binding sites for the proteins are indicated. There are many 
other interacting proteins not listed because of space limitation, e.g. NF-kB and Ets-1 interact 
with both N- and C-terminal domains; N-terminal domain interacting proteins: RXR, Pitl, Stat- 
2, HIF-1, TBP, Mdm2, p73, TALI and HNF4; C-terminal domain interacting proteins: p53, 
p/CIP, Smad, Neuro D, C/EBP (3, RNA helicase A, E2F, SF-1, Tat, CIITA, HPV E6, Py LT, 
dMad, JMY, Twist and ATF-2.
1.3.3 CBP and its homologous protein p300
CBP was originally characterized as a co-activator o f CREB, while p300, which is 
highly homologous to CBP (a 2414 amino acid residues for human p300), was first 
identified as a protein interacting with the adenovirus E lA  oncoprotein (Yee et al, 
1985; Arany et al, 1994; Eckner et al, 1994), and it is thought to participate in the 
prevention o f the Gq/Gi transition during the cell cycle, in activation o f  certain
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enhancers and in the stimulation of differentiation pathways (Wang et al., 1993). ElA is 
believed to mediate transformation and immortalization through two conserved regions, 
named CRl and CR2. CRl is responsible for binding and presumably inhibition of p300 
and CBP activity (Moran, 1993; Wang et al., 1993; Smits et al., 1996). Overexpression 
of CBP and p300 can overcome the ElA-mediated gene repression and block the 
transformation process, it suggested that ElA represses genes that inhibit cell 
proliferation by competing for a limiting amount of p300 and CBP. In agreement with 
this notion, p300 mutations were identified in certain cancers (Muraoka et al., 1996), 
suggesting that p300 might also fimction as a tumor suppressor gene.
Several protein motifs in p300 and CBP such as the bromodomain, the KIX domain, 
and three Cys/His residues-rich (C/H domains) region are well conserved in species 
ranging fi"om C. elegans. Drosophila to mammals (Parker et al., 1996; Akimaru et al., 
1997b). These domains serve as binding sites for sequence-specific transcription factors 
and other components regulating gene expression. For example, mediated by one of the 
conserved C/H domains, p300 and CBP can interact with RNA helicase A, which in 
turn binds RNA polymerase II (Nakajima et ah, 1997a). Recruitment of the RNA 
polymerase II holoenzyme by p300 and CBP appears to be an essential step in the 
process of transcriptional activation by CREB (Nakajima et al., 1997b). In mammal, 
CBP and p300 are 63% identical at the protein level. Greater similarity (85-90% 
homology) is observed in specific regions of CBP and p300, including the CREB- 
binding domain (CBD), the ElA binding site and the bromodomain (Arany et al., 
1994). 60-70% homology to mammal is observed in the same regions in Caenorhabditis 
elegans, and Drosophila homologue of CBP (dCBP) has also been identified and shown 
to have striking homology with mouse CBP (Akimaru et al., 1997b). Recently, 
p300/CBP-like polypeptides were identified in the plant Arabidopsis thaliana.
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Interestingly, homology between animal and plant p300/CBP is largely restricted to a C- 
terminus, about 600 amino acids in length, which encompasses acetyltransferase and 
ElA-binding domains (Bordoli et al., 2001).
1.3.4 Functions of CBP and p300
Both CBP and p300 contain many common structural motifs, are highly related in 
primary structure and functionally overlap to a great extent, since they bind a similar set 
of cellular target factors (Janknecht and Hunter, 1996) (Fig. 1.5). Accumulating 
evidence now suggests that both proteins have very similar cellular functions, but also 
many functional differences have recently been reported (Kawasaki et al, 1998; Yuan et 
al, 1999; Ugai et al, 1999).
CBP and p300 display pleiotropic functions, several mechanisms by which CBP and 
p300 contribute to their transcriptional regulation. First of all, CBP and p300 participate 
in a variety of cellular processes, such as cell growth, proliferation, homeostasis, viral 
pathogenesis, DNA repair and apoptosis by interaction with multiple transcription 
factors, indicating that both of CBP and p300 function as molecular integrators in 
complex signal transduction pathways. CBP and p300 can synergize with each other to 
interact with many nuclear factors when bound to the same promoter in cis position, 
while inhibition between the factors may occur when CBP and p300 are bound to 
different promoters. It has been proposed that this results from factor competition for 
limiting amounts of CBP and p300 in the nucleus (Kamei et al., 1996). For example, 
since p53 and AP-1 interact with the same domain of CBP and p300, these factors 
compete with each other functionally.
CBP and p300 directly contact components of the general transcriptional machinery, the
transcription factors TFIIB, TFIID, and RNA helicase A. The helicase is proposed to
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bridge CBP and p300 and the RNA polymerase II holoenzyme (Nakajima et al., 1997a). 
For example, as a prerequisite to activate the basal transcriptional machinery, phospho- 
CREB has to bind to CBP to further activate CREB-mediated gene transcription (Kwok 
et al., 1994). The adenovirus ElA oncoprotein may compete for the RNA helicase A 
binding site on CBP, thereby preventing CBP from interacting with RNA polymerase n. 
The ElA binding to CBP/ p300 may also dissociate CBP and p300 from phospho- 
CREB. Thus, CBP and p300 are considered as physical bridging molecules between 
upstream DNA-bound transcription factors and the basal transcriptional machinery.
CBP and p300 have also been shown to have intrinsic histone acetyltransferase (HAT) 
activity, which decreases the association of the positively charged histones with 
negatively charged DNA. CBP and p300 acetylate the amino terminal tails of 
nucleosomal histones, then destabilizes histone-DNA interactions and facilitates access 
and binding of the DNA to transcription factors. Moreover, CBP and p300 associate 
with other nuclear cofactors that have acetyltransferase activities, such as p/CAF 
(p300/CBP-associated factors). Thus, both CBP and p300, in part, facilitate 
transcription by directly modifying chromatin structure.
Despite the fact that CBP and p300 are structurally similar, their functions are not 
entirely overlapping. Mutations in one copy of the CBP gene cause serious defects in 
human (Petrij et al., 1995), while p300 does not seem to give a similar syndrome. 
Kawasaki et al. (1998) generated p300 and CBP knock-down cell lines by using 
specific hammerhead ribozymes. p300 knock-down cell line showed a resistance against 
retinoic acid-induced differentiation, but CBP knock-down cell lines did not. It has also 
been shown that both CBP and p300 proteins play different roles in the cellular 
response to DNA damage (e.g. ionizing radiation, IR). p300, but not CBP, contributes to
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IR sensitivity of cells, and IR-induced apoptosis is impaired in the p300-, but not CBP- 
deficient cells.
1.3.5 Mice with mutations in CBP and p300
The functions of CBP and its closely related protein p300 have recently been 
investigated by gene targeting in mouse. Three different alleles of CBP have been 
generated. First, using conventional knock-out technology, amino acids 29-265 were 
deleted and replaced by the neo cassette (Tanaka et al., 1997), presumably leading to a 
complete deletion of the CBP protein. Second, using a retroviral gene trap vector, an 
insertional mutation into the CBP gene was generated, leading to a truncated N-terminal 
CBP (residues 1-1084) as shown by Western blot analysis (Oike et al., 1999a). Third, 
the mouse CBP gene was targeted by homologous recombination in which exons 
encoding the first Cys/His-rich (CHI) domain (amino acids 340-443) were deleted and 
replaced by the neo cassette. It was investigated whether the mutant CBP locus 
generates a truncated N-terminal CBP (residues 1-340) by Western blot analysis, but 
none was found (Kung et al., 2000). The mouse p300 allele was also inactivated in 
which exons encoding the CHI domain were replaced with the neo cassette by 
homologous recombination (Yao et al., 1998).
The functions of CBP in vivo was firstly investigated in the mice heterozygous for CBP 
generated by replacement of amino acid 29-265 with neo cassette (Tanaka et ah, 1997). 
CBP^ ' in both BALB/c and C57BL/6 genetic background displayed abnormal skeletal 
patterning and severe growth retardation, but the significantly lower frequency of the 
different abnormalities was found in C57BL/6 background. Similar abnormalities were 
observed in the human Rubinstein-Taybi Syndrome (RTS), a haplo-insufficiency 
disorder that is characterized by mental retardation, severe developmental defects and
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patterning abnormalities and that is shown to contain mutations in the human CBP gene 
(Petrij et al., 1995) (see below, 1.3.6). The most pronounced phenotype in the CBP^' 
mice was delayed ossification of firontal bones with an enlarged anterior fontanel 
(14/21); various anomalies of the sternum (extra, fusion, reduction, and asymmetry of 
the ossification with split in the sternum) were found in one-third (7/21) of the 
heterozygotes. Asymmetric sternocostal joints were also found in the heterozygotes 
with similar penetrance; an additional phenotype found in the heterozygotes was the 
malformation of the xiphoid process and vertebrae (6/21). The expression level of bone 
morphogenetic protein 7 (Bmp7) was shown to be significantly reduced in the CBP 
heterozygous mutants. As reported recently, the Drosophila homologue of CBP (dCBP) 
functions as a coactivator of the products of the segment polarity gene cubitus 
interruptus {ci) (Akimaru et al., 1997a) and dorsal, a Drosophila homologue of the 
vertebrate NF-kB (Akimaru et al., 1997b). Ci is a critical transcription factor for pattern 
formation in the hedgehog (hh) pathway (Dominguez et al., 1996). In response to Hh, 
Ci activates the decapentapleigic (dpp) and wingless iwg) genes, which encode the 
Drosophila homologue of transforming growth factor p/bone morphogenetic protein 
(TGF-p/BMP) and the Wnt family proteins, respectively. Dorsal activates twist gene 
expression, which is critical for dorso-ventral polarity (Jiang et a l, 1991; Pan et al., 
1991; Thisse et al., 1991). Taken together, this suggests that CBP contributes to the 
conserved dpp/Bmp signaling pathway in both Drosophila and mouse. This could be the 
explanation for some phenotypes observed in RTS by haplo-insufficiency of CBP. 
Furthermore, analysis of the homozygous CBP mutant mice (75% BALB/c, 12.5% 
C57BL/6 and 12.5% CBA) (Tanaka et al., 2000) showed embryonic lethality at 
embryonic days (E) 10.5 to 12.5 as a result of massive hemorrhage caused by a defect in 
blood vessel formation in the central nervous system. In addition, CBP' ' mutants
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showed developmental retardation, delays in both primitive and definitive 
hematopoiesis, open neural tube and defects in mesenchymal cells (Tanaka et al., 2000).
A second mouse model of RTS was generated by an insertional mutation into the CBP 
gene (Oike et ah, 1999a). The heterozygous mice (C57BL/6), which had a truncated 
CBP protein (residue 1-1084) containing the CREB-binding domain, showed clinical 
features of RTS, such as growth retardation (100%, in 100 mice), retarded osseous 
maturation (100%), large anterior fontanel (100%), hypoplastic maxilla with narrow 
palate (100%), cardiac anomalies (17%) and skeletal abnormalities (7%). Importantly, 
the behavioral tests of the heterozygous mice showed that the mice were deficient in 
long-term memory (100%); in contrast, short-term memory appeared to be normal. 
They also showed poor locomotor activity (100%). The homozygous CBP mutant mice 
(background: 75% C57BL/6, 25% CBA or 87.5% C57BL/6, 12.5% CBA) died at E9.5 
to 10.5 and showed defective neural tube closure, a lack of vascular network formation, 
and an inhibition of primitive hematopoiesis in the yolk sac and complete blockage of 
definitive hematopoiesis developing in the para-aortic splanchnopleural mesoderm 
region and impaired vasculo-angiogenesis (Oike, et al., 1999b).
A detailed analysis of CBP^'' mice (background: C57BL/6) generated by replacement of 
amino acids 340-443 with neo gene was also described recently (Kung et al., 2000). 
Defects included growth retardation, craniofacial abnormalities, dramatic splenomegaly, 
e.g. grossly enlarged spleen. Significantly, the defects in hematopoietic differentiation 
and an increased incidence of hematologic malignancies with advanced age were also 
found in the CBP^'' mice, but not in p300^'' (discribed below) and wild-type mice. It 
suggests that a full complement of CBP, but not p300, is required for normal 
hematopoietic differentiation and that CBP appears to contain tumor suppressor 
activities.
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Mice lacking both copies of p300 die in utero between E9 to 11.5. Mice double- 
heterozygous for CBP and p300 mutants have a comparable phenotype to either CBP or 
p300 null mutants (Yao et al., 1998). This suggests that these two proteins exert certain 
common embryonic survival functions and that the combined dose of CBP and p300 is 
critical for mouse embryonic development, although CBP and p300 are not completely 
physiologically redundant. The p300 mutant mice were acquired by either an inbred 
cross with 129/Sv or a cross with C57BL/6 mice. The more C57BL/6 background was 
present, the less lethality among p300 heterozygous animals was observed, indicating 
that there is a modifier gene(s) in C57BL/6 mice that suppresses the lethality observed 
in 129/Sv background. The embryos nullizygous for p300 were much smaller than their 
littermates and exhibited severe open neural tube, as well as heart defects (an enlarged 
heart cavity) as observed in -20% of the ^ 500-deficient embryos at El 0.5. Remarkably, 
there was also a significant embryonic lethality in mice lacking just one copy of p300 
(as early as at El 0.5) and CBP (lower number of viable CBP^ ' mice than p300^ '^ mice). 
A significant number of the p300 heterozygotes displayed symmetrical exencephaly 
mostly in the midbrain and in the anterior part of the hindbrain region, with the rest of 
the neural tube fused normally. This partial penetrance of exencephaly was compatible 
with the restricted lethality observed among the heterozygous mutants. The heart 
development was perturbed in embryos lacking one or both copies of p300, and this 
failure of the cardiovascular system may, at least in part, be responsible for the observed 
embryonic lethality. The p300-deficient mice also showed that p300 is essential for 
normal cell proliferation in vivo and in vitro and functions as a critical cofactor of 
retinoic acid receptor (RAR)-, but not of CREB-mediated signaling pathway. This 
indicates that the physiological functions of p300 and CBP do not fully overlap, at least 
during embryonic development. Thus, a reduction in the dose of one of them cannot be 
fully compensated by a call on the other to overcome the functional deficit.
22
Chapter 1 Introduction
Thus, the importance of CBP during development is underscored by the occurrence of 
the CBP haplo-insufficiency disorder called RTS in humans. The heterozygous CBP 
mice (Tanaka et al., 1997; Kung et al., 2000) exhibit only mild RTS phenotypes in 
comparison to the phenotypes observed in the mouse model generated by Oike et al. 
(1999), which leads to a truncated CBP protein (amino acids 1-1084). Thus, a new 
mechanism by which CBP defects lead to RTS phenotypes was proposed: abnormal 
CBP derived firom the mutant allele might interfere with wild-type CBP fimction in a 
dominant manner.
1.3.6 CBP and Rubinstein-Taybi Syndrome (RTS)
If a mutation in human CBP is present in all cells of the individual, Rubinstein-Taybi 
Syndrome (RTS) emerges. RTS is a heritable human developmental disease, 
characterized by multiple abnormalities, including mental and growth retardation 
(94-100%), associated with characteristic craniofacial appearance, including 
hypoplastic maxilla with narrow palate (100%), downward slanting palpebral fissures 
(100%) and large anterior fontanel (64%); skeletal defects (broad thumbs and broad big 
toes) (100%). Additional symptoms include microcephaly (84%), stiff gait, 
electroencephalographic abnormalities (60%), agenesis of corpus callosum and 
congenital heart defects (33%) (Rubinstein and Taybi, 1963; Jones et ah, 1988; 
Hennekam et al., 1990). Thus, RTS is a multiple congenital malformation and mental 
retardation syndrome caused by a generalized dysregulation of gene expression. 
Magnetic resonance imaging (MRI) study of the brain of a RTS patient revealed 
bilateral rolandic cortical clefts and diminished white matter, which probably account 
for mental retardation (Sener, 1995). The typical features of the syndrome develop 
progressively, beginning in early infancy and reaching the fully developed phenotype
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by the age of two years. The syndrome is surprisingly common, the prevalence of RTS 
has been estimated to be about 1 in 125,000 living newborns (Hennekam et al., 1990), 
and it is important to note that RTS has also been estimated to account for as many as 1 
in 300 institutionalized subjects with mental retardation over the age of 5 years 
(Padfield et al., 1968; Roldan 1969). Since the recurrence risk for offspring of affected 
persons is estimated at 50%, an autosomal dominant inheritance pattern has been 
favoured. Verbal abilities are limited and intelligence is usually low. The average IQ 
value of the patients is below 40, and the average age and range for attainment of 
several developmental milestones such as standing, walking or speech development are 
severely delayed (Hennekam et al., 1992). Behaviourally, the patients show a shortened 
attention span and impaired executive functions, expressed as difficulties in planning 
motor acts, and the execution of locomotor and oculomotor skills is disturbed (Gotts 
and Liemohn, 1977).
However, the knowledge about the physiological features of RTS is very limited. It is 
hoped that the behavioural analysis of a genetic mouse model of the disease may help to 
elucidate the molecular mechanisms for these phenotypes. Genetically, RTS has been 
shown to be associated with the long arm of chromosome 16 (16pl3.3), including 
deletions, translocations, or point mutations. Two point mutations associated with RTS 
were characterized, and these two point mutations were located in the CBP gene (Petrij 
et al., 1995). Two patients had a premature stop codon at amino acid positions 136 and 
357, leading to truncated products missing most of the 2441 amino acid 265 kDa CBP 
protein. In 12% of the RTS cases, small deletions in 16pl3.3 have been observed (Taine 
et ah, 1998). Moreover, de novo somatic chromosomal re-arrangements account for 
about one-fourth of these cases (Breuning et al., 1993; Hennekam et al., 1993). 
Translocations of CBP to other chromosomal loci can also generate aberrant fusion
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proteins leading to e.g. acute myeloid leukemia (Borrow et al., 1996) and other diseases 
(Giles et al., 1998). Although some of the CBP mutations may generate dominant- 
negative isoforms, most of the evidence suggests that RTS is a haplo-insufficiency 
disorder.
Taken together, a genetically modified mouse model is a very useful tool to elucidate 
the physiological functions of CBP, and to understand the complex mechanisms 
underlying RTS. A molecular mechanism to explain the RTS symptoms was proposed 
based on the fact that CBP is a multiple transcriptional cofactor, for example, with Ci 
and Gli-3, which are critical for embryonic pattern formation, and with hypoxia- 
inducible factor 1 (HIF-1) which is responsible for neural tube closure. However, for 
most RTS symptoms, for example, developmental retardation and impairment of long­
term memory, the molecular mechanisms still remain unclear. However, CBP, as a 
molecular integrator, functions as a coactivator of many other transcription factors, 
including CREB, which is a central factor required for long-term memory. In vitro 
experiments using a Gal4-GFP system, the ability of CBP tethered to the promoter was 
examined by means of fusion to the Gal4 DNA-binding domain, indicating that the 
activation of NMDA receptors and voltage-sensitive calcium channels leads to CREB- 
mediated transcription in cortical neurons via regulation of CBP (Hu et al., 1999). The 
recruitment of CBP by CREB is a crucial step for the induction of gene transcription 
following Ca^  ^ flux through ligand- and/or voltage-gated ion channels in hippocampal 
neurons (Hardingham et al., 1999). Furthermore, Marek et al. (2000) presented a 
genetic and electrophysiological analysis of Drosophila CBP (dCBP) function in the 
neuromuscular junction (NMJ), which showed that postsynaptic dCBP is necessary and 
may also be sufficient for the development of normal presynaptic transmitter release at 
the NMJ, and that dCBP can inhibit the development of presynaptic transmitter release
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when overexpressed either pre- or post-synaptically. This indicates that dCBP- 
dependent mechanisms can act as both positive and negative regulators of presynaptic 
development. Although the precise relationship between CREB and CBP in the control 
of synaptic plasticity, learning and memory remains unclear, the mental retardation of 
RTS caused by mutations in CBP could be due to the impairment of CREB-mediated 
gene expression in the central nervous system. Because CBP interacts with so many 
different transcription factors, possibly at the same time point, it is difficult to dissect 
the complex components of the RTS phenotype into distinct contributions from various 
individual transcriptional pathways. It is hereby evident that conditional CBP knock-out 
mice in different tissues and at different time points will be a powerful model to 
pinpoint the mechanisms of the multiple congenital malformation and mental 
retardation syndrome observed in the RTS.
1.4 Gene targeting
Since the first transgenic mouse was reported in 1980, genetically engineered mice have 
become an invaluable biological tool for better understanding of physiological and 
pathological processes in many fields of biomedical research. Transgenic technology 
allows researchers to carry out specific genetic manipulation in all cells of a laboratory 
animal, and makes it possible to dissect deliberately selected gene function in a living 
organism and to evaluate systematically complex biological process, such as embryonic 
development and adult behaviors. Transgenic mice as described by Palmiter et al. 
(1982) are generated by pronuclear injection of oocytes with naked DNA. This 
technique allows the generation of several founders within a relatively short period of 
time, although, there are several disadvantages (for review, see Müller, 1999): 1) vector 
integration occurs randomly and the neighbouring sequence may strongly influence
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expression levels of the transgene; 2) the copy number of the transgene can be highly 
variable; 3) the regulatory elements included in the injected DNA may be located at a 
great distance from the coding sequence or within introns of large genes, thus, it is not 
sure that the transgene does follow the expected expression pattern.
Concomitantly, gene targeting, defined as the introduction of site-specific modification 
into the genome by homologous recombination, has been developed and has 
revolutionized the field of mouse genetics. It allows the analysis of diverse aspects of 
gene function in embryonic development and adult physiology. In 1981, two groups 
(Evans and Kaufinann, 1981; Martin, 1981) acquired from mouse blastocysts totipotent 
embryonic stem cell (ES cell) lines, which maintain the capacity to colonize every cell 
lineage including germline when injected into host blastocysts under appropriate 
conditions (Bradley et al., 1984). Concomitantly, Capecchi and his colleagues showed 
that homologous recombination can occur in mammalian cell lines (Folger et al., 1982), 
paving the way to altering the mouse genome at any chosen locus by homologous 
recombination in ES cells. Combining both accomplishments (i.e. embryonic stem cells 
and homologous recombination) led to the first gene targeting experiments in mouse 
(Thomas and Capecchi, 1987; Doetschman et ah, 1987). Gene targeting of this first 
generation, here referred to as conventional knock-out, leads to inactivation or 
modification of a gene of interest in all tissues in a living organism from the onset of 
development throughout the whole lifespan. This technology is widely used in all fields 
of biological research in mouse, including embryonic development, cancer research, 
immunology and neuroscience (e.g. Silva et al., 1992; Grant et al., 1992). In the field of 
neurosciences, knock-out mutants have contributed greatly to the understanding of basic 
mechanisms of brain function involved e.g., in learning and memory (Bourtchuladze et 
al., 1994), as well as to generate useful animal models for studying human neurological
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disorders (Brusa et al., 1995; Acampora et al., 1996; Mansouri et al., 1996; Brunet et 
al., 1996; Timpl et al., 1998). Despite the enormous progress that has been made by this 
technology, some intrinsic limitations are evident.
Thus, this method has been further developed with the aim of controlling the 
modification of a gene in a time- and tissue-dependent manner, here referred to as 
conditional knock-out. This is particularly useful in cases where conventional gene 
targeting leads to lethality in early developmental stages, thus, preventing phenotypic 
analysis in adults. Since a given gene often has a broad expression pattern, tissue- 
specific knock-out may define physiological roles of the gene in a certain tissue, 
without compromising functions in other tissues of the organism; knock-outs in a time 
dependent manner may allow us to analyze gene functions at different time points 
during development and in adult life. Moreover, conventional knock-out may lead to 
unexpected phenotypes, due to compensation mechanisms, since mammalians are 
generally equipped with well organized regulatory systems which may overcome 
naturally occurring disbalancies. The disruption of a gene at early developmental stage 
could induce compensation mechanisms, which could then mask some physiological 
functions of the gene in adulthood. Such mechanisms range from simple overexpression 
of other related genes with similar functions, to mis-expression of non-related genes (for 
review see Gerlai, 2000). Keeping gene function intact throughout ontogeny, time- 
specific knock-outs in adulthood might avoid such compensatory responses.
Tissue- and time-specific knock-out mice can be generated by using the Cre/loxP 
system (for review, see Sauer, 1998). Cre is a 38 kDa site-specific DNA recombinase 
isolated firom bacteriophage PI (Sternberg and Hamilton, 1981). loxP (locus of 
crossover in PI) was originally found in the PI genome, and is a sequence 34 bp long, 
consisting of two 13 bp inverted repeats flanking an 8 bp non-palindromic core
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sequence that indicates the polarity of the loxP site (Fig. 1.6). Two mouse lines are 
required for the generation of conditional knock-out mice. One is called a “floxed” 
mouse line (the sequence of interest flanked by two loxP sites), and such a mouse line 
should not display any phenotypical changes, and is therefore considered as a wild-type 
mouse. These two loxP sites are introduced into 5’ and 3’ ends of essential exons of the 
gene of interest by homologous recombination in ES cells, the cells are then injected 
into blastocysts to generate finally the floxed mouse. The second mouse line that is 
required expressing Cre recombinase, driven by regulatory sequences of interest in a 
defined tissue and/or at a distinct time point.
When these two mouse lines are crossed, Cre recombinase will recognize the two loxP 
sites and excise or invert the sequences between the loxP sites. Cre-mediated 
recombination between two directly repeated loxP sites results in the excision of the 
sequence between them as a covalently closed circle (Fig. 1.6, 1.7). Cre-mediated 
recombination between pairs of loxP sites positioned in an opposite orientation results 
in inversion of the intervening sequence rather than excision, and this inversion will 
take place continuously as long as Cre recombinase is present (Fig. 1.6).
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loxP 34 nt Cre 38 kDa
ATAACTTCGTATA GCATACAT TATACGAAGTTAT 
 > <---------------------
(1 )
(2)
A
B
Fig. 1.6: Cre/loxP recombination system. Graphical representation of loxP site (black triangle), 
Cre recombinase (blue circle) and nucleotide sequence of the loxP site. Orientation of the loxP site 
is indicated by the orientation of the 8-nucleotide core sequence. Two molecules of Cre bind to one 
loxP site (Mack et al, 1992). (1) If loxP sites are oriented ”head-to-tail”, Cre recombinase catalyzes 
an excision of the sequence between two loxP sites. (2) If loxP sites are oriented ”head-to-head”, 
Cre recombinase catalyzes an inversion of the sequence between two loxP sites.
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wild-type
modified = wild-type 
or «floxed" allele
Tissue-specific 
expression of 
Cre recombinase
Tissue-specific mutant
^  loxP site 
#  Cre recombinase 
Gene of interest
Fig. 1.7: Schematic representation of tissue-specific gene disruption using the Cre/loxP system.
Recently, Albert et al. (1995) further developed the Cre/loxP technique. They 
introduced a 5-nucleotide change into the left 13 bp element (LE) and the right 13 bp 
element (RE) of loxP site, generating LE mutant lox site (lox71) and RE mutant lox site 
(lox66), respectively. Inversion recombination between the lox71 and lox66 sites 
produces a wild-type loxP site and a LE+RE double mutant loxP site that is poorly 
recognized by Cre recombinase. This technique offers some interesting applications: 1) 
Integration: the frequency of site-specific integration via the mutant lox sites reached a 
maximum of 16%, showing high stable integration. In contrast, the wild-type loxP sites 
yielded very low frequencies (<0.5%) of site-specific integration events (Araki et al.,
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1997); 2) Inversion: this technique has not yet been applied. As proposed in this thesis, 
a conditional CBP point mutation tyrosine to alanine at amino acid 658 
can be introduced by Cre-mediated inversion with two mutant loxP sites (lox66 and 
lox71). With luciferase as report gene, Cre-mediated recombination has been shown to 
be 4 to 7-fold more efficient between lox66 and lox71 than that between double mutated 
loxP and wild-type loxP under the different Cre concentration used (0.1-20 pg) in 
tobacco protoplasts; at lower Cre concentration, the recombination between lox66 and 
lox71 was favoured (Albert et al., 1995). The strategy of the Cre/loxP mutant system is 
indicated in Fig. 1.8.
lox66 I ATAACTTCGTATA GCATACAT TATACGAACGGTA | 
I__________________________________________________ I
Iox71
loxF
+
TACCGTTCGTATA GCATACAT TATACGAAGTTAT
Cre recombinase
ATAACTTCGTATA GCATACAT TATACGAAGTTAT
+
Double 
mutant loxP TACCGTTCGTATA GCATACAT TATACGAACGGTA
Fig. 1.8: The mutated Cre/loxP system. Nucleotide sequences of loxP and its mutants are listed, 
and the mutated sequences are marked in red. Recombination between lox66 and lox71 sites 
produces a wild-type loxP and a double mutated loxP sites. Since the double mutated loxP site 
exhibits reduced binding affinity for Cre recombinase, thus, Cre-mediated recombination in the 
mutated Cre/loxP system is prefered for the direction as indicated.
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In addition to Cre/loxP, Flp/fit system is another commonly used recombination system, 
which originally derived from the yeast Saccharomyces cerevisiae (Bahineau et al, 
1985). Both have been shown to catalyse excisions, integrations, or translocations of 
DNA between their distinct recognition target sites loxP and frt, respectively, without 
requirement of additional cofactors. Flp recombinase (Flipase) functions efficiently at 
30°C, but less efficient than Cre recombinase at 37°C. However, Flipase still maintains 
recombinase activity sufficient for Flp-mediated recombination in mammalian cells, frt 
(flipase recognition target), similar to loxP, is 34 bp long, consisting of two 13 bp 
inverted repeats flanking an 8 bp non-palindromic core sequence that indicates the 
polarity of its site. As for the Cre/loxP system, the type of the recombination reaction is 
determined by the orientation of target sites relative to each other on a segment of DNA, 
specifically, directly repeated frt sites specify excision of the intervening DNA.
1.5 Aims of the thesis
Several lines of evidence demonstrate that CBP might play an important role in the 
transfer of learned information from short-term memory to long-term memory. (1) CBP 
is a major cofactor in the CREB-mediated transcriptional response, which is initiated by 
learning, and is required for the formation of long-term memory; (2) CBP is activated 
by increased intracellular concentrations of cAMP and Ca^  ^ through the kinases PKA 
and CaMKIV, respectively. As CaMKIV was reported to be restricted mainly to the 
nucleus of neurons (Means et al, 1991; Matthews et al., 1994), and catalytically 
inactive mutants of CaMKIV expressed in AtT20 cells and hippocampal neurons block 
Ca^ '*’-activated, CREB/CBP-mediated transcriptional response (Hardingham et ah, 1999; 
Chawla et al., 1998), CBP might play a crucial role in synaptic plasticity; (3) the human
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Rubinstein-Taybi Syndrome (RTS) is caused by mutations in the CBP gene and is 
characterized by mental retardation.
In order to analyse the physiological functions of CBP in neurons, I aimed to inactivate 
the CBP gene in a tissue-specific manner by using the Cre/loxP system, in the 
hippocampus, a hrain region essential for learning and memory. Conditional knock-outs 
are essential, as conventional knock-outs of CBP in mice lead to embryonic lethality. In 
addition, since CBP is a co-factor of a variety of transcription factors and kinases, and 
acts as a molecular integrator of many signaling pathways. I aimed to inactivate only the 
CREB-binding domain (CBD) of CBP.
Expression analysis o f  CBP In order to investigate the functions of CBP in CNS, it is 
necessary to characterize its expression pattern. This is especially important in the light 
of the generation of tissue-specific CBP knock-out mice. So far, the expression pattern 
of mouse CBP has not been described. Therefore, I investigated the expression of CBP 
and its highly related protein p300, in particular, in forebrain areas essential for learning 
and memory. In situ hybridization and immunohistological experiments showed 
particularly high expression of both CBP and p300 in the so-called limbic system, i.e. 
neocortex, hippocampus, entorhinal cortex and amygdala.
Mutational analysis o f  CBP in vitro Transfection assays constitute a useful tool to
obtain insights into possible physiological functions of CBP. In order to show whether it
is possible to remove only the CREB-binding domain (CBD) of CBP and to keep other
activities such as steroid hormone receptor-mediated activities, and to identify mouse
mutant phenotypes that might result specifically from disruption of the CREB-CBP
interaction, several mutants were generated: one that lacks most of CBD (CBPACBD2-
5); the second, which lacks the C-terminal domain of CBP, retaining only the first N-
terminal 1100 amino acid residues, and displaying dominant-negative effects; and the
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third, the point mutation Tyr658Ala (CBPAla658), which abolishes CREB-binding 
activity in vitro. Lastly, three RTS-like mutants were generated, containing different C- 
terminal truncations of CBP. I then tested whether these mutants lack either cAMP- 
mediated or glucocorticoid-mediated transcriptional enhancement in F9 teratocarcinoma 
cells. Both CBPACBD2-5 and CBPAla658 have a dominant-negative effect on cAMP 
signaling. This effect of CBPAla658 was shown to be dose-dependent. As expected, 
glucocorticoid-mediated transcriptional enhancement was retained in both of the 
mutants CBPAla658 and CBPACBD2-5. The three RTS-like mutants displayed 
dominant-negative effects on CBP function in the context of cAMP signalling.
Generation o f mouse CBP mutants The central part of this thesis was the generation of 
two mouse mutants of the CBP gene using the Cre/loxP system:
1) Generation o f a mouse model for RTS CBP^ °^^ ^^  ^ is characterized by a mutation in 
exon 2 of CBD, where a new stop codon was introduced at amino acid 523 disrupting 
the open reading frame of the downstream sequences of CBD. It aims to mimic a CBP 
mutation found in human RTS patients. When this mutation is present in all cells of the 
animal in a heterozygous state, some RTS-like phenotypes, e.g., developmental 
retardation, embryonic lethality and smaller size, were observed. To dissect the complex 
mechanisms underlining RTS, the generation of tissue-specific heterozygous knock-outs 
of this allele has been initiated.
2) Generation o f  a CREB-binding mutation o f CBP The second mutant generated is a 
tyrosine to alanine substitution at amino acid 658, which is reported to abolish CREB- 
binding activity of CBP in vitro (Radhakrishnan et al., 1997). When crossed with Cre- 
expressing mice, this point mutation should be generated in a conditional tissue-specific 
manner. Proof of principle of this novel technique was obtained in bacteria and 
embryonic stem cells.
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Chapter 2
Materials and methods
2.1 Materials
2.1.1 Table 2.1 Common chemicals
Chemicals Company (Catalog number)
a-Iodoacetamid Calbiochem, USA (407710)
2-Mercaptoethanol Roth, Germany
2-Mercaptoethanol (for cell culture) GIBCO, Germany (31350-010)
Acetic anhydride Sigma, Deisenhofen, Germany (A0933)
Acrylamide (29:1) Roth, Germany (A 515.1)
Agar, agarose GibcoBRL, Germany
Ampicillin (sodium salt) Sigma, Deisenhofen, Germany (K029.2)
APS (ammonium peroxodisulfat) Roth, Germany (9592.2)
Bromophenol blue MERCK, Germany (1.08122.0005)
Casamino acids Sigma, Deisenhofen, Germany
Chloramphenicol Sigma, Deisenhofen, Germany (C-0378)
Chloroform MERCK, Germany (6340.2)
DEPC (diethylpyrocarhonate) Roth, Germany (K028.1)
Dextransulfate Sigma, Deisenhofen, Germany (D-8906)
DMSO (dimethylsulfoxide) Sigma, Deisenhofen, Germany (D-5879)
Drying pearls Roth, Germany (0728.1)
DTT (dithiothreitol) MERCK, Germany (1.120.130.001)
EDTA (ethylenediaminetetraacetic acid) Sigma, Deisenhofen, Germany (E5134)
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Ethanol
Ethidium bromide 
Ficoll 400 
Formamide 
Gancyclovir 
Gelatin
Geneticin G418 
Glutaraldehyde (25%)
Guanidium isothiocyanate 
Hydrochloric acid 
Hydrogen peroxide (30%)
IPTG (isopropyl-P-thiogalactopyranoside)
Isopropanol
L-Glutamine
LIF (Leukemia Inhibitory Factor)
Maleic acid 
Maltose 
Methanol 
M gS04
N’ -N-dimethyl-formamide 
Paraformaldehyde 
PEG 8000
Penicillin-Streptomycin
Phenol
Puromycin
MERCK, Germany (1.00983.1000) 
Sigma, Deisenhofen, Germany 
Sigma, Deisenhofen, Germany (F2637) 
MERCK, Germany (1.09684.2500) 
Cytovene, Syntex, USA 
BDH, England (44045)
GIBCO, Germany (11811 -03)
Serva, Heidelberg, Germany (23115) 
Roth, Germany (0017.2)
Roth, Germany
MERCK, Germany (1.072.100.250) 
Roth, Germany (2316.2)
Roth, Germany
GIBCO, Germany (25030-024)
GIBCO, Germany (13275-029) 
MERCK, Germany (8.003.800.500) 
Roth, Germany (8951.1)
Roth, Germany (4627.2)
MERCK, Germany (1.05883.0500) 
MERCK, Germany (D-8654)
MERCK, Germany (1.045005.1000) 
Sigma, Germany (P-5413)
GIBCO, Germany (15140-114)
Roth, Germany (0038.2)
Sigma, Germany
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Retinoic acid (RA, all trans) Sigma, Germany (R-2625)
Saponin Sigma, Germany (S-7900)
Scintillation solution Roth, Germany (0016.2)
Sodium acetate MERCK, Germany
Sodium citrate Sigma, Deisenhofen, Germany
SDS (sodium dodecyl sulfate) Roth, Germany (2326.2)
Sodium N-lauryl sarcosine MERCK, Germany
Spermidine Sigma, Deisenhofen, Germany (S-0266)
TEMED Roth, Germany (2367.3)
TEA (Triethanol amine) Roth, Germany (6390.1)
Tris (Trihydroxymethyl-aminoethane) Riedel-de Haen, Seelze, Germany (33742)
Trypton GibcoBRL, Germany (50014-034)
Tween-20 Sigma, Deisenhofen, Germany (P-9416)
X-Gal Roth, Germany (2315.2)
Xylene cyanol MERCK, Germany (1.105900.0005)
Yeast extract GibcoBRL, Germany (30393-029)
2.1.2 Table 2.2 Antibodies and enzymes
Antibodies/enzymes Company (Catalog number)
Anti-CBP (A-22) sc-369 Santa Cruz Biotechnology, Inc., USA
Anti-CBP (C-1) SC-7300 Santa Cruz Biotechnology, Inc., USA
Anti-Digoxigenin-AP Roche, Gemany (1093274)
Anti-Digoxigenin-POD Roche, Germany (851299923-07)
Anti-HA (F-7) sc-7392 Santa Cruz Biotechnology, Inc., USA
Anti-p300 (C-20) sc-585 Santa Cruz Biotechnology, Inc., USA
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Cloned Pfii polymerase 
DNase I (RNase-ffee)
MMLV reverse transcriptase 
Mung Bean Nuclease 
Proteinase K
Restriction enzymes (incl. lOx Buffer)
RNase A
RNasin
Shrimp alkaline phosphatase (SAP)
Streptavidin-AP
T3-, T7-RNA polymerase
T4 DNA ligase 
T4 DNA polymerase 
T4 polynucleotide kinase 
Taq DNA polymerase 
Vent DNA polymerase
Stratagene, Heidelberg, Germany 
Roche, Germany (84105421-23) 
GibcoBRL, Germany (28025-013) 
New England BioLabs, USA (250S) 
Roth, Germany (7528.2)
New England BioLabs, USA 
GibcoBRL, Germany 
Roche, Germany 
Roche, Germany (109142)
Promega, USA (N251B)
Roche, Germany (1758 250)
Roche, Germany (85777720)
Roche, Germany (85121525- 
22/85502020-45)
New England BioLabs, USA (202S) 
New England BioLabs, USA (203S) 
New England BioLabs, USA 
Roche, Germany (1647679)
New England BioLabs, USA (254S)
2.1.3 Table 2.3 Nucleotides and nucleic acids
Nucleotide/Nucleic acid Company (Catalog number)
Deoxynucleotide (dATP, dCTP, dGTP, Roche, Germany (1277049) 
dlTP)
DIG RNA labeling mix Roche, Germany (1277073)
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DNA-Marker: X Roche, Germany (1498037)
Smart Ladder Eurogentec, Belgium (MW-1700-02)
Herring sperm DNA Roche, Germany (85346024-39)
Ribonucleotide (rATP, rCTP, rGTP, rUTP) Roche, Germany (85730020-50)
[a-^¥]-dCTP Amersham, Germany
[a-’^S]-UTP NEN Lifescience, Boston, USA
(NEG039H)
tRNA Roche, Germany (84694421-87)
2.1.4 Table 2.4 Kits and special materials
Kits and special materials Company (Catalog number)
Antifoam A Emulsion Sigma, Germany (A-6457)
Autoradiography Emulsion NTB-2 Kodak, New Haven, USA
Blocking reagent Roche, Mannheim, Germany (1096176)
BSA (Bovine serum albumin) Sigma, Deisenhofen, Germany (8076.2)
HCG (human chorionic gonadotropin) Intervet GmbH, Germany (27541)
LIQUID DAB Concentrated Substrate BioGenex, Germany (HK 153-5K)
5x lysis buffer (for transfection assay) Promega, USA (E397A)
NZ Amine (caseine hydrolysate) Sigma, Germany (A-2427)
NZY broth GIBCO, Germany (13635-024)
peqGOLD RNAPure™ peqlab, Erlangen, Germany
PMSG (pregnant mare serum Intervet GmbH, Germany (28509)
gonadotropin)
QIAprep Plasmid Purification Kit (Midi, QIAGEN, Hilden, Germany
Maxi and Endo-fi*ee)
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QIAquick Nucleotide Removal Kit 
Random primer labelling kit 
Rapid-hyb buffer 
RNeasy mini kit 
Swine serum 
Trypsin/EDTA (Ix)
Trypsin inhibitor (from soy bean) 
TSA™ Biotin System
Vector® Red Alkaline Phosphatase 
Substrate Kit I
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QIAGEN, Hilden, Germany 
GIBCO, Germany
Amersham Life Science, UK (NIF939) 
QIAGEN, Hilden, Germany 
Vector Laboratories Inc., USA (S-4000) 
0.25% trypsin, 1 mM EDTA 
(25300-054, GIBCO, Germany)
Sigma, Germany (T-9003)
NEN™ Life Science Products, Inc.,
Boston, USA (NEL700)
Vector Laboratories, Burlingame, USA 
(SK-5100)
2.1.5 Table 2.5 Commonly used media, buffers and stock solutions
Mediums/Buffers/Stock solutions Recipe
O.lx TE plus RNaseA 1 mM Tris-HCl pH 7.2 
0.1 mM EDTA
100 pg/ml heat-inactivated RNaseA
1 M Na-phosphate buffer 257.3 g/lNa2HP04.12H20 
38.5 g/1 NaH2P04.H20, pH 7.2 
autoclaved
lOx PBS 120mMNaCl 
2.7mMKCl 
7 mM Na2HP0 4
3 mM NaH2P0 4 , pH 7.4, autoclaved
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1 mM Tris-Base
0.83 mM boric acid
20 mM EDTA, pH 8.0, autoclaved
20x SSC 3MNaCl
0.3 M sodium citrate, pH 7.0, autoclaved
2x freezing medium 50 % PCS
20% DMSO, inDMEM
5x Loading buffer 20% Ficoll 400 
0.05% bromophenol blue 
0.05% xylene cyanol 
40 mM EDTA
50xTAE 2 M Tris-Base
1 M sodium acetate
50 mM EDTA (pH 8.0), autoclaved
Ampicillin (stock of ampicillin Na-salt) 100 mg/ml in 75% ethanol 
Stored at -20°C
Cell lysis buffer 10 mM Tris-HCl, pH 7.5
(for extraction of DNA from ES cells) 10 mM EDTA 
lOmMNaCl
0.5% sodium N-lauryl sarcosine 
Prior to use, add 1 mg/ml Proteinase K
Denaturing solution
(for blotting of DNA onto membrane)
0.4MNaOH
Denaturing solution (for phage screening) 1.5MNaCl
0.5MNaOH
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2 ml DEPC in 21 ddH20, shaking 
vigorously, leaving for 4 h at RT, then 
autoclave twice
Developing solution D 19 Kodak, New Haven, USA
DNase stop mix 5.5 mM EDTA
0.1 M Tris-HCl, pH 8.5
dNTP-Mix 5 mM deoxyadenosine triphosphate 
(dATP)
5 mM deoxycytosine triphosphate (dCTP) 
5 mM deoxyguanine triphosphate (dGTP) 
5 mM deoxythymidine triphosphate 
(dTTP)
E l4 complete medium 500 ml DMEM (GIBCO, Germany)
(41966-029)
75 ml FCS, heat inactivated
(210471, Boehringer, Germany)
5 ml L-glutamine (200 mM)
(25030-024, GIBCO, Germany) 
5ml penicillin (10,000 units/ml)/ 
streptomycin (10,000 pg/ml) 
(15140-114, GIBCO, Germany) 
500 pi p-mercaptoethanol
(50 mM, 31350-010, GIBCO)
60 pi Leukemia Inhibitory Factor (LIF) 
(13275-029, GIBCO, Germany)
43
Chapter 2 Materials and Methods
Fixation solution Kodak, New Haven, USA
Heat-inactivated RNaseA Dissolve 40 mg in 4 ml Ix TE, heat for 10 
minu tes at 95°C.
Let slowly cool down to RT.
Make aliquots and store at -20°C.
Hybridization buffer 0.5 M Na-Phosphate buffer, pH 7.2 
7% SDS
10 mM EDTA, pH 8.0
HyMix (for in situ hybridization) 50% formamide 
O.SMNaCl
20 mM Tris-HCl, pH 8.0 
5 mM EDTA 
10% dextran sulfate 
0.02% Ficoll 400 
0.02% polyvinylpyrrolidone 
0.02% BSA
0.5 mg/ml yeast transfer RNA 
0.2 mg/ml carrier DNA 
200 mM DTT
IPTG 100 mg/ml in H2O, sterile filtered, 
stored at -20°C
Luria Broth (LB) Medium 1.0% trypton 
0.5% yeast extract 
1.0%NaCl 
autoclaved
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Neutralizing solution (for blotting of DNA 
onto membrane)
0.2 M Tris-HCl, pH 7.5 
Ix SSC
Neutralizing solution (for phage screening) 1.5MNaCl
0.5 M Tris-HCl, pH 7.4
NTE (for in situ hybridization) 500mMNaCl
10 mM Tris-HCl, pH 8.0
5 mM EDTA, pH 8.0
NZY broth 5g/lNaCl 
2 g/1 MgS04.7H20 
5 g/1 yeast extract
10 g/1 NZ amine (caseine hydrolysate)
NZY plate NZY broth
1.5% Difco bacto agar, autoclaved
SM buffer 0.58% NaCl 
0.2% MgS04.7H20 
50 mM Tris-HCl, pH 7.5 
0.01% gelatin, autoclaved
SOC-Medium 2.0% trypton 
0.5% yeast extract 
10 mM NaCl 
2.5 mM KCl
10mMMgSO4
10 mM MgCl2 , autoclaved
20 mM glucose (sterile filtered, added
after autoclaving)
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Solution D (for RNA isolation) 4 M guanidium isothiocyanate 
25 mM sodium citrate pH 7.0 
0.5% sodium N-lauryl sarcosine 
inDEPC-HzO
Tail lysis buffer 50 mM Tris-HCl, pH 8.0 
0.1 M EDTA 
0.1 M NaCl 
1% SDS, autoclaved
TE 10 mM Tris-HCl, pH 8.0 
1 mM EDTA, pH 8.0
TENS O.lMNaOH
0.5% SDS in TE buffer
Top agar NZY broth
0.7% agarose, autoclaved
TSS Ix LB
10% PEG 8000 
5% DMSO
50 mM MgCli, adjusted to pH 6.5
X-Gal 20 mg/ml in N’-N-dimethylformamide, 
sterile filtered
2.1.6 Table 2.6 Oligonucleotide primers and probes
Sequence Position Products 
at cDNA level*
ZOl F 5'- ACC ACA ACT CCA TTT GGA CAA F 811-831
Z02 R 5'- TGC ACC AAC AGA ACC AAT TGT R 1363-1383
Including the strong TAD 
of CBP
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Z03 F 5'- GCA GGG CAA CAG AAT GCC ACT T F 1381-1402 Including the CBD of
Z04 R 5'- CGT GTC CTC CGC TTT TCT TCT A R 1991-2012 CBP
Z05 F 5'- GCT GGA AGA AGG AGA AGA CTT F 817-837 p300 sequence
Z06 R 5'- TCC ACC CAT CAG CCC TGT GTT R 1358-1378 homologous to TAD
Z07 F 5'- CTA GGT ACG GGG CTT CTA GTA F 1380-1400 p300 sequence
Z08 R 5'- GTC GGA GGA GCA CGT GAG TAA R 1958-1978 homologous to CBD
Z09 F 5'- GAA GAA AAG CGG AGG ACA CGT F 1993-2013 Downstream sequence of
ZIO R 5'- GCC ATG CTG TTC ATC TGC ACA R 2247-2267 CBD
Z ll F 5'- TTC CAC CAG CCC AGT CTG TAA F 2081-2101 Amplification of sequence
Z12 R 5'- CTG AGG CCA TGC TGT TCA TCT R 2252-2272 from exon 6 to 7
Z13 F 5'- TGC CTT TGC CAG TGA ATC GCA F 2120-2140 Amplification of sequence
Z14 R 5'- GAG GCA TCC GTG AAG GAG AAA R 2288-2308 from exon 6 to 7
Z15 F 5’- TCT CAA TGC CCT AG(G TA)A TGG F 1556-70(GTA)2111-30 Generation of mutant
GCC CCT GCC TTT GCC A (including ^ vrll) CBPACBD2-5
Z16 R 5’- TCT GGG ATT CCT AGG AGC TGA 
GGA TCT ACA
R 3345-3374 
(includingv4v/*n)
Z17 F 5'- AGA ATC AGC TCT TCC AAC TTC CTT F 1638-73; 1820-39 Generation of mutant
GGG GGC TAC CAA (exon 3) CGT TCA CBPACBD3
AGC CAT CTT CCC A
Z18 R 5’- AGA GTG CTT CTA GAG TTG GCA 
TAA GTG CCT
R 3278-3307
Z19 F 5’- AGA ATC AGC TCT TCC AAC TTC CT F 1638-1660 Generation of mutant
Z20 R 5'- TTT GTA TTT T(CG C)*GA TTT TCT 
CTGCT
R 1959-1984 CBPAla658
Z21 F 5'- GCA GAG AAA ATC (GCG)* AAA ATA 
CAA AAA GA
F 1960-1988 Together with Z18 (* for 
introduction of Ah/1 site)
Z24 F 5'- GCC GAA GCT TCT CGT GAT AAC TTC Generation of Iox66 site
GAT TAG CAT ACA TTA TAC GAA CGG T 
Z25 R 5'- ACC GGA ATT CCC GGA CTA CCG TTC 
GTA TAA TGT ATG CT
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Z26 F 5 '-GCC GAA GCT TCT CGT GTA CCG TTC 
GTA TAG CAT ACA T 
721 R 5'- ACC GGA ATT CCC GGA CAT AAC TTC 
GTA TAA TGT ATG CTA TAC GAA CGG T
Generation of lox71 site
F at loxP site Screening for 
R 15841-15865** right homology arm
Z22 F 5’- CCT CGA CAT AAC TTC GTA TAA TGT 
Z28 R 5’- ATC CAA TGT CTA TCT CAG TGT GCA
Z29 F 5'- GAC CAA GCT TGA TCC AGA ATG GCC 
GAG AAC TT 
Z30 R 5'- ATT AGC GGC CGC TAC TGT TTG GGC 
AGG TTG GGT GT 
Z31 R 5’- ATT AGC GGC CGC TAC TGC TGC TGT 
ATC AGT TTG CGT 
Z32 R 5'-ATT AGC GGC CGC TAT AGG GCA TTG 
AGA GTC CTC AT
F at the translation start codon of cDNA 
clone, including Hind III site in polylinker 
R 384-407+Aot I
Generation of MutRTSl 
R 1046-1068+Aot I
Generation of MutRTS2 
R 1548-1570+Aot I
Generation of MutRTSS
Z33 F 5'- GGT CCA GCT GGC AAA CTA AAT GAT 
GGG CTC TCA 
Z34 R 5'-AAC TCG AGT TGA TAT CAA AGA GCA 
CTA AGC AAA CAA GCT
F P v « n + 11884-11907**
Shortening of Aexon5 
R 4417-4440+EcoR V +Xho I**
Z35
Z36
F 5'- TTC TGT AGG CGG AAA GAA CCA GCT 
R 5'- AGG CAA CCA GGG TGA GGA TCA TAT
F at Neo gene 
R 13484-13507**
For screening of
Z37
Z38
F 5'- CCT CTG AAG GAG AAA CAA GCA 
R 5’- ACC ATC ATT CAT CAG TGG ACT
F 9927-9948**
R 10142-10162**
Genotyping of 
CBp®*°p^ ^
Z39 R 5'- CTC ATT AGT GTA AGC TGT AGT CT 
WithZ22
R 9633-9655** (Genotyping of floxed mice 
without neo in CBP®*°^ “^
Z40 F 5'- ATG TAA GAA CAG CCC CAA ACA 
With Z38
F 9415-9435** Check for Cre-mediated 
deletion in CBP^ °P^ ^^
Z41
Z42
F 5’- CTC TGG TAA CAT TGG AAG CCT 
R 5’- CAT CCC TTG AGA AAC CTG CAT
F 1698-1718 
R 2140-2160
Check of splicing pattern 
of inverted MutAexon5
Z43 R 5'- CTT CTA GTT CTT TTT GTA TTT TCG C 
WithZ41
R CGC+1975-96 Check of splicing pattern 
of inverted MutAexon5
48
Chapter 2 Materials and Methods
Z44 F 5’- CAT TTA TTA GCA GAG AAA ATC GCG 
WithZ42
F 1951-72+GCG CGC and GCG comprise 
the point mutation at 658
B34 F 5’-GTG GAT CGA TCC TAC CCC TTG CG Genotyping of Flipase
B35 R 5’-GGT CCA ACT GCA GCC CAA GCT TCC deleter mouse
B42 F 5’- GAT CGC TGC CAG GAT ATA CG Genotyping of Cre-
B43 R 5’- CAG CGC CAT CTT CCA GCA G deleter mouse
ZlOl 5'- ATG AAT ACT ATC ATT TAT TAG CAG 
AGA AAA
F 1940-1969 Sequence from CREB 
Ser-133 binding region
* Position at cDNA level, referring to appendix I 
** Position at genomic level, referring to appendix II
2.1.7 Table 2.7 Bacteria strains
Bacteria strains
DH 5a YfendAl, hsdR17 ( r ^ " supE44, thil, recAX, gyrA (Naf), relAVl
LE392 F' el4'(McrA') hsdR514 (r^mk^) glnV44 supF58 lacYl or
A(laclZY)6 galK2 galT22 metBl trpR55 
XL-1 Blue F ::4 recAl, endAl, gyrA96, thi-1, hsdR17, supE44, relAl, lac [F‘
proAB lacPZAMlS TnlO (Tet^]
2.1.8 Table 2.8 Plasmids
Plasmids
CRE-Iuciferase
GRE-Iuciferase
p705-Cre
Dr. Beat Lutz (Lutz et ah, 1999)
Gift firom Dr. C Behl, Max-Planck-Institute of 
Psychiatry, Munich, Germany 
Dr. F Stewart, EMBL, Heidelberg, Germany 
(Zhang et a l, 1998)
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pBluescript® KS - (pBS) 
pCAGGS-FLPe
pCEV (catalytic subunit of PKA) 
pCre-Pac
pGEM-7Zf(+)
pHD-CREB
pRc/RSV-mCBP.HA.RK
pSVaZll-PGK-Neo
pTM-loxP
pUSEFUL (containing tk gene)
Stratagene, Heidelberg, Germany (212207)
Gift from Marcus Conrad, GSF, Munich, Germany 
(Buchholz et ah, 1998)
Dr. Beat Lutz (Lutz et al., 1999)
Gift fi*om RalfKist, GSF, Munich, Germany 
(Taniguchi et al., 1998)
Promega, USA
Dr. Beat Lutz (Lutz et al., 1999)
Gift fi*om Dr. Richard H. Goodman, Vollum 
Institute, Oregon Health Science University 
(Kwok et ah, 1994)
Gift fi*om Dr. Bernhard Liischer, University of 
Zurich, Switzerland
Gift from Dr. Theo Mantamadiotis, DKFZ, 
Heidelberg, Germany
Gift from Dr. Allan Bradley, Baylor College of 
Medicine, Houston, TX, USA
2.2 Methods
2.2.1 Basic DNA/RNA methods
2.2.1.1 DNA isolation
2.2.1.1.1 Plasmid mini-preparation
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From transformation plates, one single colony was inoculated in 2 ml LB medium 
containing 100 pg/ml ampicillin, incubated with rotation at 37°C for overnight. Then 1 
ml of culture was poured into a 1.5 ml Eppendorf tube, the rest of the culture was kept 
at 4°C to make later a glycerol stock. The medium was removed by centrifugation at
13,000 rpm for 10 seconds in a microfuge (Heraeus, Germany). After pouring off the 
LB, about 50 to 100 pi of LB was left in the tube, cells were resuspended completely by 
vortexing, mixed well with 300 pi of TENS solution by inversion, 150 pi of 3.0 M 
sodium acetate pH 5.2 was added and mixed completely by vortexing. The mixture was 
put on ice for 5 minutes and a centriftigation step was performed at 13,000 rpm for 8 
minutes at RT. 400 pi of supernatant was transferred into a fresh tube which contained 
900 pi of 100% ethanol, mixed well and put on ice for 5 minutes. The plasmid DNA 
was pelleted by centrifugation at 13,000 rpm for 8 minutes at RT. The DNA pellet was 
washed once with cold 70% ethanol, and then dried for 3 minutes in a Speed Vac® Plus 
(BACHOFER, Reutlingen, Germany). The pellet was resuspended in 30 pi of O.lx TE 
containing 100 pg/ml heat-inactivated RNaseA. 2 pi of this preparation was mostly 
sufficient for a enzymatic digestion in 20 pi.
2.2.1.1.2 Large scale plasmid preparation
Plasmid DNA preparations were performed by using QIAprep Plasmid Purification Kits 
(Midi or Maxi kits for preparation of up to 100 pg or 500 pg of plasmid DNA, 
respectively; Endo-Free Maxi kit for preparation of up to 500 pg of endotoxin-ffee 
plasmid DNA) (QIAGEN, Hilden, Germany). The concentration of DNA was measured 
at OD260 nm with Spectro photometer Du®640 (BECKMAN, USA).
51
Chapter 2 Materials and Methods
2.2.1.1.3 Preparation of genomic DNA from embryonic stem (ES) cells
ES cells were cultured in gelatinized 96-well plates until cells grew to confluency or the 
medium changed to a yellow colour. The cells were washed twice with PBS. 50 pi of 
lysis buffer/well was added and plates were incubated at 50°C overnight in a sealed 
humidified box. The plates were spun briefly to save the condensation water present in 
the lid. 100 pi of precipitation solution (150 pi of 5 M NaCl plus 10 ml of cold 100% 
ethanol) was added into each well. The plates were shaken at RT for 30 minutes. After 
centrifugation at 2,500 rpm for 2 minutes, the supernatant was carefully discarded by 
inverting the plates onto paper towels. The pellets were washed three times with 70% 
ethanol. Genomic DNA was stored at -20°C in 70% ethanol until use, or air dried for a 
few minutes and then used immediately for enzymatic digestion.
2.2.1.1.4 Preparation of genomic DNA from mouse tails
Ahout 1 cm of tail in length was cut and incubated in 700 pi of tail lysis buffer 
containing 40 pi of freshly added 10 mg/ml Proteinase K overnight at 56°C in a shaking 
Eppendorf thermomixer (Eppendorf, Germany). Tail lysate was vortexed vigorously for 
5 minutes, 300 pi of 7 M NaCl solution was added, and lysate was shaken for another 5 
minutes. After centrifugation at 13,000 rpm for 10 minutes at RT, 750 pi of the upper 
phase was immediately transferred into a new tube, mixed well with 500 pi isopropanol 
by inversion and then spun at 13,000 rpm for 5 minutes at RT. Supernatant was 
discarded carefully using a pipette. Pellet was washed once with 1 ml of 70% ethanol, 
air dried for about 30 minutes and dissolved into 200 pi TE buffer by incubation at 
37°C for 10 minutes and gently vortexing. DNA was stored at -20°C until use.
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2.2.1.2 RNA isolation
RNA isolation from cultured cells. Cells were rinsed once with PBS. 4 ml Solution D 
was added to a 150 mm-dish or 1.6 ml to a 100 mm-dish. The lysate mixture was 
transferred into a Greiner centrifuge tube.
RNA isolation from animal tissues. After dissection, the tissue was homogenized. 
Solution D (1.5 ml/100 mg tissue) was pipetted into the tube containing the sample and 
grinded immediately using a Polytron. Prior to use, 7.2 pi of 2-mercaptoethanol/ml 
(final concentration 100 mM) and 12 pi Antifoam A Emulsion/ml were added to 
Solution D.
Extraction. 100 pi acidic NaOAc (pH 4.5)/ml lysate was added and shaken well. Then, 
1 ml phenol was added to the mixture, which was shaken well by inversion. Afterwards, 
200 pi of chloroform/isoamylalcohol (24:1) was added, and shaken vigorously for 10 
seconds. The mixture was chilled on ice for 15 minutes. The top (aqueous) phase was 
transferred into a new tube after centriftigation at 13,000 rpm for 15 minutes at 4°C. An 
equal volume of isopropanol was added, mixed well by inversion, and then incubated at 
-20°C for at least 2 hours. The pellet was formed by centriftigation at 13,000 rpm for 15 
minutes at 4°C, then resuspended in 500 pi Solution D. Another 50 pi of acidic NaOAc 
and 400 pi of phenol was added and mixed well by vortexing 10 seconds. 400 pi of 
chloroform was added and mixed by vortexing. The mixture was put on ice for 15 min 
and centriftiged at 13,000 rpm for 15 minutes at 4°C. The top phase was transferred into 
a new tube, mixed well with 550 pi of isopropanol, incubated at -20°C for at least 2 
hours. The RNA was pelleted by centriftigation at 13,000 rpm for 15 minutes at 4°C, 
then washed once with 1 ml ice-cold 70% ethanol and air-dried. The RNA pellet was 
resuspended in 100 pi of DEPC-H2O, and stored at -80°C.
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RNA isolation from ES cell culture with peqGOLD RNAPure reagent. ES cells 
cultured on a 10 cm-gelatinized plate was rinsed twice with PBS, then, 1.8 ml of 
peqGOLD RNAPure solution was added. The lysate was scraped, collected into a 2 ml 
tube, then mixed with 0.4 ml chloroform by inverting 15 seconds and finally incubated 
at RT for 5 minutes. After centrifugation at 12,000 rpm for 15 minutes at 4°C, 1 ml of 
supernatant was transferred carefully into a fresh tube and mixed with an equal volume 
of isopropanol. The mixture was incubated for 10 minutes at RT. The RNA was pelleted 
by centrifugation at 13,000 rpm for 10 minutes at 4°C. The pellet was washed twice 
with 1 ml 70% ethanol, air dried, resuspended in 40 pi of DEPC-H2O, and then stored at 
-20°C.
2.2.1.3 Agarose gel electrophoresis
0.8-2.0% agarose gels containing 0.5 pg/ml ethidium bromide were prepared to check 
and/or isolate DNA fragments. DNA containing Ix loading buffer was separated for 30 
minutes to overnight at about 5 V/cm in Ix TAE buffer. Gels were photographed on UV 
transilluminator.
2.2.1.4 PCR reaction
Table 2.9 Standard 50 pl-PCR reaction
H2O 36 pi
dNTPs (5 mM each) 2 pi
lOx Taq polymerase buffer (100 mM Tris- 5 pi
HCl pH 8.3, 500 mM KCl, 15 mM MgCb)
Forward primer, 10 pmol/pl 2.5 pi
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Reverse primer, 10 pmol/pl 2.5 pi
DNA template (include also a control 1 pi
without DNA!)
Taq polymerase (0.5 unit/pl) 1 pi
Conditions: 95°C, 3 min Ix
95°C, 1 min 30 to 35 times
50-60°C, 1 min
72°C, 1 min
72°C, 5 min Ix
(for Stratagene Robocycler 96)
2.2.1.5 RT-PCR
DNase treatment of RNA
Table 2.10 DNase mix ( 6  pi total)
3 pi lOx DNase buffer (200 mM Tris-HCl pH 7.2, 50 mM MgCb, 10 mM DTT)
0.25 pi RNase-ffee DNase I
0.25 pi RNasin
2.5 pi H2O
Table 2.11 DNase reaction (30 pi)
6 pl DNase mix
24 pi RNA (2-10 pg total)
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After 30 minutes incubation at 37°C, 33 pi of DNase-stop mix was added. RNA mixture 
was extracted with 70 pi of phenol/chloroform (1:1). The supernatant was transferred 
into a new tube and precipitated by adding of 1/10 volume of 3 M NaOAc (pH 5.2) and
2.5 volumes of 100% ethanol, incubating at -20°C for at least 2 hours. After 
centriftigation at 13,000 rpm for 15 minutes at 4°C, RNA pellet was washed with 100 pi 
cold (-20°C) 70% ethanol. Pellet was dried at RT for 10-20 minutes and dissolved into 
10 pi DEPC-H2O.
After DNase treatment, purification of RNA was also performed with RNeasy mini kit.
Table 2.12 RT reaction (10 pi)
2 pi 5x RT-buffer
1 pi d(N)ô ( 1 0 0  pmol/pl)
1 pi dNTP mix (5 mM each)
1 pi DTT (0.1 M)
0.3 pi RNasin
1 pi BSA (1 mg/ml)
1 pi MMLV reverse transcriptase (or H2O for control)
3 pi RNA (150-1000 ng) (denatured for 2 minutes at 70°C and chilled on ice,
quick spin in centrihige, then pipette above reagents as a pre-mix into 
this tube)
The reaction was carried out at 37°C for 30 minutes and then at 55°C for another 30 
minutes. The reverse transcriptase was inactivated by heating for 4 minutes at 95°C.
PCR. 1-2 pi of RT reaction was taken for a 50 pl-PCR reaction.
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Table 2.13 Standard digestion
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lOx incubation buffer 2  pi
lOx BSA 2  pi or not (depending on enzyme)
DNA (1 pg/pl in O.lx TE) Ip l
restriction enzyme 1 unit/pg DNA
H2O Added to 20 pi
Table 2.14 Genomic DNA digestion
lOx incubation buffer 3 pi
lOxBSA 3 pi or not (depending on enzyme)
DNA (from ES cells prepared from 1 well X pi
of a 96-well plate or 15 pg tail DNA)
RNase (10 mg/ml) 0.3 pi
Spermidine (0.1 M) 1 . 2  pi
restriction enzyme 1 0 0  units
H2O Added to 30 pi
Digestion mixture was incubated at 37°C or special temperature as product’s description 
for a proper time. Genomic DNA was generally digested at 37°C or special temperature 
at least overnight.
2.2.1.7 Blunting of DNA
Table 2.15 Fill-in of sticky ends with T4 DNA polymerase (100 pi)
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DNA digestion (ca. 2-5 pg total) 30 pi
lOx T4 DNA polymerase buffer 1 0  pi
BSA (10 mg/ml) 5 pi
dNTP mix (5 mM, each) 2  pi
H2O 51.5 pi
T4 DNA polymerase (3 units/pl) 1.5 pi
Mixture was incubated for 20 minutes at 11°C. Enzyme was inactivated by adding 2 pi 
of 0.5 M EDTA. DNA was purified by QIAquick PCR Purification kit.
Table 2.16 Removal of single-stranded extensions with Mung Bean Nuclease (50 pi)
DNA digestion (1-2 pg total) 20 pi
lOx Mung Bean Nuclease buffer 5 pi 
H2O 24.8 pi
Mung Bean Nuclease (10 units/pl) 0.2 pi
Mixture was incubated at 30 °C for 30 minutes. DNA was purified by QIAquick PCR 
Purification kit.
2.2.1.8 Table 2.17 Phosphatase treatment (20 pi)
DNA digest (about 100 ng) 3 pi
1 Ox phosphatase buffer 2 pi
H2O 13 pi
Shrimp alkaline phosphatase (SAP) (1 unit/pl) 2 pi
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Mixture was incubated 1 hour at 37°C for blunt-ends; and 10 minute at 37°C for sticky 
ends. SAP was inactivated for 15 minutes at 65°C. The reaction mix can be used for 
ligation directly, 20-30 ng of dephosphorylated vector is good for one ligation.
2.2.1.9 Ligation (20 pi reaction)
20 ng of vector was generally taken for a 20 pi standard ligation reaction. The amount 
of insert principally depends on the size ratio of vector to insert. Mostly, a molar ratio of 
between 3 and 6  (insert to vector) was taken.
Insert (ng) =20 ng x insert (bp)/vector (bp) x ratio
Table 2.18
Vector 20 ng
Insert 3-6 fold molar excess
lOx ligase buffer (supplied with ligase) 2  pi
T4 ligase 1 pi
H2O Added to 20 pi
Mixture was incubated at 16°C for overnight, or at RT for 2 hours.
2.2.1.10 Preparation of competent bacteria
A single colony of XLl blue or D H 5 a  was inoculated in 1 ml LB medium and 
incubated at 37°C overnight. 100 ml of pre-warmed LB medium was inoculated with 
the overnight culture and incubated with shaking at 37°C to ODgoonm = 0.3 - 0.4 (about 
2 hours). After centrifugation at 3,000 rpm for 10 minutes at 4°C, supernatant was
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carefully discarded, and cell pellet was gently resuspended on ice with 1 0  ml of ice-cold 
TSS solution. On ice, 250 pi and 500 pi aliquots were made in Eppendorf tubes, and 
immersed into a dry-ice/ethanol bath for a few minutes and then stored at -140°C.
2.2.1.11 Transformation
1 0  pi of the ligation reaction was mixed gently with 2 0 0  pi competent bacteria that were 
thawed on ice for about 15 minutes. The mixture was incubated for 30 min on ice, heat- 
shocked at 42°C for 90 seconds, then chilled on ice for 2 minutes. 800 pi SOC was 
added, and incubated with shaking for another 30 min at 37°C. 100 pi and 400 pi of the 
reaction mix were plated onto LB plates with proper selection antibiotic(s). Plates were 
air-dried and incubated in an inverted position overnight at 37°C.
2.2.2 Southern blot
Blot. DNA digestions were run on a 0.8% agarose gel (containing 0.5 pg/ml ethidium 
bromide) in Ix TAE buffer. After electrophoresis, gels were photographed on a UV 
transilluminator. Pre-treatment of gels was performed by the following steps: shaking 6  
minutes in 0.25 N HCl; brief rinsing of gels with distilled water; shaking 30 minutes in 
dénaturation buffer and then in neutralization buffer. Appropriate size of Hybond NX 
membrane (Amersham, USA) was immersed briefly in H2O and 15 minutes in lOx SSC 
buffer, then used for transferring DNA. Capillary blot was set up according to the 
protocol described in “Molecular Cloning” (Sambrook et ah, 1989) in lOx SSC buffer 
for about 18 hours. After blotting, the membranes were treated 1 minute in 0.4 M NaOH 
and 1 minute in 0.2 M Tris-HCl/lx SSC, were then air-dried and crosslinked under the 
condition of “autocross link” with a Stratalinker (Stratagene, Heidelberg, Germany).
60
Chapter 2 Materials and Methods
Hybridization. Rapid-hyb buffer (Amersham) and hybridization bottles were pre­
warmed at 65°C. The blotted membranes were pre-wetted firstly with H2O, then with 2x 
SSC, and placed onto nylon mesh. The membrane/mesh was rolled and put into 
hybridization bottle, then un-rolled. For the prehybridization, 10 ml pre-warmed Rapid- 
hyb buffer was required, for at least half a hour at 65°C. Afterwards, heat denatured 
(95°C, 5 minutes) ^^P-labelled probe was added into hybridization bottle directly. 
Hybridization was carried out at 65°C for 2 hours.
Washes. After hybridization, membranes were subjected to washing steps: rinsing 
briefly twice in 50 ml of 2x SSC at RT in the bottles; washing once at 65°C with 
shaking for 15 minutes in 500 ml of 2x SSC/0.1% SDS and 0.2x SSC/0.1% SDS, 
respectively; rinsing briefly once more in 2x SSC. The membranes were kept wet and 
sealed in plastic bags immediately, then exposed at -80°C for a few hours to a few days 
to autoradiographic film with an intensifying screen.
2.2.3 In situ hybridization
Preparation of riboprobes. After digestion, the linearized plasmid was extracted with 
equal volume of phenol/chloroform (1:1). After centriftigation at 13,000 rpm for 3 
minutes at RT, the supernatant was transferred into a fresh tube and added with 1/10 
volume of 3 M NaOAc and 2.5 volumes of 100% ethanol to precipitate the DNA. The 
mixture was incubated at -20°C for at least two hours and then centriftiged at 13,000 
rpm for 15 minutes at 4°C, the DNA pellet was washed once with cold 70% ethanol, 
and air-dried for a few minutes, dissolved in 10 pi DEPC-treated H2O. The 
concentration of probes was measured and then adjusted to 1.0 pg/pl with DEPC- 
treated H2O.
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Table 2.19 Labelling of riboprobes with digoxigenin (50 pi)
31.5 pi DEPC-treated H2O
5.0 pi lOx transcription buffer
5.0 pi DIG RNA labelling mix
1.5 pi linearized plasmid DNA (1.0 pg/pi)
2.0 pi RNasin (40 units/pl)
5.0 pi T3 or T7 RNA polymerase
The mixture was prepared at RT and was incubated at 37°C for 3 hours. Integrity of 
RNA was checked by running of 0.5 pi of above reaction mix on 1.0% agarose gel. The 
remaining 49.5 pi of the reaction was treated with 2 pi DNase, 1 (RNase-ffee) for 15 
minutes at 37°C.
Purification of riboprobes. The DNase-digested reaction mix was mixed well with 5 
pi of 5 M NH4OAC and 50 pi of isopropanol, incubated 30 minutes at -20°C. After 
centrifugation at 12,000 rpm for 15 minutes at 4°C, the pellet was washed once with 
cold 70% ethanol, and air-dried for 5-10 minutes. RNA was then dissolved in 20 pi 
DEPC-H2O very well by vortexing vigorously.
Quantitation of DIG-labelled riboprobes. It was achieved by using of DIG 
Quantitation and DIG Control Teststrips (Roche, Germany).
Pre-treatment. Cryosections (20 pm) were cut coronally fi*om unfixed mouse brain. 
Pre-treatment was performed as follow: fixed for 20 minutes with 4% parafomaldehyde 
(PEA) in PBS; rinsed twice with Ix PBS for 5 minutes; quenched for 15 minutes with 
1% H2O2 in 100% methanol; washed twice with Ix PBS; quenched for 8  minutes with 
0.2 M HCl; washed twice with Ix PBS; digested with 20 pg/ml proteinase K (0.4
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units/ml) in 50 mM Tris-HCl, 5 mM EDTA (pH 8.0) for 10 minutes; rinsed with Ix PBS 
for 5 minutes; fixed with 4% PEA for 20 minutes; acetylated with acetic anhydride in 
0.1 M triethanol amine/HCl (pH 8.0) (by adding of 600 pi acetic anhydride to the 
solution as it is being stirred in a hood, 3 minutes late, another 600 pi acetic anhydride 
was added. Total acétylation treatment time was up to 10 minutes); rinsed with Ix PBS 
for 5 minutes; washed with 0.9% NaCl for 5 minutes; dehydrated with 30% and 50% 
ethanol for 20 seconds each; transferred into 70% ethanol for 1 minute; passed through 
Ix 80%, Ix 95%, and 2x 100% ethanol for 20 seconds each and air dried.
Hybridization. Before adding probes to the complete hybridization mix, riboprobes 
were placed for 2  minutes into boiling water to be denatured, then spun quickly to 
remove condensation water from the cap of the tube. The probes were added to the 
complete pre-warmed hybridization mix (HyMix/10 mM DTT/ 400 U/ml RNasin) to the 
final concentration of 200 ng/ml and left at 54°C in heating block (Thermomixer, 
Eppendorf, Germany), while it is being added onto the slides. 100 pi of hybridization 
mix containing riboprobe was placed onto each slide that was covered with coverslip. 
This was done carefully to avoid the formation of bubbles over and around the sections. 
Slides were then placed into a humidified chamber containing 50% formamide/5x SSC 
and incubated overnight at 54°C.
Post-hybridization. Coverslips were removed and slides were firstly washed at 62°C 
as follow; in 5x SSC/0.05% Tween-20 for 20 minutes; 50% formamide, 2x SSC/0.05% 
Tween-20 for 30 minutes; 50% formamide, Ix SSC/0.05% Tween-20 for 30 minutes 
and O.lx SSC/0.05% Tween-20 for 30 minutes. Then slides were washed at 30°C with 
NTE/0.05% Tween-20 and twice with NTE/0.05% Tween-20.
Antibody reaction. Slides were blocked 1 hour with 4% heat-inactivated sheep serum
in TNT (0.05% Tween-20 in 100 mM Tris/150mM NaCl, pH 7.6), washed 3 times with
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TNT, and incubated for 30 minutes with NEN-TNB blocking buffer (600-700 pl/slide) 
and for 1.5 hour with anti-Dig(Fab)-POD, 1:1200 diluted in TNB (400-500 pl/slide). 
Afterwards, slides were washed 3 times with TNT, incubated for 12 minutes with 
tyramine-biotin (TB) (TSA Individual Reagent Packs) diluted 1:50 with NEN reaction 
buffer (150-200 pl/slide). Slides were washed with wash buffer (100 mM 
maleate/150mM NaCl/0.05% Tween-20, pH 7.5), incubated for 1 hour with 
streptavidine-POD antibody, 1:750 diluted with 1% Roche's blocking reagent in wash 
buffer (400-500 pl/slide), washed again 3 times with wash buffer followed by two 
washes with TNT.
Evaluation. Reaction was visualized by incubation with BioGenex-DAB substrate at 
RT for up to 40 minutes and stopped by dipping in H2O. Counterstain was performed as 
follow: staining 10 seconds in toluidin blue (0.1% in distilled H2O); twice rinsing 30 
seconds in H2O; destaining 45 seconds in 70% ethanol containing 1-2 drops of 100% 
acetic acid and rinsing again 45 seconds in 100% ethanol. Lastly, the slides were air 
dried at RT and covered with HistoFluid and coverslipped.
2.2.4 Immunostaining
8  pm thick paraffin sections were made from mouse brains. Pre-treatment was 
performed in cuvettes as follow: sections were deparaffinized in xylene twice for 1 0  
minutes; washed twice with 100% ethanol for 5 minutes, once with 95% ethanol for 2 
minutes and once with 70% ethanol for 5 minutes, then rinsed twice in H2O for 2 
minutes. After incubation for 15 min in 0.3% H2O2 in H2O (freshly prepared) at RT, 
sections were washed 3 times in PBS for 2 minutes at RT, then incubated for 30 minutes 
in 5 pg/ml saponin in H2O at RT. Afterward, sections were washed 3 times in PBS for 2 
minutes at RT. Slides were removed from the cuvette, drained quickly and encircled
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with Pap Pen. Then, slides were placed horizontally and blocked for 20 minutes in 1.5% 
swine serum/PBS in humidified chamber, washed once with PBS, incubated with 100- 
200 pi primary antibody appropriately diluted in 1% BSA/PBS overnight at 4°C or for 
60 min at room temperature in humidified chamber. Slides were then rinsed quickly 
with PBS by using Pasteur pipette and wash 3 times in PBS in cuvette. Biotinylated 
secondary antibody was added onto the slides placed horizontally and incubated for 30 
minutes at RT in humidified chamber. Slides were placed horizontally and washed 3 
times with PBS for 5 minutes, then incubated with Streptavidin-Peroxidase Complex 
(pre-incubated for at least 30 min on ice) for 30 min at RT. Slides were again washed 3 
times with PBS for 5 minutes and rinsed once with TBS (10 mM Tris-HCl, pH 7.8, 150 
mM NaCl) containing 0.5% Tween-20. Diaminobenzidine (DAB)-stain was done as 
follow: two DAB tablets and two H2O2 tablets (Sigma fast DAB tablets, D-4168) were 
dissolved in 5 ml TBS, and vortexed vigorously for 1 minute. DAB solution was added 
immediately onto sections and staining was controlled through microscope. Generally, 
staining time was 5-15 minutes. Reaction was stopped by removal of DAB solution and 
transferring slides into cuvette containing H2O. Counterstain was done with 0.1% 
toluidin blue (referring to Chapter 2.2.3, in situ hybridization). Slides were dehydrated 
in an ethanol series (70%, 95%, 100%) for 30 seconds for each step, washed once in 
xylene for 2 minutes and air dried, lastly covered with Histofiuid and coverslipped.
2.2.5 Transfection
Wild-type or mutant CBP together with CRE-luciferase or GRE-luciferase reporter 
construct were co-transfected into F9 teratocarcinoma cells with Effectene™ 
Transfection Reagent Kit (QIAGEN, Germany) to measure the luciferase activity 
induced by PKA or dexamethasone, respectively. 1.5x 10^  F9 cells/well were plated in
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6 -well tissue culture testplate {TPP, Switzerland) and treated for three days with 5 pM 
retinoic acid (RA). For each well, 3.0 pg total amount of plasmid DNA were transfected 
into RA pre-treated F9 cells, including 0.25 pg pCREB, 0.25 pg pCEV, 1.0 pg CRE- 
luciferase, 1.0 pg WT or mutant CBP, and empty vector pRc/RSV to 3.0 pg (pRc/RSV 
was obtained by Hind III and Not I double digestion of pRc/RSV-mCBP.HA, isolation 
of the 5.2 kb vector backbone, fill-in of both sticky ends and self-ligation). 16-18 hours 
later, cells were fed with fresh medium containing 5 pM RA. 2 days after transfection, 
the cells/well were lysed with 150 pi Ix lysis buffer, harvested into a Eppendorf tube. 
After centriftigation at 13,000 rpm for 10 minutes at 4°C, 50 pi of the supernatant was 
transferred into a 96-well plate for the measurement of luciferase activity in Wallac 
VictorxM  ^1420 multilabel counter (Wallac distribution GmbH, Germany).
2.2.6 Isolation of genomic CBP DNA
Genomic DNA fragments spanning CREB-binding domain of CBP were isolated from 
X phage genomic DNA libraries prepared from E14 and D3 ES cells. The libraries were 
generated by insertion of the Sau3A I partially digested fragments into A, DASH II 
phage vector digested with BaniR I, provided by Dr. Klaus Kaestner, Philadelphia, 
USA.
2.2.6.1 Preparation of host bacteria and phage
A single colony of the host Escherichia coli bacterial strain LE392 was inoculated into 
50 ml of LB medium supplemented with 0.2% maltose and 10 mM MgS0 4 . The 
bacteria were then incubated at 30°C with shaking for overnight. After centriftigation of 
the culture at 2,000 rpm for 10 minutes at RT, the bacterial pellet was resuspended
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gently in 30 ml of 10 mM MgS0 4 , then the concentration of the host bacteria was 
measured with Spectro photometer Du®640 (BECKMAN, USA) and adjusted to 
OD6oonm= 0.5 with 10 mM MgS0 4 . Definite amount of El 4 or D3 phages were used for 
screening. 1 0 0 , 0 0 0  plaque forming units (pfu) was taken for the primary screening of 
each X phage genomic library, and 1 0  times and 1 0 0  times lower numbers of phages for 
the secondary and tertiary screenings, respectively.
2.2.6.2 Absorption of phage into host bacteria
For primary screening, 22 x 22 cm^ (or 10 cm diameter dishes for the secondary and 
tertiary screenings) NZY agar plates were prepared and pre-warmed at 42°C for at least 
2 hours. The mixture of 1.8 ml LE392 (ODôoonm = 0.5) and 0.9 ml phage (appropriate 
amount of phages) was incubated at 37°C for 15 minutes, then 25 ml of top agar which 
pre-warmed at 48°C was added, mixed well and poured immediately onto each pre- 
warmed plate. The plates were cooled down at RT for 15 minutes, then incubated at 
37°C overnight.
2.2.6.3 Blotting of phage onto membranes
When phage plaques appeared to be visible in the bacterial lawn, the plates were 
transferred into 4°C for hours. Two appropriately sized Hybond NX membranes 
(Amersham pharmacia Biotech, UK) (a little smaller than 22 x 22 cm^) were prepared 
for each plate. The first one was carefully placed onto the plate, and left soaking for 2 
minutes. Meantime, for orientation of the membrane and corresponding plate, eight 
asymmetrical holes were punched through the membrane into the NZY agar plate with a 
syringe needle containing black ink. After removal of first membrane, the second one 
was placed onto the plate for another soaking of 5 minutes. Both membranes blotted
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with phage plaques were placed onto series of sheets of 3 MM filter paper (Whatman, 
USA) saturated by dénaturation solution and neutralization solution, respectively, then 
committed to dénaturation for 5 minutes and neutralization twice for 3 minutes each. 
The membranes were then submerged in 2x SSC and washed vigorously to get rid of 
proteinous debris. Afterwards, membranes were air-dried and UV crosslinked under the 
condition of “autocross link” with a Stratalinker (Stratagene, Heidelberg, Germany).
2.2.6.4 Hybridization
Hybridization buffer (referring to Tab. 2.5) and hybridization bottles were pre-warmed 
at 65°C. The blotted membranes were pre-wetted firstly with H2O, then in 2x SSC, and 
placed onto nylon meshes. The membrane/mesh stack was rolled and put into the 
hybridization bottle, then un-rolled. 2 0  ml of pre-warmed hybridization buffer was 
required for the pre-hybridization at 65°C for at least one hour. Afterwards, 
hybridization buffer was substituted with 1 0  ml of fresh hybridization buffer and heat 
denatured (95°C, 5 minutes) ^^P-labelled probe. The probes were acquired by double 
digestion of the plasmid pBS-CBP.TAD and pBS-CBP.CBD (see Chapter 3; Results) 
with HinàSl and EcdBl, then purified through the QIAquick Gel Extraction Kit. 
Quantitation of the probes was carried out by comparison of the extracted band with the 
Smart Marker on the agarose gel. 50 ng of each probe was labelled with a  ^^P-dCTP for 
2 hours at RT with Random primer DNA labelling system. Purification of probe was 
performed by MicroSpin™ S-300HR column (Amersham Pharmacia Biotech, UK). The 
probes were heat denatured at 95°C for 5 minutes, then immediately cooled down on ice 
before use. Hybridization was carried out at 65 °C for 2 hours.
After hybridization, hybridization mix (including probe) was frozen at -20°C, which 
was re-used up to 3 times (only for phage re-screening). The membranes were subjected
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to washing steps: rinsing briefly in 50 ml of 2x SSC/0.1% SDS at RT in the bottle; 50 
ml of 2x SSC/0.1% SDS at 65°C with rotating for 10 minutes in the bottle; twice in 500 
ml of O.lx SSC/0.1% SDS at 65 °C with shaking for 10 minutes; rinsing briefly once 
more in 2x SSC/0.1% SDS. The membranes were kept wet and sealed in plastic bags 
immediately, then exposed to film at -80°C with intensifying screen for a few hours to a 
few days for autoradiography.
2.2.6.5 Screening for genomic CBP DNA from phage libraries
After hybridization with CBP probe TAD and CBD, the phage plaques that showed 
signals on both membranes from the same plate were considered as positive. The 
surrounding areas (about 0.5 cm^) of the positive plaques were picked and transferred 
into Eppendorf tubes, each containing 1 ml of SM solution. The agar containing phages 
was split into pieces with tips, and incubated at RT for 3 hours. After brief 
centriftigation, 2 drops of chloroform was added into the phage supernatant for long­
term storage of phages at 4°C.
The flirther screenings were carried out as the primary screening, but with the 
differences that more diluted phage titers were plated out, and smaller surrounding areas 
of positive plaques were picked from plates. Generally, four rounds of screening were 
required for isolation of the phages, which was considered when all plaques on one 
plate were positive after hybridization.
2.2.6.6 Large scale preparation of phage DNA
To prepare a large phage stock, 5 ml of SM buffer was added into a confluent phage
plate (10 cm diameter), incubated at RT with shaking for 4 hours. Phage eluent was
collected as completely as possible, then mixed with 0.1 ml chloroform, stored at 4°C.
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After titeration, 3x 10^  pfu of each positive phage in 0.5 ml SM buffer were prepared 
and mixed with Ix 10^  host bacteria LE392 in 0.5 ml 10 mM MgS0 4  and 0.5 ml 
MgCVCaCb solution (10 mM each). The mixture was incubated at 37°C for 10 
minutes and then inoculated into 400 ml of NZCYM broth (NZY broth plus 1 g/1 
Casamino acids) and incubated at 37°C with shaking overnight until phages lysed. 0.8 
ml chloroform was added into the flask, and then incubated at 37°C for further 15 
minutes. The cell debris were spun down at 7,000 rpm for 10 minutes at 4°C in 
chloroform-resistant 500 ml-bucket, the supernatant was cleaned by filtration and 
transferred into a 1 liter-glass beaker, and 23.4 g NaCl and 40 g polyethyleneglycol 
(PEG 8,000) were added. After shaking at 37°C until complete dissolving of PEG, the 
beaker was placed in an ice-water bath for about 45 minutes to precipitate phages. 
Phages were then collected by centrifugation at 7,000 rpm for 30 minutes at 4°C. The 
phage pellet was resuspended in 6.5 ml Ix buffer A (freshly prepared by mixing of 5 ml 
lOx Buffer A, 45 ml H2O and 20.5 pi 14.63 M 2-mercaptoethanol). Phages were 
harvested as much as possible into a 50 ml-Falcon tube, incubated with 16 pi DNase I 
(10 mg/ml) and 40 pi RNase A (10 mg/ml, heat-inactivated) for 30 minutes at 30°C. 
Removal of PEG was performed by extraction once with an equal volume of 
chloroform, the mixture was shaken gently for 5 minutes and spun at 3,000 rpm for 10 
minutes at 20°C. The upper phage layer was carefully collected. In order to purify the 
phage DNA, an one-step gradient in conical polyallomer 10 ml-tube (14x89 mm, 
Beckmann, USA) was set up with the bottom layer of 0.75 ml 40% glycerol/lx Buffer 
B/6 mM 2-mercaptoethanol, the middle layer of 2.5 ml 5% glycerol/lx Buffer B/ 6 mM 
2-mercaptoethanol and upper layer of 8 ml phage solution, and centrifuged at 35,000 
rpm for 1 hour at 4°C with L8-70M Ultracentrifuge (Beckman, USA). The supernatant 
was carefully discarded, the phage pellet was resuspended into 1.6 ml of 2x ET buffer 
(40 mM Tris-HCl, pH7.5/0.1 M EDTA) and transferred into a 5 ml-cryotube (Nunc,
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Germany). After adding of 0.4 ml of 10% SDS, the suspension was incubated overnight 
at 55°C. Phage DNA was then extracted with an equal volume of phenol, 
phenol/chloroform and chloroform by gentle inversion and centriftigation at 2,000 rpm 
for 5 minutes at RT, respectively. Afterwards, the upper phase was carefully transferred 
into a ft-esh 15 ml-Falcon tube. Phage DNA was precipitated by mixing well with 2 
volume of 100% ethanol at RT. The visible DNA clump was pulled out with a bended 
glass capillary and briefly washed by dipping the clump 5-10 times in 70% ethanol, then 
dissolved into 500 pi of O.lx TE buffer. The phage DNA solution was stored at -20°C 
until use.
2.2.6.7 Sequence analysis
After restriction mapping, sbucloning and sequencing, the genomic CBP was analysed 
by using HUSAR program (Heidelberg Unix Sequence Analysis Resources, German 
Cancer Research Center, DKFZ, Germany).
2.2.7 Embryonic stem (ES) cell culture
2.2.7.1 Preparation of mouse fibroblast feeder cells
G418-resistant fibroblast feeder cells were isolated jfrom the G418-resistant C57BL/6 J- 
TgN (PGK-Neo bpA) 3-Ems transgenic mouse strain, and purchased ft-om The Jackson 
Lab., USA. The G418-resistant feeder plates were prepared same as the commonly used 
feeder plates described below.
Primary embryonic fibroblast cells were isolated fi*om mouse embryos at 14-16 days
post coitus (dpc). The pregnant mouse was killed, the uterus was isolated and placed in
a 10 cm Petri dish containing PBS. The embryos were dissected from the uterus free of
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all the extraembryonic membranes, then transferred into a new dish containing PBS and 
heads were removed. The embryos were transferred into dishes without PBS, all 
internal organs (liver, heart, kidney, lung and intestine) were removed, about 10 
carcasses were isolated in this way and put in new dishes containing PBS. The carcasses 
were then washed three times in a 50 ml Falcon tube with 35 ml PBS to remove as 
much blood as possible. After sucking off the PBS, the carcasses were transferred into a 
Petri dish (on ice) and quickly minced with a sterile scalpel. The minced bodies were 
collected in 10 ml of 0.25% trypsin/EDTA solution (GIBCO, Germany) supplemented 
with 200 pg/ml of DNase I, and incubated for 15 minutes at 37°C. A mesh was 
sterilized in boiling water for 30 minutes, then cooled down to RT, washed with PBS 
and 0.25% trypsin/EDTA solution and placed on an Erlenmeyer flask. The minced 
bodies were pressed with the syringe plunger without needle through the mesh. A total 
about 50 ml 0.25% trypsin/EDTA solution was used to flush the mesh. The elution was 
incubated with shaking for 30-45 minutes at 37°C. The cell suspension was decanted in 
two 50 ml Falcon tubes, filled up with feeder DMEM medium (same as E14 complete 
medium, but without LIF) and spun down at 1,500 rpm for 5 minutes. The cell pellet 
was washed at least twice with DMEM, and then resuspended in 10 ml feeder DMEM 
medium, and viable cells were counted using Trypan blue method (Sigma, Germany).
5 X 10^  viable cells were plated onto 15 cm-dish containing 25 ml feeder DMEM 
medium and were incubated at 37°C, 5% CO2 overnight, the next day changed with 25 
ml of fresh feeder DMEM medium. 2 or 3 days later, the fibroblast cells were 
trypsinized and split 1:5 onto new dishes for further incubation. After another 2 or 3 
days, cells were confluent and to be frozen at -80°C (about 5-10 x 10  ^cells/vial), then 
stored in liquid nitrogen.
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One vial of frozen primary embryonic fibroblast cells was quickly thawed at 37°C and 
transferred into a 15 ml Falcon tube containing 10 ml feeder DMEM medium. After 
centrifugation at 1,200 rpm for 5 minutes at RT, the cells were resuspended into 5 ml 
feeder DMEM medium. The cell suspension was distributed evenly onto five 15 cm- 
dishes each containing 25 ml feeder DMEM medium and incubated at 31°C, 5% CO2 
until cells reaching a confluent mono-layer (about 4 days). The cells were trypsinized 
and transferred in Falcon tubes. After centrifugation, the cell pellet was resuspended 
into feeder DMEM medium. The cell suspension was then distributed evenly onto 
twenty 15 cm-dishes and incubated for 3 days, then treated with feeder DMEM medium 
containing 0.01 mg/ml mitomycin C (stock one: 1 mg/ml in PBS, stored in dark at 4°C 
and used within two weeks) for 3 hours at 37°C, 5% CO2 . Lastly, cells were trypsinized 
as usual and plated onto convenient dishes at the concentration of 1 x lO"^  cells/cm^. The 
feeder plates were then fed with feeder DMEM medium, and stored at 37°C, 5% CO2 up 
to 7 days.
2.2.7.2 ES cell culture
E14 mouse embryonic stem cells originally isolated from inbred blastocysts of 129/Ola 
strain (Hooper et al., 1987), were kindly provided by Dr. Klaus Pfeffer, Department of 
Immunology, Technical University of Munich, Germany.
2.2.7.2.1 Trypslnization of ES cells
Trypsinization was performed as following: cells were washed once with Ix PBS 
(without Ca^  ^and Mg^ ,^ GIBCO, Germany). After aspiration of PBS, ES cells were 
mixed with proper amount of 0.25% trypsin/EDTA solution (Tab. 2.22) and incubated 
at 37°C, 5% CO2 for 15 minutes. Cell suspension was transferred into a 15 ml Falcon
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tube containing 10 ml E14 complete medium (see Tab. 2.5). After centrifugation at 
1,200 rpm for 4 minutes at RT, cell pellet was resupended in the medium and was ready 
for further expansion, or other purposes.
Table 2.20 Parameters of cell culture plates or dishes
Dish and plate Area (cm^) Amount of medium (ml) Amount of trypsin (ml)
15 cm-dish 145 25 7.5
10 cm-dish 56.7 10 4
6 cm-dish 20.8 6 2
6 well-plate 8.7 2.5 0.5
24 well-plate 1.9 1 0.15
96 well-plate 0.33 0.2 0.05
2.2.1.22 Thawing and expanding of ES cells
A vial of E14 ES cells (approx. l-2x 10^  cells) was quickly thawed in a 37°C water 
bath, then transferred into a 15 ml Falcon tube containing 10 ml of E l4 complete 
medium and mixed gently by inversion. After centrifugation at 1,200 rpm for 5 minutes 
at RT, the cell pellet was resuspended in 6 ml E l4 complete medium, then plated onto a 
6 cm-feeder dish, and incubated at 31°C, 5% CO2 overnight. The next day, the cells 
were washed once with Ix PBS, fed with 6 ml of fi*esh E14 complete medium and 
incubated at 37°C, 5% CO2 for another day. The cells were trypsinized and plated in an 
approximately 1:3 dilution onto a 10 cm-feeder dish, incubated at 37°C, 5% CO2 for 
another 2 days. The cells were split again onto three 10 cm-feeder dished for further 
expansion on gelatinized dishes (gelatin pre-treatment of dishes was performed by 
incubation with 0.1% gelatin for a few minutes. Afterwards, gelatin solution was
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aspirated, and dishes were filled with E14 complete medium.) for another 2 days. ES 
cells were then ready for electroporation.
2.2.T.2.3 Electroporation of ES cells, antibiotic selection, picking, expansion and 
freezing of cell clones
Electroporation of ES cells. E14 ES cells on gelatinized dishes were trypsinized and 
resuspended in PBS. After counting (Neubauer improved cell count slide, Marienfeld, 
Germany), 7 x 10^  cells in 800 pi cold PBS of E14 cell suspension was prepared and 
transferred into one 0.4 cm electrode gap gene puiser cuvette. Targeting constructs were 
linearized by digestion with proper restriction enzymes (see Construction of targeting 
vectors in Chapter 4) for overnight. Complete linearization of targeting constructs was 
checked by agarose gel electrophoresis. The enzymes were then heat-inactivated at 
70°C for 20 minutes. 20 pg in a volume of each linearized DNA was added into the 
cuvette. Electroporation was performed with the conditions of 240 V, 500 pF for about
6.0 milliseconds with a BioRad Gene Pluser. The cuvette was then incubated for 15 
minutes on ice. The cell suspension was distributed evenly onto two 10 cm-feeder 
dishes (or G418 resistant feeder dishes if Neo selection was performed) each containing 
10 ml of E l4 complete medium. ES cells were incubated at 37°C, 5% CO2 overnight.
Antibiotic selection. The day after electroporation, the medium was substituted with 
selection medium. When Neo selection gene was used, the cells were daily changed 
with E14 complete medium supplemented with 200 pg/ml geneticin G418 until 
formation of ES cell colonies ready for picking. When thymidine kinase gene was used, 
ES cells were daily changed with freshly prepared E l4 complete medium supplemented 
with 2 pM gancyclovir for 2 days, then daily changed with E l4 complete medium 
without gancyclovir until the formation of ES cell colonies ready for picking. When
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puromycin resistant gene was used, selection was performed for the first two days with 
1 pg/ml puromycin in E14 complete medium. Then, the cells were daily fed with fresh 
E l4 complete medium without puromycin until the formation of ES cell colonies for 
picking.
Picking of single ES clones. Generally, after 8-9 days of selection and growth of ES 
cells, ES cell colonies were visible and ready for picking. The cells were fed with fresh 
E l4 complete medium, and the colonies were picked with 200 pi aerosol resistant filter 
tips (USA) under the microscope (Leica MZ6, Germany) into 96 well-feeder plates 
containing fresh E l4 complete medium without any selection antibiotics, and the plates 
were then incubated at 37°C, 5% CO2 overnight.
Expansion of ES clones. One day after picking, “tryplation” was performed. Each cell 
clone was washed once with Ix PBS and trypsinized with 50 pi of 0.25% trypsin/EDTA 
at 37°C, 5% CO2 for 15 minutes. Then 150 pi of E14 complete medium was added to 
stop trypsinization. The cell clumps were pipetted up and down carefully to get single 
cells in the original 96 well-feeder plates, and cells were then incubated at 37°C, 5% 
CO2 for two days. Principally, ES cells have to be trypsinized every two-days, 
otherwise they might start to differentiate. For slower growing clones, trypsinization 
was performed every two days until reaching proper density. Finally, the ES cells were 
split into three 96 well-feeder plates and incubated at 37°C, 5% CO2 . Two days late, the 
cells of one of the 96 well-feeder plate were split again into three 96 well-gelatinized 
plates, incubated for another two days or until reaching confluency. They were then 
ready for genomic DNA extraction and later for Southern blot analysis. The cells of the 
two other feeder plates were be frozen.
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Freezing of ES clones. For freezing of ES cells in 96 well-plates, ES cells were firstly 
trypsinized as usual with 50 pi of 0.25% trypsin/EDTA at 37°C, 5% CO2 for 15 
minutes. Then, 50 pi of E14 complete medium was added to stop trypsinization, and 
cells were mixed well by pipetting up and down with 100 pi of cold 2x freezing 
medium. The plates were sealed with Parafilm (American National CanxM, USA) and 
frozen immediately at -80°C up to three months.
Expansion of positive clones. After the positive clones were examined by Southern 
blot and/or PCR, the corresponding frozen clones in 96 well-feeder plates were thawed 
quickly in a 37°C water bath, and expanded progressively on feeder cells in the order of 
96 well-plates, 24 well-plates, 6 well-plates, 6 cm-dishes and finally 10 cm-dishes. The 
cells on 10 cm-feeder dishes were trypsinized and resuspended in 2 ml of E14 complete 
medium, then, evenly distributed into four 2 ml-freezing vials (Nalgene, UK). 0.5 ml of 
ES cell suspension/vial was added and mixed well with an equal volume of pre-cold 2x 
freezing medium. The vials were immediately transferred into pre-cooled Cryo 1°C 
Freezing Container (Nalgene, UK), stored at -80°C for a few days and then transferred 
into liquid nitrogen until use.
2.2.8 Blastocyst injection
Blastocyst injection was performed as described by Hogan et al. (1994), including 
superovulation by hormone injection using pregnant mare serum gonadotropin (PMSG) 
and human chorionic gonadotropin (HCG), glass microinstrument fabrication, 
blastocyst collection, identification of pseudopregnant females, surgical transfer of 
blastocysts to pseudopregnant recipients, and microinjection of ES cells into the 
blastocoeles of C57BL/6 blastocysts.
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2.2.9 Examination of Cre-mediated inversion in ES cells
One of the correct homologously recombined ES cell lines (F3B12) from targeting 
vector CBP^^^^^^^^was expanded and finally, Ix 10  ^ES cells in 800 pi PBS buffer were 
prepared and transferred into the electroporation cuvette (Gene Pluser Cuvette 0.4 cm 
electrode gap, BioRad Laboratories, USA), mixed with 20 pg pCre-pac plasmid which 
contains the genes for Cre recombinase and puromycin resistancy driven under 
constitutive promoters. After electroporation (240 V, 500 pF), the cuvette was 
incubated for 15 minutes on ice. Cell suspension was then evenly distributed onto three 
10 cm-feeder dishes, fed with DMEM (Dulbeccos’ Modified Eagles Medium, high 
glucose, plus Na-Pyruvate) E l4 complete medium and incubated at 37°C, 5% CO2 
overnight. The cells were then daily fed for two days with fresh E l4 complete medium 
supplemented with 1 pg/ml puromycin for selection of Cre recombinase expression, 
then daily fed with E14 complete medium until formation of ES colonies. 96 single 
colonies were picked and expanded, from where two batches of cells on 96-well feeder 
plates were frozen at -80°C and three batches of cells were expanded on 96-well 
gelatinized plates for Southern blot analysis.
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Chapter 3 
Results
3.1 Expression pattern of CBP
3.1.1 Introduction
CBP is expected to be expressed in most, if not all, tissues, due to its characteristics as a 
multifunctional molecular integrator of many signalling pathways. As outlined in 
Chapter 1, the physiological roles of CBP in the cAMP-CREB pathway were to be 
investigated, for example, in the context of learning and memory. An 
immunohistological study showed that CBP is expressed in the nuclei of a large number 
of neurons and glial structures in rat brain and spinal cord. Intense CBP-labelling was 
found, among others, in the hippocampus, amygdala and the thalamus, suggesting that 
CBP may be involved in the formation of long-term memory and modulation of cortical 
activities (Stromberg et al., 1999). However, the expression pattern of CBP in the adult 
mouse brain has not yet been characterized. As the examination of the expression of 
CBP at a single cell resolution is a prerequisite for better understanding o f the 
physiological functions of CBP in mouse, in situ hybridization and 
immunohistochemistry experiments were performed.
3.1.2 Preparation of riboprobes
To determine the expression patterns of CBP and pSOO, both radioactively (^^S) and 
non-radioactively (digoxigenin) labelled riboprobes were used for in situ hybridization 
experiments. The templates were generated by RT-PCR from cDNA derived from total 
mouse brain RNA. The primers were synthesized based on the cDNA sequence
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deposited in GenBank (accession number S66385 for mouse CBP, and AF000581 for 
mouse p300). The sequence of the CREB-binding domain (CBD) from CBP and the 
related sequence from p300 were amplified by PCR with primers Z3-Z4 and Z7-Z8 (see 
Table 2.6), respectively, then subcloned into plasmid pBSII KS (-) and used as 
templates for riboprobe synthesis. The sequences were confirmed by sequencing. The 
generation of sense and antisense riboprobes for CBP and p300 are described in Table
3.1 and were made by in vitro transcription.
Table 3.1
Plasmid probe Enzyme for linearization / RNA polymerase
pBS-CBD.CBP Antisense Bind III/T7
Sense £coR I/T 3
pBS-CBD.p300 Antisense FcoRI/T3
Sense Bind III /T7
The riboprobes for CBP and p300 (including antisense and sense probes) were labelled 
with ^^S-UTP or digoxigenin-labelled UTP. The integrity of DIG probes was 
determined by 1.0% agarose gel electrophoresis, and the quantitative analysis was 
achieved by using DIG Quantitation and DIG Control Teststrips.
3.1.3 In situ hybridization with radioactive probes
In situ hybridization experiments on mouse brain sections derived from adult wild-type 
C57BL/6 mice revealed that both CBP and p300 were highly expressed in most of areas 
of the forebrain, including different layers of cortex, hippocampal CAl and CA3 
regions and dentate gyrus, entorhinal cortex, amygdala and various thalamic nuclei (Fig. 
3.1). Sections hybridized with sense control probes showed no signal.
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In situ hybridization
antisense sense
Fig. 3.1: Expression pattern of CBP and its related protein p300 using ^^S-labelled riboprobes. 
Both genes are strongly expressed in neocortex (CX), hippocampus (CAl, CA3 and DG), 
entorhinal cortex (Ent), amygdaloid (AMD) and central medial thalamic (CM) areas. Control 
hybridization with sense probes did not show any signal.
3.1.4 In situ hybridization with non-radioactive probes
As the hybridization signals obtained with radioactive probes were rather low in 
intensity, it was not possible to evaluate the expression pattern at a single cell 
resolution. Thus, digoxigenin-labelled CBP riboprobes were used for in situ 
hybridization on wild-type C57BL/6 adult mouse brain sections. As shown in Fig. 3.2, 
CBP is expressed in most of the neurons in cerebral cortex, hippocampal CAl, CA3 
pyramidal layers (pyl) and dentate gyrus (DG), but remarkably expression is not 
ubiquitous, e.g. many interneurons in the hippocampal formation do not express CBP.
Cells lacking CBP transcripts were not only found in hippocampal areas, but also in the 
neocortex. Different intensities of CBP expression levels were found in the different 
layers of the cortex (Fig. 3.2A); layers I, II, III, V and VI showed strong expression
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levels of CBP, but layer IV, eomprising mostly granular cells, showed only sparse CBP 
expression. Many cells were also found negative for CBP in white matter (WM), 
hippocampal polymorphic (pi) and molecular layers (ml) (Fig. 3.2C), and all three 
layers of the dentate gyrus (Fig. 3.2D).
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Fig. 3.2: Expression pattern of CBP using DIG riboprobe (brown staining) in cortex (visual 
cortex) and hippocampus. All sections were counterstained with toluidine blue. A. CBP is 
strongly expressed in most layers of cortex, but layer IV and white matter (WM) show sparse 
CBP expression intensities. B: CBP appears to be highly expressed in most hippocampal areas. 
C, D: Higher magnification of areas indicated in B, showing CBP expression in three layers of 
hippocampal CAl areas (C) and dentate gyrus (D), respectively, pi: polymorphic layer, pyl: 
pyramidal layer, ml: molecular layer.
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CBP expression was further examined in other regions of the limbic system. Both 
entorhinal cortex and amygdala showed rather strong expression levels (Fig. 3.3), where 
only very few CBP-negative cells were detected .
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Fig. 3.3: Expression pattern of CBP using DIG riboprobe (brown staining) in entorhinal cortex 
and amygdala. Sections were counterstained with toluidine blue. A. Both entorhinal cortex and 
amygdala areas showed strong expression level of CBP. B, C. Higher magnification of areas 
indicated in A, showing CBP-labelling in entorhinal cortex (B) and amygdala (C), respectively.
83
Chapter 3 Results
3.1.5 Immunostaining
The expression of CBP at the protein level was examined by immunostaining with a 
monoclonal antibody to the C-terminus of CBP (Santa Crus, C-1) on paraffin sections 
of adult mouse brain. All sections were counterstained with toluidine blue. Intense CBP 
labelling was found in most of the neocortex and in most principal neurons of 
hippocampal CAl/CA3 areas and granular cells of dentate gyrus. Few of the cells, 
however, were CBP-negative in the visual cortex (Fig. 3.4A, B), and hippocampal CAl 
and DG areas (Fig. 3.5A, B).
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Fig. 3.4: Immunostaining with anti-CBP antibody (brown staining) in visual cortex and
hippocampal CAl areas. Sections were counterstained with toluidine blue. A. CBP appears to 
be highly expressed in most of the neocortex and hippocampal CAl areas. B. Higher 
magnification of areas indicated in A, showing CBP expression in neocortex. Note that CBP is 
not ubiquitously expressed in cortex: the highest frequency of negative cells is found in layer IV 
(B). I to VI: cortex layers, WM: white matter, pi: polymorphic layer, ml: molecular layer.
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Fig. 3.5: Immunostaining with anti-CBP antibody (brown staining) in hippocampal CA1/CA3 
and DG areas. Sections were counterstained with toluidine blue. A. CBP appears to be highly 
expressed in most of the hippocampus. B. Higher magnification of areas indicated in A, 
showing CBP expression in dentate gyrus. Note that CBP is not ubiquitously expressed in 
dentate gyrus (B).
Immunostaining was further performed in other regions of the limbic system, such as 
entorhinal cortex (Fig. 3.6) and amygdala (Fig. 3.7), where CBP was found to be 
present in many cells.
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Fig. 3.6: Immunostaining with anti-CBP antibody (brown staining) in entorhinal cortex.
Sections were counterstained with toluidine blue. A. CBP appears to be highly expressed in 
entorhinal cortex. B. Higher magnification of areas indicated in A, showing that CBP 
expression is not ubiquitous. Few of CBP-negative cells were found in entorhinal cortex.
85
Chapter 3 Results
AKSÿ’ffl I
Fig. 3.7: Immunostaining with anti-CBP antibody (brown staining) in amygdala. Sections were 
counterstained with toluidine blue. A. CBP appears to be highly expressed in amygdala. B. 
Higher magnification of areas indicated in A, showing that CBP expression is not ubiquitous: 
few CBP-negative cells indicated by arrows were found in amygdala.
In conclusion, both CBP and p300 arc present in most of neuronal population in mouse 
forcbrain, i.c. ncocortcx, hippocampus, entorhinal cortex and amygdala, and central 
medial thalamic areas. However, CBP expression is not ubiquitous as predicted, even in 
the forcbrain region. Many CBP-ncgativc cells were found in the dentate gyrus, cortical 
layer IV and few cells in hippocampal CAl and CA3 areas. CBP expression pattern in 
protein level detected by Immunostaining was highly correlated with it in mRNA level.
3.2 Mutational analysis of CBP in vitro
Six CBP mutants were proposed for mutational analysis in vitro (Fig. 3.8). Three of 
them were generated in order to know whether it is possible to interfere with cAMP 
signalling by removing only part or all of the CBD, but to keep intact other functions of 
CBP, such as steroid hormone receptor-mediated transcriptional regulation. The 
deletion mutation CBPACBD2-5 lacks amino acids 524 to 704 (almost the whole CBD); 
CBP658Ala is a point mutation at residue 658, which fully abolishes the CREB-binding
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activity of CBP in vitro (Radhakrishnan et al., 1997); lastly, CBPllOOaa retains only 
the N-terminal 1100 amino acid residues of CBP, including the whole CBD. Another 
three mutants are so-called RTS mutants: RTSl and RTS2 are CBP mutants that retain 
only the N-terminal 136 and 357 amino acid residues, respectively. Both correspond to 
the CBP mutations found in RTS patients (Petrij et al., 1995). RTS3 is a longer 
truncated CBP mutant that retains the N-terminal 523 amino acid residues, including the 
N-terminal transactivation domain of CBP, but lacking most of the CREB-binding 
domain.
CREB Binding Domain
CBPwt
/ y / y y y y y /
y
Amino acid J |0 1 461 661 1621 1891 2163 2441
Deletion mutant y y y y
7 ^  "yA exon2-5
(CBPACBD 2-5) J /
524 704
aa 658 
☆
Point mutant 
l'yr658AIa 
(CBPAIa658)
Deletion mutant 
N-llOOaa  
(CBPllOOaa)
RTSl
R1S2
/ y
--------
y y y y /
y
y / y / /
1100
Z7
136
Z =
357
RTS3
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523
Fig. 3.8: Schematic representation of six CBP mutants. The CREB-binding domain is marked 
in yellow. Amino acid residue 658 in CBD exon 5 is indicated with asterisk. The grey and white 
areas are different binding domain to many other proteins (for further details, see Fig. 1.5).
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Wild-type CBP or these mutants, together with either CRE-luciferase or GRE-luciferase 
reporter constructs were co-transfected into F9 cells, and the luciferase activities 
induced by PKA or dexamethasone, respectively, were measured. The mutants that lack 
an intact CBD should also lack PKA-induced transcriptional enhancement through 
CRE-luciferase, but retain dexamethasone-induced enhancement through GRE- 
luciferase. By these experiments, it should be able to define which part of CBP is 
essential for its transcriptional activation through the cAMP pathway, and provide an 
evidence how to generate a CBP knock-out mouse which lacks its cAMP-mediated 
activation potential, but retains other fiinctions mediated by other transcription factors, 
this mutant mouse could let us get insight into its functions through cAMP-CREB 
pathway.
3.2.1 Generation of CBP mutants
CBPACBD2-5: a deletion mutation, in which the CREB-binding domain (CBD) 
encoded by CBD exons 2 to 5 was deleted by PCR, without affecting the rest of the 
CBP coding region. Amino acid residues 524-704 are encoded by these exons, and 
comprise almost the entire CBD of CBP. The whole cDNA clone of mouse CBP 
(pRc/RSV-mCBP.HA) (Fig. 3.9) was used as template to amplify the fragment 
containing sequence nt 1556-1570 + nt 2111-3374 (for cDNA sequence and 
coordinates, see Appendix 1) with Pfu polymerase and primers Z15-Z16 (see Table 
2.6). Z15 is a 37-nucleotides forward primer, containing 17 nucleotides (nt 1556-1570 
+ GTA) from the 3’ end of CBD exon 1 including one endogenous ^vrll site, and 
another 20 nucleotides (nt 2111-2130) located at the very 5’ end of CBD exon 6. There 
is another Avril site located on the reverse primer Z16 (nt 3345-3374). Thus, the Z15- 
Z16 PCR fragment is flanked by two Avril sites. After purification of the PCR product
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with QIAquick PCR purification kit, it was digested by ^vrll at both ends. The DNA 
fragment Z15-Z16//4vrII was subcloned into pBSllKS plasmid, which had first been 
digested by ^vrll and then dephosphorylated with shrimp alkaline phosphatase (SAP). 
The final clone was confirmed by restriction digestion and sequencing. The whole 
insert fr*om the correct clone was the subcloned into the expression vector pRc/RSV.
CBPAla658: a point mutation, tyrosine 658 was changed into alanine by overlapping 
PCR with two pairs of primers, Z19-Z20 and Z21-Z18. The fragment vdth the point 
mutation was obtained by PCR with primers Z19 and Z18, and both Z19-Z20 and Z21- 
Z18 PCR products were used as further templates. Firstly, the whole cDNA clone of 
mouse CBP (pRc/RSV-mCBP.HA, see Fig. 3.9) was used as template to amplify two 
fragments, nt 1637-1984 and nt 1960-3307, with primers Z19-Z20 and Z21-Z18, 
respectively. There are 24 nucleotides of overlap between the two PCR fragments. 
Concomitant with the point mutation Tyr658Ala generated by primers Z20 and Z21, a 
new unique Nrul restriction site was introduced. The original unique sites Sapl and 
Xbal are located in primers Z19 and Z18, respectively. Both fragments Z19-Z20 and 
Z21-Z18 were then used as templates to amplify the fragment nt 1556-3374 including 
the unique sites the Sapl and Xbal at both ends with primers Z19-Z18. The PCR 
product Z19-Z18 was purified by QIAquick PCR Purification Kit and digested by Sapl 
QXïàXbal. The DNA fragment Zl9-Zl^/Sapl-Xbal was subcloned into pBSllKS vector, 
which was firstly digested hy Xbal and then partially digested by Sapl, because there is 
one additional Sapl site in the vector backbone. The sequence of the final clone was 
confirmed by restriction digestion and sequencing. The whole insert from the correct 
clone was the subcloned into the expression vector pRc/RSV.
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Fig. 3.9: Restriction map of pRc/RSV-mCBP.HA, including whole cDNA of mouse CBP with 
the HA (hemagglutinin) tag at its 3’ end. The CBD, amino acid residue 658 and useful 
restriction sites are indicated.
CBPllOOaa: CBPllOOaa was generated by deletion o f  the whole C-terminus o f  CBP
downstream from the position o f  a unique restriction site Xbal at nt 3300. In order to
keep the HA tag at the 3’ end o f  the mouse cDNA clone in frame (referring to Fig. 3.9),
mung bean nuclease and T4 polymerase were used for removal and fill-in o f  the 5 ’
overhang after BamHl and Xbal digestions, respectively. There are two Xbal sites in
the original plasmid pRc/RSV-mCBP.HA, one is located at nt 3300 (amino acid residue
1100), another in the 3’ poly linker region; two BamHl sites are present, one is in the 5 ’
polylinker region and another between the CBP cDNA and the HA (hemagglutinin) tag;
one Hin&lll site is also located in the 5’ poly linker region. To generate CBPllOOaa,
which encodes only the N-terminal 1100 amino acid residues and the HA tag,
pRc/RSV-mCBP.HA was digested with BamHl, and the 5.2 kb vector backbone was
isolated by agarose gel electrophoresis. The fragment was treated with mung bean
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nuclease to remove the 5’ overhang, and then digested with /fwdlll. The vector 
backbone with one Hinàill sticky end and one modified BamHl blunt end was purified. 
For the insert, pRc/RSV-mCBP.HA was digested with Xbal, and the fragment 
containing the vector and the 5’ end of CBP was purified by agarose gel 
electrophoresis, and then treated with T4 polymerase to fill in the 5’ overhang. After 
purification, the fragment was digested with H in^ll. The 3.0 kb 5’ CBP fragment with 
one Hindlll sticky end and one modified Xbal blunt-end was isolated by agarose gel 
electrophoresis and purified by QIAGEN Gel Purification Kit. After ligation of this 
fragment to the vector fragment with a Hinâill sticky end and a BamYH modified blunt 
end and recovery of colonies in E. coli, the sequence of mutant CBPllOOaa was 
confirmed by restriction digestion and sequencing.
RTS mutants’, three RTS mutants were generated by PCR using the original cDNA 
clone of CBP as template. Forward primer Z29 was common to all three mutants, 
which is located approximately at the start codon of the cDNA (see Fig. 3.9), and 
includes a Hindlll restriction site located in polylinker. Reverse primers Z30, Z31 and 
Z32 (referring to Table 2.6 for the sequence and location) were used for amplification 
of CBP RTSl, RTS2 and RTS3 fragments, respectively (see Fig. 3.8 for positions of 
truncations), together with primer Z29. A unique Notl site and a stop codon were 
included in the 5’ end of these three primers, respectively. After PCR with Pfu 
polymerase, the three PCR products were digested with Hindlll and Notl, and then 
subcloned into the expression vector pRc/RSV. The correct clones were confirmed by 
restriction digestion and sequencing.
Several errors were found in the GenBank cDNA sequence of CBP (accession number 
S66385) by sequencing of the cDNA plasmid clone pRc/RS V-mCBP.HA during the 
mutagenesis experiment. Thymidine (T) at nucleotide 2008, 2477, 2871 and 2932 of
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the mouse cDNA clone were detected instead of adenosine (A) in the published mouse 
cDNA sequence. Interestingly, all these discrepancies in mouse cDNA were 
replacement of the corresponding human cDNA sequence of CBP gene.
3.2.2 Transfection assays
PKA activity is increased upon differentiation of F9 embryonal carcinoma (EC) cells, 
but cannot be activated by cAMP in undifferentiated F9 cells, although PKA is 
expressed at the protein level both by undifferentiated and differentiated F9 cells 
(Kingsley-Kallesen et ah, 1999). Furthermore, the Ser^^^-phosphorylated form of CREB 
is present in the nucleus of differentiated F9 cells, but is not detected in the nucleus of 
undifferentiated F9 cells. Thus, the differentiated F9 cells were used to test the functions 
of CBP in vitro.
CBP wild-type and two CBP mutants (CBPAla658 and CBPACBD2-5, respectively) 
were separately cotransfected into differentiated F9 cells together with pHD-CREB, 
pCEV (catalytic unit of PKA) and reporter construct CRE (CREB responsive element)- 
luciferase. Two days later, luciferase activity was measured. Both mutants significantly 
interfered with the cAMP-regulated transcription (Fig. 3.10A). Relative to levels of 
reporter gene expression obtained using 1 pg CBP, 73% CRE-luciferase activity was 
observed without any CBP added, 45% activity when the CBPAla658 mutant was used 
instead of wild-type CBP, and 50% activity when the CBPACBD2-5 mutant was used 
instead of wild-type CBP. This suggests that both mutants have a dominant-negative 
effect on cAMP signalling. This effect of CBPAla658 was dose-dependent (Fig. 
3.1GB). Increasing the ratio of CBPAla658 to wild-type CBP led to a concomitant 
decrease in CRE-luciferase activity, 70% of control activity was observed for the ratio 
0.5/1.0, and 54% for 1.0/1.0 (pg/pg).
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Fig. 3.10: CRE-luciferase activity induced by CBP wild-type and CBD mutants. A.
Cotransfection of differentiated F9 cells with CBP wild-type (CBP) and mutants (CBPAla658 
and CBPACBD2-5, respectively) together with pHD-CREB, pCEV (catalytic unit o f  PKA) 
and reporter construct CRE (CREB responsive element)-luciferase. B. Dose-dependent 
effect of CBPAla658 on cAMP pathway. Note that all data shown represent the means of three 
independent experiments, and that both CBPACBD2-5 and CBPAla658 have a dominant- 
negative effect on the cAMP signalling, and the effect of CBPAla658 was shown to be dose- 
dependent.
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In order to investigate whether the mutations that affect the CREB-binding domain, and 
still retain other functions of CBP, for example, steroid hormone receptor-mediated 
transcriptional regulation, CBP wild-type and two CBP mutants (CBPAla658 and 
CBPACBD2-5, respectively) were separately cotransfected into F9 cells together with 
the reporter construct GRE (glucocorticoid receptor responsive element)-luciferase. As 
expected, dexamethasone (Dex)-induced enhancement through GRE-luciferase was 
retained for both mutants CBPAla658 and CBPACBD2-5 (Fig. 3.11). In comparison to 
transfection of wild-type CBP (normalized as 100%), 151% GRE-luciferase activity 
was observed with CBPACBD2-5, and 142% with CBPAla658. The fact that none of 
the mutants interfer with dexamethasone induction is consistent with that wild-type 
CBP being used as a transcriptional cofactor both by GR (glucocorticoid receptor) and 
by phospho-CREB, but the mutants being used as transcriptional cofactors only with 
GR. This could also be a reason for the fact that not much difference of GRE-luciferase 
activity was observed when comparing transfections with and without wild-type CBP 
(93% activity without CBP) (Fig. 3.11).
The RTS mutants were also evaluated for their functions in the cAMP signalling 
pathway. All three RTS mutants strongly inhibited expression of CRE-luciferase, in 
contrast to the wild-type CBP (Fig. 3.12). 81% luciferase activity was observed for the 
basal level (without CBP), only 36% activity for RTSl, 18% activity for RTS2 and 28% 
activity for RTS3. This indicated that RTS mutants might have dominant-negative 
effects on CBP function in the context of cAMP signalling. Other pathways have not yet 
been tested.
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Fig. 3.11: GRE-luciferase activity induced by wild-type and mutant CBP, with (+Dex) and 
without dexamethasone (-Dex). In this experiment, the same amounts o f  wild-type and o f  
each CBP mutant were applied in different transfections. Glucocorticoid-mediated 
transcriptional enhancement was retained in both CBPAla658 and CBPACBD2-5 mutants. All 
data shown represent the means of three independent experiments.
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Fig. 3.12: CRE-luciferase activity induced by wild-type CBP and the RTS mutants.
Cotransfection of differentiated F9 cells with CBP wild-type (CBP) and mutants (RTSl, RTS2 
and RTS3, respectively) together with pHD-CREB, pCEV and reporter construct CRE - 
luciferase. Three RTS mutants displayed dominant-negative effect on CBP function in the 
context of cAMP signalling pathway. All data shown represent the means of three independent 
experiments.
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3.3 Genomic oi^anization of CBP
3.3.1 Isolation of genomic CBP DNA
To carry out gene targeting of the CBP gene, it was necessary to obtain mouse genomic 
clones of this gene. Genomic DNA fragments spanning the CREB-binding domain of 
CBP were isolated from % phage genomic DNA libraries derived from embryonic stem 
cell lines E l4 and D3. The libraries had been generated by insertion of <Shrw3AI partially 
digested fragments into XDASHII phage vector digested with BamYH, and were 
provided by Dr. Klaus Kaestner, Philadelphia, USA.
3.3.1.1 Preparation of probes for genomic DNA screening
Based on the CBP cDNA sequence available from GenBank (Accession number 
S66385), a 573-bp fragment from the transactivation domain (TAD) region (Swope et 
aL, 1996) and a 632-bp fragment from the CREB-binding domain (CBD) region (Chrivia 
et aL, 1993) of CBP were amplified by RT-PCR on RNA from adult mouse brain using 
two pairs of primers, Z1-Z2 and Z3-Z4 (see Table 2.6), respectively. The PCR products 
were subcloned into EcoRV-digested pBSII KS vector, and the subclones were 
designated as pBS-TAD.CBP and pBS-CBD.CBP. Both clones were sequenced and 
confirmed to be correct by comparison to the published CBP cDNA sequence. The 
hybridization probes were obtained by double digestion of the correct plasmids with 
Hindlll and EcdBl, purified and used for hybridization after ^^P-labelling.
3.3.1.2 Cloning, restriction mapping and sequencing of CBP
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After screening of the phage libraries, two independent phage clones containing part of 
genomic CBP were isolated. Following restriction mapping and Southern blot analysis, 
several genomic CBP restriction fi*agments were purified and subcloned into pBSII KS(-) 
plasmid vector. These smaller clones facilitated further analysis, including sequencing and 
construction of targeting vectors. All plasmid clones of genomic CBP were examined 
and confirmed by restriction enzyme digestion and sequencing. Sequencing was 
performed by MWG-Biotech (Ebersberg, Germany).
3.3.2 Genomic structure of CBP
3.3.2.1 Phage clones of genomic CBP
Several phages were identified which hybridized to the TAD and CBD probes and to 
oligonucleotide ZlOl, which is 30-nucleotides in length and is located at the 5’ end of 
exon 5 of the CBD domain (referring to Table 2.6). Together, they comprised about 28 
kb of genomic CBP sequence around the CREB-binding domain (CBD) (Fig. 3.13). 
Based on the digestion patterns and Southern blot analyses, two phage clones firom the 
E14 library (El4-1 and E l4-2) were positive for the CBD and the TAD region, while 
another three phage clones fi*om the D3 library (D3-1, D3-2 and D3-3) were positive for 
the CBD region and the oligonucleotide ZlOl. This indicated that the TAD probe 
sequence is located furthest upstream in the region covered by the E14 phage clones in a 
region where the sequence is not yet known, that the CBD probe sequence is located on 
both phage clones, and that the D3 phage clones have more downstream sequences of 
CBP.
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including 6 exons (1 to 6) in CBD region
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Q  region of genomic CBP not sequenced
Fig. 3.13: Schematic representation of part of the mouse CBP locus around the CBD region. The 
two phage clones isolated comprise about 28 kb of genomic CBP sequence. The BsaHi site used 
for ligation of the two phage inserts is marked in red. The restriction sites marked in blue were 
used for subcloning of parts of CBP into plasmid vectors, and sites marked in green were used for 
the ends of homology arms in the targeting constructs; Nhel for the left arm of the targeting 
construct CBP®*”p^ \^ DralW for the left arm of the targeting construct and Nde\ for
the right arms of both constructs. 5’ and 3’ hybridization probes for the characterization of 
targeted ES clones are indicated with black bars. Important plasmid clones are indicated by black 
lines.
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3.3.2.2 Plasmid clones of genomic CBP
I attempted to subclone the two inserts of genomic CBP into the pBSII KS plasmid 
vector, but only the insert from phage clone E l4-1 was successfully subcloned. Firstly, 
the whole insert was isolated from an agarose gel after digestion with Not I, then 
subcloned into Not I-digested plasmid pBSII KS, which had been dephosphorylated with 
shirmp alkaline phosphatase (SAP). The correct plasmid clone was confirmed by 
restriction digestions and sequencing, and named pBS.E14.CBP.
Several subclonings were carried out for fiirther evaluation of CBP genomic structure 
and subsequent construction of targeting vectors. The plasmid clones pBS-CBD.12kb, 
pBS-CBD.4kb and pBS-CBD.lOkb were derived from the E l4-1 phage clone (see Fig. 
3.13). The plasmid clone of the whole E14-1 phage insert (pBS.E14.CBP) was digested 
by Notl and Sail, then 12 kb Notl-Sall and 4 kb SaB-Notl fragments were isolated and 
subcloned into Notl and Sail double digested pBSII KS vector. The 10 kb Acc65l-Notl 
fragment was also isolated from the pBS.E14.CBP clone and sucloned into the pBSII KS 
vector. The correct plasmid clones were confirmed by restriction digestions and 
sequencing.
A BLAST search using the isolated CBP genomic sequence (from the sequencing data in 
this thesis) as a query revealed about 2.3 kb of repetitive sequences (alignment score > 
200) at 1 kb downstream of CBD exon 5 in clone D3-1. This may have been the reason 
for the failure to subclone the whole phage insert into plasmid vector. I attempted 
unsuccessfully to subclone this fragment into four bacterial strains (DH5a, XL-1 Blue, 
JM109 and SURE). The plasmids pBS-6kb, ^H^-Nhe-Spe and pBS-5kb were therefore 
designed by subcloning 6 kb and 5 kb EcoBl fragments of the D3-1 clone, respectively, 
into pBSII KS (Fig. 3.13). Plasmid clones pBS-6kb and pBS-5kb were obtained, but
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pBS-Nhe-Spe was very difficult to obtain in its full length: only subclones carrying 
truncated versions of this fragment were frequently obtained, possibly due to the 
repetitive sequence.
3.3.2.3 Structure of the CBP gene
About 23 kb of the 28 kb isolated genomic CBP were sequenced using convenient 
plasmid subclones. The sequence is depicted in Appendix II. There is only about 280 bp 
of sequence overlap between the two isolated phage clones E14-1 and D3-1, and the 
BsaHL restriction site was the only possible site (Fig. 3.13) to combine the two phage 
inserts.
By comparing this genomic sequence with the cDNA sequence, the genomic structure of 
CBP was characterized and the exon/intron junctions of CBP in the CBD region were 
determined. Eleven exons, covering 2 kb of cDNA sequence, were found in the 28 kb 
isolated from the CBP locus. Of these, six exons were identified to be located in the 
CBD region (Fig. 3.13).
As the unique Ba^ aHI site was detected in both phage clones, E14-1 and D3-1, it was 
used to combine these two phage inserts. Several convenient restriction sites were 
identified for the construction of the targeting vectors (see Fig. 3.13).
Based on the sequencing data of exon/intron junctions in the CBD region, there are two 
possible ways to delete the CBD without disrupting the open reading frame of the 
downstream sequence of CBP. One is the deletion of CBD exon 3 and the other is a 
larger deletion of CBD exons 2 to 5. Deletion of exon 2 leads to a frameshifr mutation, 
which introduces an in-frame stop codon just two amino acid residues downstream of
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CBP residue 523, thus preventing expression of the region containing tyrosine 658, 
which is critical for CREB-binding activity and is encoded by CBD exon 5 (Fig. 3.14).
CBD exon 1 (243 bp) 2 (103 bp)
1473 bp 256 bp
:::GCC CTA G GT—-AGGA AAC AAC:::ACC AAGT—AG 
Ala Leu G ly Asn Asn Thr As
amino acid 522 523 525 526 527
703 bp 837 bp
T CCA CTG ATG:::AAA CTGT—AGC GTT CAA:::AGC AGGGT—AG
n Pro Leu Met Lys Le u Val Gin Ser Arg
559 560 561 606 608 609 645 646
5(171 bp) 6 (45 bp)
422 bp
GAT GAA:::TAT::: CCAAGT--AGAT GGG CCC:::
Asp Glu Tyr Pro A sn Gly Pro
647 648 658 703 705 706
Fig. 3.14: Exon/intron structure of CREB-binding domain of CBP. There are six exons in this 
region. Deletion of CBD exon 3 or exon 2 to 5 will not disrupt the open read frame of the rest of 
CBP. Deletion of exon 2 leads to a frame shift mutation, and the new stop codon marked in pink 
will be introduced. The amino acid tyrosine 658 critical for binding of phosphoiylated-CREB in 
vitro is encoded by exon 5.
3.3.3 Targeting constructs for generation of conditional CBP knock-out mice
In order to test the hypothesis mentioned in Chapter 1 that CBP might play an important 
role on the formation of LTM, it was proposed to inactivate essential exon(s) of the 
CREB-binding domain of CBP in a tissue-specific manner by using the Cre/loxP system. 
The knowledge of the genomic structure and restriction map of the CBD region of CBP 
allowed the design of appropriate targeting constructs to introduce relevant mutations 
into the mouse germline.
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The first mutation is a deletion of CBD exon 2, which results in a ffameshift of the rest of 
CBP and the introduction of a stop codon located at the third codon downstream of 
residue 523 (Fig. 3.15A). Thus, a truncated N-terminal CBP fragment of 523 amino acid 
residues together with two C-terminal amino acid residues unrelated to CBP is encoded 
by this lesion (named CBP^ °^ ^^ )^. This mutation mimics the human genetic disease RTS 
(Petrij et ah, 1995). In the construct, CBD exon 2 was flanked by two loxP sites in a 
direct repeat orientation. The positive selection marker, phosphoglycerate kinase- 
neomycin phosphotransferase (PGK-Neo) was included between the two loxP sites and 
flanked by two FRT sites.
The second construct is a substitution of tyrosine to alanine at amino acid residue 658 in 
CBD exon 5 (CBP^ "^^ ^^ "^ '^ ), which should disrupt transcriptional enhancement through 
the cAMP pathway by abolishing binding of phospho-CREB to CBP (Radhakrishnan et 
ah, 1997). The point mutation construct (CBP^^^^^^^) was designed by using two 
mutant loxP sites (lox66 and lox71) in opposite orientations: the lox66 and lox71 sites 
flanked a sequence containing both the wüd-type exon 5 and an inverted copy of exon 5 
with the Tyr658Ala substitution (Fig. 3.15B). The PGK-Neo cassette was introduced 
between two mutant loxP sites as positive selection marker. The thymidine kinase (tk) 
cassette was placed at the end of the right homology arm as negative selection marker, 
because of the repetitive sequences downstream of CBD exon 6. And to avoid including 
these repetitive sequences in the targeting construct, only 1 kb of sequence is available 
for the right homology arm. The DNA sequence flanked by the mutant loxP sites was 
expected to be almost fully inverted and the mutated exon 5 was then put into a position 
to be transcribed and correctly spliced when the floxed mouse line was crossed with Cre 
recombinase-expressing mice.
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loxP  FRT FRT loxP 
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Fig. 3.15: Schematic representation of the two targeting constructs and their expected protein 
products after Cre-mediated recombination. PGK-Neo cassette flanked by two FRT sites are 
marked in pale blue; tk cassette is marked in yellow; CBD is marked in orange and aa 658 is 
indicated by red asterisk; Other domains of CBP are marked in grey and white (for detail, see Fig. 
1.5). A. Deletion mutant CBP®‘°p^ ^^ . B. Point mutant CBP^^^ '^^®
3.4 Probes for screening for correct homologous recombinants
As described below in sections 3.5.1 and 3.6.1, both constructs share the same probes 
for diagnosis of correct homologous recombination.
3.4.1 Preparation of probes
5’ probe. The clone pBS-CBD.12kb was digested with Acc65l and Sad, then the 1.4 
kb fragment (Fig. 3.13) was isolated using agarose gel electrophoresis and purified using
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a QIAGEN gel extraction kit. Both sticky ends of the fragment were made blunt using 
T4 polymerase. The 1.4 kb fragment was then subcloned into «Swal-digested pBSII KS 
to give pBS-5’-probe. The 5’ probe was obtained by double digestion of pBS-5’-probe 
with BamHl and Pstl followed by purification of the 1.4 kb fragment.
3’ probe. The clone pBS-CBD.6kb was digested with Seal and EcoBl, and the 820 bp 
fragment (Fig. 3.13) was isolated and purified. The EcoBl end of the fragment was made 
blunt using T4 polymerase. The 820 bp fragment was then subcloned into 6'marl-digested 
pBSII KS to give pBS-3’-probe. The 3’ probe was obtained by double digestion of pBS- 
3’-probe with BamHl and Pstl followed by purification of the 820 bp fragment.
Neo probe. The clone pBS-PGK.Neo (obtained during the cloning steps of the targeting 
constructs) was digested with Xbal. A 300 bp fragment from the neo gene (see Fig. 3.26 
and 3.43) was then purified and subcloned into A%al-digested pBSII KS to give the 
plasmid pBS-Neo-probe. The Neo probe was obtained by double digestion of pBS-Neo- 
probe with Natl and Pstl followed by purification of the 300 bp fragment.
3.4.2 Qualitative analysis of probes
Reverse Southern blotting was used to test whether the probes used contained repetitive 
sequence. Phage clones E l4-1 and D3-1 were digested with different restriction 
enzymes, including the digestions used for generation of the 5’ and 3’ probes. Blots of 
these digests were hybridized with ^^P-labelled genomic DNA from the 129/Ola mouse 
strain. Control DNAs (clones p i2/3 SN6000 and p i2/3 NS9000, from the orphan 
nuclear receptor Ear2 gene, obtained from Dr. Beat Lutz) were included in the analysis, 
as it was known that these clones contain some repetitive sequences.
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Fig. 3.16: Qualitative analysis of the diagnostic probes using a reverse Southern blot. A. 
Agarose gel electrophoresis of different digestions of GBP phage clones. B. Reverse Southern 
blot pattern obtained with ^^P-labelled genomic 129/Ola DNA. Lane 1 and 18 are marked in red 
and are the two control DNAs, SN6000/AZ)aI and NS9000/EcoRI, respectively; lanes 2-17 are 
different digestions of the two CBP phage clones. Among them, lanes 8 and 17 marked in blue 
are Acc6S\-Nhe\ digestion of phage E l4-1 and EcoRl-^crzl digestion of phage D3-1, which 
contain the 5’ probe and 3’ probe, respectively. Note: lane 8 showed a positive band of 1.8 kb, 
indicating repetitive sequences. No positive band of 0.8 kb was found in lane 17, therefore, the 3’ 
probe is good for Southern blot screening. Refer to Fig. 3.13 for a restriction map that shows the 
sites cut by the relevant restriction enzymes.
105
Chapter 3 Results
A reverse Southern blot with ^^P-labelled mouse strain 129/Ola genomic DNA showed 
that the two control DNA samples showed hybridization signals as expected, that the 3’ 
probe is good for Southern blot screening, while the 1.8 kb Acc65\-Nhe\ fragment 
contains repetitive sequences (Fig. 3.16). The 5’ probe was obtained by ^ cc65I and Sad  
double digestion of pBS-CBD.12kb, excluding a 0.4 kb Sad-Nhd  fragment (referring to 
Fig. 3.13). This 1.4 kb fragment was conhrmed to be devoid of repetitive sequences by a 
reverse Southern blot and a BLAST search (data not shown).
3.5 Generation of CBP * knock-out mouse
3.5.1 Construction of the targeting vector
To generate a mouse model for the human genetic disease RTS, targeting vector 
(^ gpstop523 3 17 to 25) was constructed, in which CBD exon 2 was flanked by two 
loxP sites, leading to deletion of whole CBD exon 2 and a frameshift, and introduction of 
a new stop codon. A truncated protein with only N-terminal 523 amino acids of CBP is 
encoded by this mutation. To achieve this, two loxP sites in the same orientation were 
introduced 5’ and 3’ of exon 2 in the targeting vector. A PGK-Neo cassette was also 
introduced as a positive selection marker. ES cells containing this antibiotic resistance 
gene have the ability to survive in the presence of the neomycin derivative geneticin 
(G418). The integrity of the final targeting vector was confirmed by sequencing of all 
critical regions, i.e. loxP sites, FRT sites, exons and cloning junctions.
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Fig. 3.17 Subcloning of PGK-Neo cassette flanked 
by two FRT sites into pBlueScript vector 
DBS II KS(-)
Fig. 3.18 Combination of PGK-Neo cassette with 
loxP
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Fig. 3.19 Subcloning of loxP-PGK-Neo into
pGEM-7zf(+) to introduce a diagnostic 
AccGB  I site
Fig. 3.20 Subcloning of loxP into pGENI-7zf(+) to  
introduce a diagnostic EcoR I site
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Fig. 3.21 A insertion of loxP-PGK-Neo into CBD intronl
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Fig. 3.21 B Insertion of exon 1-loxP-PGK-Neo into 
CBD intronl
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Fig. 3.22 A Insertion of loxP into CBD intron2 Fig. 3.22 B Insertion of exon 3 and 4
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Fig. 3.23 Extension of the left homology arm
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Fig. 3.24 Combination of C B P  fragments from two 
phage clones
There is one BsaH I site in both CBP genomic fragments 
from two phage clones, and additional one BsaH I site 
exists in the vector bone. Thus, a three fragment ligation 
w as made to achieve it.
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Fig. 3.25 Final construct of
Extension of the right homology arm
G enotyp ing  o f c o n s tru c tio n  o f
Linearization: S a c  II digestion
5’-diagnostic enzyme: A cc65  I
WT: 11.6 kb 
Mut: 7.0 kb 
3’-diagnostic enzyme: EcoR I
WT: 8.8 kb
Mut: 6.8 kb
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homologous recombination and random integration:
S a /1-Sea I: 10 .4 kb
#  : loxP site
0 : FRT site
I .. I : PGK-Neo cassette
 I : repetitive sequence downstream of
CBD region of CBP gene
Fig. 3.17 to 25: Flow chart of construction of the targeting construct. CBD exon 2 is
flanked by two loxP sites in the same orientation. The PGK-Neo cassette, flanked by two FRT 
sites in the same orientaion, is included between the two loxP sites as a positive selection marker.
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3.5.2 Screening for the homologous recombinants of the targeted allele
100 [ig of the targeting construct (Fig. 3.25) was fully linearized by Sac II
digestion and confirmed by agarose gel electrophoresis. 20 pg of the linearized clone was 
electroporated into mouse E14 ES cells. After nine days of G418 selection (200 pg/ml), 
resistant colonies were visible. 300 single colonies were picked into 96-well feeder 
plates, and then expanded on 96-well feeder plates for fi*eezing and on 96-well 
gelatinized plates for Southern blot analysis. The screening strategy is shown in Fig. 
3.26.
_  . ,   ^ AccSS ITargetingVector EcoR I
I FRT FRT I
1 I #  IlkK-Nejn h i  É  1:1
.  loxP
Genomic CBP
Acc65 I sa / i  EcoR I
loxP
EcoR I
^ cc6 5  I
Seal
i n 3 n HE
Targeted CBP locus ^^^5 , 
' Sal I EcoRi EcoR!
É. lEpGK^ ecLll LgJ V kml
EcoR I
Acc65 1 
Seal
HE Is!  ra h
I Neo probe io.4 kb
W T II .6 kb
Mutant 7.0 kb
WT 8.8 kb
5’ probe Mutant 6.8 kb
3’ probe
Fig. 3.26: Schematic representation of homologous recombination between the targeting
construct and CBP gene locus. Diagnostic patterns of restriction fragments are also
indicated: the 5’ probe with Acc65l digestion was used for screening for correct homologous 
recombination of the left arm, the 3’ probe with EcoRl digestion for correct homologous 
recombination of the right arm, and the Neo probe for exclusion of random integration events. 
Note: Fragment sizes are not drawn to scale.
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A. 3’ probe screening
WT 8.8 kb — >
MUT 6.8 k i/  ^
B. 5’ probe screening
WT 11.6 kb
MUT 7.0 kb
C. Neo probe screening
10.4 kb
Fig. 3.27: Screening for correct recombinants of the targeting construct using
Southern blot analysis. A. Screening for the correct right arm with the 3’ probe. Digestion with 
EcoRA gives an 8.8 kb band for the wild-type allele and a 6.8 kb band for the mutant allele. B. 
Screening for the correct left arm with the 5’ probe. Digestion with Acc65I gives an 11.6 kb band 
for the wild-type allele and a 7.0 kb band for the mutant allele. C. Screening of 9 clones with the 
mutated 5’ and 3’ fragments for non-random homologous recombination with the Neo probe. 
Digestion with SaR and Seal shows one single band of 10.4 kb, and no additional bands were 
visible. Note: A, B and C are not duplicate blots, but contain DNA from different subsets of 
G418-resistant cell lines.
I l l
Chapter 3 Results
As the PGK-Neo selection cassette was inserted into CBD intron 1, and close to the left 
homology arm, it is more likely that G418-resistant ES cell clones, whether or not they 
arose by homologous recombination, will include the left homology arm. Thus, the 3’ 
probe for diagnosis was first used for the primary Southern blot screening with EcdRl- 
digested genomic DNA. The strategy and results of screening for the homologous 
recombinants of CBP^ ®^ ^^  ^are shown in Fig. 3.27.
Southern blot analysis showed that 9 of 300 (recombination efficiency: 3%) picked 
clones gave the expected pattern of one 8.8 kb wild-type band and one 6.8 kb targeted 
band. A further Southern blot analysis ofAcc651 digestions using the 5’ probe revealed 
that all these 9 positive clones showed one wild-type 11.6 kb and one targeted 7.0 kb 
band (see Fig. 3.26 for predicted restriction map). These 9 positive clones were further 
subjected to Southern blot analysis to examine possible random integrations, but all 
showed one single band of the expected size of 10.4 kb after Sail and Seal double 
digestions and hybridization with Neo probe. Therefore, these 9 ES cell clones were 
good candidates to be injected into blastocysts for the germline.
3.5.3 Mating for germline transmission
E14 cells were originally derived fi*om the 129/Ola mouse strain. Therefore, injection of 
these cells into C57BL/6 blastocysts will yield chimeras which can manifest coat color 
chimerism. The alleles of coat color genes that are present in 129/Ola are as follows: 
Agouti, which is paler than A and encodes agouti color; Albino, (Chinchilla) 
which displays a reduction of tyrosinase activity and a reduction of deposition of yellow 
and, to a lesser extent, black pigment. The alleles carried by C57BL/6 are: Agouti, a 
which displays plain black pigment; Albino, + .^ Thus, chimeras contain a
112
Chapter 3 Results
creamy/brownish color on black. Mating of the chimeras with C57BL/6 mice results in 
E14-derived agouti colored pups and C57BL/6-derived black pups. As all the ES cell 
lines are male, germline transmission is usually through male chimeras.
Four E14 cell clones (SA6, S3A3, M2C4 and M2D6) positive for the targeted 
allele were selected for injection into C57BL/6 blastocysts. The percentage of E14- 
derived coat was evaluated based on coat colour of the chimeras. The result of blastocyst 
injection of the targeted CBP^ °^ ^^  ^cell lines is summarized in Table 3.2.
Table 3.2 Summary of blastocyst injections of the tai^eted CBP ES cells
Cell clone
Number of 
injected 
embryos
Number of 
bom pups
Number of chimeras 
(% of E14-derived coat)
Germline
transmission
SA6 197 17 3 (10, 20, 20%) No
S3A3 107 4 1 (50%) No
M2C4 212 22 5 (10, 40, 50, 80,100%) Yes
M2D6 126 9 2 (50, 60%) No
Eleven mice (6 males and 5 females) with 10-100% E14-derived coats were bom, and all 
were mated at the age of 8 weeks with wild-type C57BL/6 mice to check for germline 
transmission. Only one male with 40% of its coat derived from E l4, from cell line 
M2C4, gave agouti pups. About 1 cm of tail was cut from 3 week-old offspring of 
chimeras for genotyping. Germline transmission of the targeted allele was examined by 
PCR of the tail DNA with the primers Z37 and Z38 (referring to Table 2.6). Six of 9 
agouti pups were confirmed to contain the mutated CBP allele (Fig. 3.28A, B). Forward 
primer Z37 is located in CBD exon 2 and reverse primer Z38 at the end of CBD intron 2.
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A 230 bp fragment was amplified from the wild-type allele. Because of the insertion of 
loxP, a 300 bp fragment was amplified in the mutated CBP allele. Both bands were easily 
distinguishable on a 2.0% agarose gel (Fig. 3.28C). A single lower 230 bp band indicates 
mice homozygous for wild-type CBP, two bands (230 and 300 bp) indicate a 
heterozygous CBP^ °^ ^^  ^ genotype, and a single 300 bp upper band indicates 
homozygosity for the CBP^ °^ ^^  ^allele.
A. Targeted allele
0  0  p  s to p 5 2 3
Z37
loxP —► loxP
------------------ 1 111 #  [t ]roK^ Ueo[[] I2l $ lit H E
FRT FRT
Z38
300bp
B. Wild-type CBP
Z37
3Ü m  M-
Z38
230 bp
0. PCR with Z37-Z38
M 1  2 3 4  5 6  7 8  9 w t P N
Mut 300 bp 
WT 230 bp
Fig. 3.28: Examination of the germline transmission of the targeted CBP®*®^^^  ^ allele by PCR. A. 
Targeted CBP °^^^^  ^ allele. B. Wild-type CBP allele. C. Testing for germline transmission by 
PCR using primers Z37 and Z38, six of 9 agouti samples (1 to 9) show a 230 bp band for the 
wild-type allele and a 300 bp band for targeted allele. M: DNA marker, wt: wild-type mouse 
genomic DNA, P: the final plasmid clone of the targeting construct as positive control, N: H2O as 
negative control.
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3.5.4 Generation of a mouse model for human RTS
Crossing with Cre deleter mice. Three heterozygous males with the targeted 
allele were crossed with a Cre deleter mouse line (Schwenk et al., 1995), in which Cre 
recombinase is expressed under the control of the human cytomegalovirus (CMV) 
minimal promoter sequence (Pbw) (Baron et al., 1995). The Cre deleter mice highly 
express Cre recombinase in almost all types of tissues, including germ cells. The Cre- 
mediated excision was checked by PCR of tail DNA using primers Z40 and Z38. A 
control PCR was also included using primers Z37 and Z38 (Table 2.6; Fig. 3.29A,B). 
The forward primer Z40 is located in CBD intron 1 and the reverse primer Z38 in intron 
2. These primers amplified a 750 bp fi*agment firom wild-type mouse genomic CBP, and a 
260 bp fi*agment fi*om the targeted allele in which CBD exon 2 and PGK-Neo cassette 
were excised by Cre recombinase. In principle, a 2.6 kb band fi*om the targeted allele 
which contains CBD exon 2 and PGK-Neo cassette should also be amplified if Cre- 
mediated excision did not occur. However, this fi*agment was too big to be amplified 
simultaneously with the other firagments (Fig. 3.29C).
The genotyping of the progeny of this cross was performed by PCR using primers Z40 
and Z38. Only 1 of 24 pups fi*om 3 litters was positive for the Cre deletion. The DNA 
fi*om this mouse (#62) was used as template for another PCR using primers Z37 and Z38 
to confirm the excision (Fig. 3.29D). Because of the mosaic situation of deleted and non­
deleted CBD exon 2, FI offspring still contain the 300 bp band of the targeted allele. The 
positive FI offspring (#62) was further mated with C57BL/6 mice to obtain non-mosaic 
mice heterozygous for the Cre-mediated deletion.
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A. Cre-mediated recombination of targeted alleie
Z40 Z37
—►  loxP - ►  loxP
I a  I U 1 I s  I IfiL >
FRT FRT
Cre recombinase
300 bp
la!..- -{41 I s .I Id h
260bp Z38
B. Wiid-type CBP ^40 Z37 230bo
ZE IK.
Z38
750 bp
0 . Z40-Z38 D. Z37-Z38 Z40-Z38
M wt 57 58 59 60 61 62 63 M N Tg 62 63 N’ 62 63
750bp 
^ 260  bp
750bp 
300 bp
260 bp 
230 bp
Fig. 3.29: Examination of Cre-mediated excision in the targeted allele by PCR. A.
Targeted CBP®‘°*’^ ^^  allele in which CBD exon 2 and PGK-Neo cassette are excised by Cre 
recombinase. B. Wild-type CBP allele. C. Testing for Cre-mediated deletion by PCR with 
primers Z40 and Z38. The 260 bp band results from deletion of CBD exon 2 (mouse #62) and 
the 750 bp band from wild-type genomic CBP (the others). D. The control PCR with primers 
Z37 and Z38 shows the 300 bp band for the targeted allele, and the 230 bp band from wild-type 
genomic CBP. M: DNA marker. N and N ’: H2O as negative controls for the two pairs of primers 
used, wt: tail DNA from wild-type mouse. Tg: tail DNA from the targeted CBP®*®^^^  ^ mouse. 
Numbers 57 to 63: tail DNA from the FI offspring from the mating of the targeted mice with Cre 
deleter mice.
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Two of six F2 offspring examined were shown to be heterozygous for the CBD exon 2 
deletion, using PCR with primers Z40 and Z38. Control PCR with primers Z37 and Z38 
indicated that mice #291 and #292 are non-mosaic heterozygotes (Fig. 3.30), as both 
mice show only the 230 bp band of the wild-type allele. This allele was named CBD2. 
Meanwhile, the presence of Cre recombinase was also examined by PCR using primers 
B42 and B43 which gave about 600 bp fragment for Cre recombinase (data not shown).
Z40-Z38 Z37-Z38
M N 62 63 291 292 N' 62 63 291 292
750 bp
y 300 bp
<4------ 260 bp
^ 2 3 0  bp
Fig. 3.30: Genotyping of F2 mice obtained after Cre-mediated deletion. Primers Z40-Z38 were 
used to check for Cre-mediated deletion, Z37-Z38 were used to check both for the presence of the 
3’ loxP site and the wild-type CBP allele (Fig. 3.29). M: DNA marker, N and N ’: negative 
controls for the two pairs of primers used, Numbers 62, 63: Tail DNA from FI offspring of Cre- 
mediated excision. Numbers 291, 292: Tail DNA from F2 mice that were progeny of FI mouse 
#62. Note that the FI mouse #62, positive for Cre-mediated deletion, is mosaic, as control PCR 
using primers Z37-Z38 still shows the 300 bp band from the targeted allele. While the F2 
offspring (named CBD2) are non-mosaic heterozygous mice, as the control PCR only shows the 
230 bp band from the wild-type allele.
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3.5.5 Generation of mice lacking the Neo cassette
In addition to generating mice carrying the CBD2 allele, which should express 
in all tissues, I wished to generate mice in which tissue-specific Cre expression could be 
used to express this product only in specific tissues. However, the Neo selection marker 
gene should be removed firom the targeted allele before mating with different Cre- 
expressing mouse lines to generate conditional CBP knock-out mice, since the Neo 
cassette inserted into an intron of the CBP gene might inflence its expression. Several 
mice heterozygous for the targeted CBP^ ®’’^ ^^  allele were crossed with “Flp-deleter” mice 
in which Flp recombinase is ubiquitously expressed under the control of the human p- 
actin gene (h/4C7ff) (Dymecki, 1996). Because of the rather low efficiency of FIp- 
mediated recombination, FI mice are likely to be mosaic. Therefore, these mice were 
mated with C57BL/6 mice to allow screening for non-mosaic heterozygous F2 mice, 
named CBD2.floxed mice. Removal of the Neo cassette was determined by PCR of tail 
DNA with primers Z22 and Z39 (Table 2.6; Fig. 3.31). Firstly, mice that still retained the 
Neo gene were identified as being negative in this PCR reaction. Crossings between 
these mice were performed to generate mice homozygous for the construct that still 
retained the Neo gene (CBD2.fioxed.neo), which can be used to analyse possible 
mutagenic effects of the Neo cassette (Artelt et ah, 1991; Fiering et ah, 1993; Rijli et aL, 
1994) on CBP expression. Secondly, sixteen of 115 FI generations were detected as 
positive for Neo deletion by PCR, showing a fi*agment 220 bp for the deletion using the 
same primers (Fig. 3.31).
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A. Flp-mediated recombination in targeted CBP
Z22
- ►  FRT FRT
---------------------1 1 1 1 $  U  PGK-Neo [f l j l l ________L l l ...............[£:
sto p 5 2 3
H
loxP loxP
Z39
> 2  k b Flp recombinase
Z22
m o t r g  m . *  h i
Z39
B.
2 2 0  b p
M N 81 82 83 84 85 86 87 88
220 bp
Fig. 3.31: Examination of Flp-mediated excision in the targeted allele by PCR with
primers Z22 and Z39. A. Targeted allele in which PGK-Neo cassette is excised by Flp
recombinase. B, Testing of Flp-mediated deletion by PCR with primers Z22 and Z39. This 
shows a 220 bp band for mouse numbers 81, 83 and 86. Numbers 81 to 88: Tail DNA of FI 
offspring from the mating of targeted mice to Flp-deleter mice. M: DNA marker, N: H^O as 
negative control.
The presence of Flp recombinase was also measured by PCR using primers B34 and B35 
(Table 2.6) which give a 750 bp fragment (data not shown). After Flp-mediated 
recombination, it is advisable to get rid of Flp from the floxed mice, as homozygosity for 
Flp leads to mouse embryonic lethality (Baur et a l, 2000; Dymecki 1996). Therefore, the
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F2 offspring positive for Flp-mediated deletion were fiirther mated with wild-type 
C57BL/6 mice.
/
3.5.6 Towards the generation of a tissue-specific mouse mutant
In order to generate the tissue-specific CBP knoc-out mice, I planned to use transgenic 
mice in which Cre expression is driven by the CaMKIIa promoter. Expression of Cre 
starts postnatally in forebrain neurons, mostly in the hippocampus, the brain region 
essential for learning and memory, in the first 3-4 weeks when many neural circuits have 
already been formed (Burgin et ah, 1990). Therefore, recombination and CBP-deficiency 
wiU occur in forebrain neurons postnatally. This will avoid developmental defects caused 
during neurogenesis, as observed in conventional knock-outs of CBP (Tanaka et al., 
1997; Oike et al., 1999a; Kung et al., 2000). We wül therefore be able to analyse the 
mutants in learning and memory paradigms. A transgenic mouse line has been obtained 
from Prof. Schütz (DKFZ, Heidelberg) which carries a bacterial artificial chromosome 
(BAG) covering the CaMKIIa gene locus and which expresses Cre recombinase under 
the control of all regulatory elements of the CaMKIIa gene. I am currently in the process 
of accumulating CBD2.floxed/CBD2.floxed mice (see section 3.5.5) for crossing to the 
CaMKIIa-Cre mouse fi'om Prof. Schütz.
3.5.7 Preliminary phenotypic analysis of mice
Developmental defects of heterozygous mice. After Cre-mediated excision,
only one mouse had earlier been shown to be mosaic for CBP^ °^ ^^  ^ heterozygosity (Fig. 
3.29). Presumably because of its mosaic status, this FI mouse did not display any 
apparent phenotype. When further mating of this FI mouse with wild-type C57BL/6 was
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performed, only two of the 15 F2 progeny were confirmed to be heterozygous for CBD 
exon 2 (CBD2)-deletion by PCR (Fig. 3.30). Clearly, the heterozygous mutant mice 
were under-represented among weaned pups according to the Mendelian inheritance 
rule, and this situation had actually been observed in the mosaic status. Either a fraction 
of the heterozygous embryos probably died in utero or less CBD2 deletion was existing 
in mosaic FI than non-CBD2 deletion. The heterozygous F2 mice (CBD2 )
were profoundly smaller than the wild-type littermates (Fig. 3.32). One of them died at 
the age of 4 weeks.
CBD 2*'* CBD 2*''
Fig.3.32 Comparison of heterozygous mutant mouse (CBD2^") with its wild-type
littermate at the age of 5 weeks.
Investigation of embryos suggested that a fraction of heterozygous embryos died in 
utero. In total, 8 of 19 (42%) of analyzed embryos were shown to be CBD2^ by PCR 
(50% expected). Four of 10 embryos were CBD2 " in one mouse, and 2 of them died 
and started to be absorbed at E l0.5; Four of 9 embryos at E8.5 in another mouse were
1 2 1
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CBD2^ ', no dead embryos were found. This indicates that the lethality in heterozygous 
CBD2 mutants occurs after E8.5.
3.6 Generation of knock-out mouse
3.6.1 Construction of the targeting vector CBP^^^^^
The targeting vector (Fig. 3.33 to 3.42) was constructed by introduction of a
tyrosine to alanine substitution at residue 658 in CBD exon 5. The two loxP mutants 
lox66 and lox71 (see Fig. 1.8) flanked the sequence containing the wild-type exon 5, the 
inverted exon 5 with the Tyr658Ala point mutation, and the PGK-Neo cassette as a 
positive selection marker. According to BLAST searches, there is about 2.3 kb repetitive 
sequence in CBD intron 6 (referring to Fig. 3.37), therefore, only 1 kb of sequence is 
available for the right homology arm of construct CBP^^^^^^. In order to increase the 
efficiency of the homologous recombination in surviving clones and to decrease random, 
non-homologous integration, the thymidine kinase (tk) gene was also included at the end 
of the shorter right homology arm as a negative selection marker. ES cells that do not 
contain any random integration do not contain the tk cassette and therefore have the 
ability to survive in the presence of 2 pM Gancyclovir.
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Generation of two loxP mutants 
pBS-lox66 and pBS-lox71:
Primer Z24-Z25 were used to amplify the lox66 site 
with Hind III and EcoR I recognition sites at both 
ends, then subcloned into pBS II KS(-)/ffi«d lII-EcoR 
I.
Primer Z26-Z27 were used to amplify the lox71 site 
with Hind 111 and EcoR I recognition sites at both 
ends, then subcloned into pBS II KS(-)//7md lU-EcoR 
I.
Symbols used for the construction:
D FRT site loxTf
1 I PGK-Neo (3^ lox66
Sal S a c  II
Hind III EcoR
pBS-PGK-Neo
S m a  I S al I, blunted
SacSac II
Xho  I EcoR V EcoR I
4K HH*-
pBS-PGK-Neo-lox71 
5-1
Fig. 3.33 Cloning of lox71 into pBS-PGK-Neo:
se e  construct (Fig. 3-17 to 25)
Z22 Z21
> >-czznazz
< <
Z 20 Z 23
1. Two PGR fragments, Z22-Z20 and Z21-Z23, were 
amplified a s  template.
2. Overlap PGR was performed with primer Z22-Z23 to 
amplify 1.0 kb genomic GBP including point mutation 
exon 5
* There is complemental overlapping between Z20 and Z21, 
both together introduced a new Nru I site following the 
point mutagenesis at aa658.
S T "
pBS-PGK-Neo-lox71
5-1
Z33-Z34 to  
genom ic 
exon5 m utan t
EcoRV
Pvu  I
XTiqlEcoR V (Vrol —
Z L t i c n L
Xho  I EcoR V Nru (
— kzzAz3-Q-[
EcoR I
Sm a  I S ac  1
Nru\
pBS-mut.exon5
x h » L U
Fig. 3.34 Mutagensis of a point mutation of CBP at 
aa658 in CBD exon 5 (CBDAexonS).
Fig. 3.35 Combining of PGK-Neo-lox71 with 
mutant CBDAexonS
123
Chapter 3 Results
Sac I Sm a  I Acc65 I Xho  I
Sac I N ot I Spe I
EcoR I Hind III
Hind III, blunted
Sac I
Sac
Not I Spe I
5-3
Fig. 3.36 Subcloning of loxSS into pGEM-7zf(-) 
to introduce a new A c c 6 5  I site used  
for diagnostic Southern blots
BsaH N de  I C/a I
pBS-CBD.6kb
N de  l-C/a I. blunted 
then self-ligation
BsaH I 
EcoR I
Spe I
Xho  I
I si y
pBS-CBD.6kb'
Fig. 3.37 Removal of the repetitive sequence from 
downstream CBD region by self-ligation 
of N d e  l-C/a I digested clone, pBS- 
CBD.Gkb
3 S E H Z
pBS -CBD.Skb’
Not I, blunted
EcoR I, blunted
Spe I
Spe I
BsaH I
5-4a
BspH I A cc65  I Xho I
BsaH I SpeI 
EcoR
PBS-CBD.6kb'
Acc65 I, blunted
Spe I, blunted
X h o\
8saH I Acc65 I Xho  I
/---1  —f " 1st M l—^
Fig. 3.38 A Insertion of lox66 into CBD intron 4 (step 1 )
Fig. 3.38 B Insertion of lox66 into CBD intron 4 (step 2) 
A ccG S  I site is retained
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BsaH I Not 1
Xho  I
bt- y.. i.3i
Insert 1
Acc65 I
pBS>CBD.4kb
Insert 2
BsaH
Not I, blunted 
(Vector backbone)
(Insert 1)
Xho  I, blunted
(Insert 2) 
EcoR V S a c  IIBsaH
BsaHI —
Fig. 3.39 Combining of CBP fragments from the two 
different phage clones
There is a BsaH I site In both CBP genomic 
fragments from two phage c lo n e s ,  and additionally 
one BsaH I site exists in the vector. A three 
fragment ligation w as made to combine the two 
CBP fragments in the vector.
Xho  I EcoR V
EcoR I
Sm a  I S ac  II
M h h e z z h k ij- U
EcoRV
Sac
BsaH I EcoRV S ac II
Xho  I EcoR V Nru I EcoR I S ac  II
Fig. 3.40 A Insertion of 5-2 into CBD intron 5 
(step1)
XhgJ  E c o R .V ^ ^ , EcoR I S ac  II
r-1—UiHHZZ3fl<lU-----
5-6a
/tcc65 I
Xho  1 BsaH I Nru I
EcoR V Sacll
Xho 1
5-5EcoRV
Xho  I
EcoRV
EcoR I S ac  II
5-6
pUSEFUL (containing tk cassette)
Not I + BarnH I,Sac II, blunted
blunted
2.11 kb tk cassette with
blunt ends
Xho  I SsaH
4 ill H M
Acc65 I
i  I j EcpRI Sac II
5-6
Xho  I B s ÿ t I I Nru I
f
5-6
ftzzzHnJ-cEim
Fig. 3.40 B Insertion of 5-2 with the right 
homology arm (5-6a) into CBD 
intron 5 (step 2)
Fig. 3.41 introducing tk cassette  at the end of 
the right homology arm
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[■ a M E lB lI i l iV lE li lE ir i!
Xho  I, blunted
Sal pBS-CBD.IOkb
Dra III, blunted
S a /1
S a /1 B say I
I r T
l i a i E i B l B K I E I  iBIJt i W w  I t  L
f
5-7
Fig. 3.42 Final targeting construct of
Extension of the left homology arm
Genotyping of allele:
Linearization; Dra III digestion
5’ diagnostic enzyme: >Acc65 I
WT: 11.6 kb 
Mut: 9.3 kb
3’ diagnostic enzyme: EcoR 1
WT: 8.8 kb 
Mut: 4.5 kb
Or PCR with primers Z35-Z36
For distinction homologous 
recombination versus random integration: 
Acc65 I: 4.8 kb
Fig. 3.33 to 3.42: Flow chart of construction of CBD exon 5 and inverted CBD
exon 5 with the point mutation were flanked by two mutated loxP sites lox66 and Iox71 in 
opposite orientations. The PGK-Neo cassette flanked by two FRT sites in same direction was 
included between the two loxP sites as a positive selection marker. The tk cassette was included 
at the end of the right homology arm as a negative selection marker.
3.6.2 Screening for correct homologous recombinants of the targeted CBP  ^
allele
100 Bg of the targeting construct CBP^ "^^ ^^ '^^  (Fig. 3.42) was linearized by Dralll 
digestion and checked by agarose gel electrophoresis. 20 jag of linearized plasmid was 
electroporated into mouse ES cells and grown in selection medium (0418, 200 pg/ml for 
entire period; and gancyclovir, 2 jaM for the first two days). After nine days, resistant ES
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colonies were visible, and 500 colonies were picked into 96-well feeder plates, then 
expanded on 96-well feeder plates for freezing and on gelatinized 96-well plates for 
Southern blot analysis. The screening strategy is shown in Fig. 3.43.
Targeting Vector E c o r i >)cc65 I EcoR I
11 |2 |  |3 |  l4 l 1 5 I 15 I lllPGK-Neoin | J  [Sl |tK |
lox71lox66Genomic CBP
Acc€5
EcoR IAcc65 I
Targeted CBP locus
A cc65l EcoR I Acc65 I EcoR I Acc65 I
Seal
l l  y  | 3 l  h i  K )  i s  M s  I  n  |PGK-Nej[l
11 kb____Z36
Neo probe
4.8 kb Acc65l
WT 11.6 kb Acc65\
M utant9.3 kb Acc65l
WT 8.8 kb EcoRl
5’ probe Mutant 4.5 kb EcoRl
3’ probe
Fig. 3.43: Schematic representation of homologous recombination between the targeting
construct and CBP gene locus. Diagnostic probes and restriction fragments are also
indicated: the 5’ probe for correct homologous recombination of the left arm, the 3’ probe for 
correct homologous recombination of the right arm, and the Neo probe for confirmation of 
homologous recombination and exclusion of additional random integration events. PCR using 
primers Z35 and Z36 (indicated with arrows) are performed instead of the 3’ probe screening, a 
1.1 kb band is expected for the right homologous arm.
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A. 5’ probe screening
WT 
MUT
B. 3’ PCR screening 
H2O
1.1 kb
C. Neo probe screening
#
4.8 kb
Fig. 3.44: Screening for correct homologous recombinants of the targeting construct 
A. Southern blot of Jcc651 digested DNA from ES cell lines hybridized with the 5’ probe was 
expected to show one 11.6 kb band for the wild-type and one 9.3 kb band for the targeted allele 
(Fig. 3.43). B. PCR using primers Z35-Z36. All 10 clones positive in the Southern screening 
using the 5’ probe showed a positive band of 1.1 kb. H2O as a negative control was included. C. 
Southern blot analysis of 10 clones with the mutated 5’ and 3’ fragments using the neo probe 
showed that these 10 clones gave one single band of 4,8 kb, thus excluding random integration.
128
Chapter 3 Results
Hybridization of the 5’ probe to Acc651 digestions of ES cell DNA was used for the 
primary screen for homologous integration. Southern blot analysis (Fig. 3.44) showed 
that 17 of 500 (recombination efiSciency: 3.4%) picked clones gave the expected pattern 
of one 11.6 kb wild-type and one 9.3 kb targeted band (see Fig. 3.43). Southern blot 
analysis of EcoRI digestions with the 3’ probe faded, because the genomic DNA samples 
could not be fiiUy digested with EcoBl. Verification was therefore carried out by PCR 
using forward primers Z35, located in the Neo gene, and reverse primer Z36, located just 
downstream of the right arm. Ten of 17 clones positive in the 5’ screening had shown 
simdarly intense hybridization signals for both targeted and wdd-type bands using the 5’ 
probe, and these 10 clones were therefore committed to further analysis by PCR. All 10 
clones showed a positive band of 1.1 kb (Fig. 3.44), showing that correct homologous 
recombination occured in the right arm. Furthermore, these 10 clones ad showed one 
single band of the expected size of 4.8 kb (see Fig. 3.43 and 3.44) after Acc651 
digestions and hybridization using the neo probe, indicating that no random integrations 
were detected in the 10 ES clones.
3.6.3 Examination of Cre-mediated inversion in allele
In order to test whether point mutation can be induced in the mouse genome by using 
Cre-mediated inversion and mutant loxP sites, I firstly tried to test it in bacteria and ES 
ceds.
3.6.3.1 Examination of Cre-mediated inversion in bacteria
A Cre expressing plasmid, 705-Cre (carrying a chloramphenicol resistance gene), was 
transfected into DH5a bacteria. To examine the lox66/lox71 -mediated inversion, the
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targeting construct (Z74, containing the ampicillin resistance gene) was
transformed into competent DH5a (705-Cre) bacteria. Plasmid 705-Cre contains a 
temperature sensitive origin of replication that allows replication at 30°C but not at 
37°C, where the plasmid will integrate into the genome. Five transformed colonies were 
inoculated into 2 ml of LB medium containing ampicillin (100 pg/ml) and 
chloramphenicol (25 pg/ml), and then incubated with shaking at 30°C overnight. Cre- 
mediated inversion was examined by restriction enzyme digestion of the DNA with 
v4cc65I and iVrwI. All picked clones showed bands of 8.0, 4.2, 1.7 and 1.0 kb, and the 
control clone (clone Z74) showed bands of 5.9, 4.2, 3.8 and 1.0 kb. From the restriction 
map of the targeting construct (Fig. 3.45), it appeared that the two loxP mutant sites 
were able to mediate complete inversion. In contrast, the inverted sequence containing 
one wild-type loxP site and one double mutant loxP site was poorly recognized by Cre 
recombinase, because the digestion pattern of the initially transformed plasmid was not 
detected in the inverted Cre-expressing bacteria (Fig. 3.45), implying that the reverse 
reaction did not occur at a detectable frequency.
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Targeting vector
accqs \ 1 2 3 4
I n  n  n n
Acc65 I
5 .9  kb
m
5
Q
Nru I
Ü
FRT FRT |j
f | iPGK-Neoic ^ - - |n  II
1.0 kb
3 .8  kb
4 .2  kb
ACC 651 1 2  3  4
recombinase
• Acc65 I 6
8.0 kb LJ
1.0 kb
1 .7  kb
4 .2  kb
Acc65 I + Nru I
M Z74 1 2  3 4 5
5.9 kb— »  -M .  —  ® “
3 .8  k b  A -  Æ --------
—  1 .7  kb
Z74: final construct of CBpTy*:***
1-5: five colonies of Z74 after Cre-mediated inversion
Fig. 3.45: Cre-mediated inversion in bacteria. The final clone of construct was
transformed into E. coli DH5a that expressed Cre recombinase. Digestion patterns of DNA 
before and after transformation showed that the two loxP mutant sites were able to mediate 
complete inversion. In contrast, the inverted sequence containing one wild-type loxP and one 
double mutant loxP sites was poorly recognized by Cre recombinase, because the digestion 
pattern of the initially transformed plasmid was not detected in the Cre-expressing bacteria, 
implying that the reverse reaction did not occur at a detectable frequency.
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3.6.3.2 Examination of Cre-mediated inversion of CBP  ^ in ES cells
As a next step to verifying that tissue-specific generation of a allele would be
possible, induction of the Tyr658Ala substitution using Cre-mediated inversion was 
evaluated in one of 10 correct homologous recombinants (F3B12) by a transient 
transfection of Cre recombinase (plasmid pCre-pac) (Fig. 3.46).
Targeted allele
Hind III
FRT
{ ^ IPGK-Neo
Hind III 
FRT
iox6 6  ___
6.6 kb__________ ^  Neo probe
A
lox71
Hind III
Cre recombinas
Hind III ☆
D— 0— 1 ill 8
Neo probe 4.6 kb
Hind III
Hind III
6.6 kb
4.6 kb
1. Targeted allele
2. Inverted allele 
(named clone FC2)
Fig. 3.46: Cre-mediated inversion in ES cells. The targeted CBpTyr658Aia gg ^jone F3B12 was 
transfected with plasmid pCre-pac. Southern blot analysis of HinA\\\ digested DNA using the 
Neo probe showed a 6.6 kb band for the original targeted allele and a 4.6 kb band for the 
inversion pattern of the targeted locus.
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Southern blotting of Hinàlll digested DNA from transfected cells using the Neo probe 
was carried out as shown in Fig. 3.46. The original targeted cell clone F3B12 gave one
6.6 kb band. After transient transfection with Cre recombinase, one 6.6 kb band from the 
original targeted allele and one 4.6 kb band from the inversion were detected, thus, 
indicating that inversion can work in ES cells. The presence of a 6.6 kb band suggests 
that either the picked clone was contaminated with the original clone F3B12 or that 
inversion was incomplete.
3.6.4 Examination of splicing pattern of the inverted allele of the targeted
ç g p T y r6 5 8 A Ia
3.6.4.1 Excision of PGK-Neo cassette
To allow the analysis of the splicing pattern of the modified CBP locus, one of the ES 
cell clones containing the inversion (FC2) (see Fig. 3.46) was transiently transfected with 
the Flp-encoding plasmid pCAGGS-FLPe to achieve the removal of the PGK-Neo 
cassette.
Southern blotting using the Z33-Z34 PCR product (CBDAexonS, see Fig. 3.35) as a 
probe was carried out as shown in Fig. 3.47. If the PGK-Neo cassette is fiiUy excised, 
one 2.6 kb band and one 6.1 kb wild-type band are expected. Because of the low 
efficiency of recombination catalysed by Flp, lack of excision and insufficient excision of 
PGK-Neo were also observed.
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Fig. 3.47: Flp-mediated excision of the PGK-Neo cassette in the inverted targeted 
allele. A. The ES cell line FC2 was transfected with pCAGGS-FLPe. B. CBP wild-type allele. 
C. Southern blot analysis using the Z33-Z34 PCR product as a probe showed a 4.6 kb band for 
the original inverted allele, a 2.6 kb band for the excision pattern of PGK-Neo and a 6.1 kb band 
for the wild-type allele. Lanes 1,2,5,6; ES cell lines in which PGK-Neo was not excised; lane 3: 
wild-type ES cells; lane 4: PGK-Neo was excised in some cells; lane 7: PGK-Neo was efficiently 
excised (named clone FC4).
3.6.4.2 Examination of splicing pattern of the inversion allele
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RNA was then isolated from the “inversionVneo“” ES cell clone (FC4 in Fig. 3.47). RT- 
PCR was performed with primers Z41 and Z42. The expected 460 bp fragment was 
obtained. Unfortunately, after digestion of the 460 bp band with Nru I, no further cutting 
was observed, indicating the lack of Nru I and, thus, the lack of mutated exon 5. Another 
two runs of PCR with two pairs of primers (Z41-Z43 and Z42-Z44, for the positions of 
all primers, see Table 2.6) were therefore carried out, showing that the splicing patterns 
at both 5’ and 3’ to the mutated exon 5 were wrong (Fig. 3.48).
A  Z41 Z44
5’ GCGCGC 3’
aa658
B
- < 3 ----- - <-------
299 bp Z 43 Z 42
210 bp
460 bp
Z41-Z42 Z41-Z43 Z42-Z44
M N FC4 M N P  FC4 N P FC4
460 bp
299bp
210bp
Fig. 3.48: Examination of splicing pattern of the inverted targeted allele. A.
Positions of primers Z41 to Z44 in cDNA sequence are labelled. The substitution of Ala658 is 
marked in red, both 3’ ends of Z44 and Z43 complemental to this residue are also marked in red. 
Numbers 3 to 6 represent the CBD exons 3 to 6. B. RT-PCR using primers Z41-Z42 gave the 
expected 460 bp band. RT-PCR using two other pairs of primers (Z41-Z43 and Z42-Z44) 
revealed lack of correct splicing in FC4 cell clone. M: DNA marker X; N: H2O as negative PCR
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controls; P: Mutant CBPAla658 as positive PCR controls; FC4: an ES cell clone which is 
“inversionVneo"” (referring to Fig. 3.47).
3.6.5 Mating for the germhne transmission of the targeted
In order to obtain mice from the ES cell clones containing the targeted allele,
three correct recombinant ES cell clones F2B3, F2H6 and F3B12 (obtained in Section 
3.6.2) were selected for injection into C57BL/6 mouse derived blastocysts. The result of 
blastocyst injection of the targeted CBP^^^^^^ ES cell lines (in which WT CBP should 
be expressed) was summarized in Table 3.3.
Table 3.3 Summary of blastocyst injection of the tai^eted ES cells
Number of Number of chimeras
injected Number of (% of E14-derived Germline
Cell line embryos pups bom coat) transmission
F2B3 143 16 2 (60, 80%) Mating
F2H6 22 5 2 (30, 85%) Mating
F3B12 354 29 4 (30, 50, 50, 70%) Mating
Eight chimeras, which contained 30-85% of ES-derived coat were bom. One, from ES 
cell line F3B12, died at the age of 6 weeks, and the others were mated with wild-type 
C57BL/6 mice for germline transmission. So far, no germline transmission of the 
targeted has been observed. This suggests that the targeted allele leads to
dominant embryonic lethality. If the splicing in this line is incorrect, as it is in the ES lines 
containing the targeted construct (Fig. 3.48), then either truncated or other unknown 
CBP variants could be formed, and have dominant negative effects on viability of the 
mouse, as observed in the CBD2^ ‘^mouse line.
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In order to obtain germline transmission, the matings are still continuing, but mouse 
strain CDl is used for crossing to the chimeras instead of C57BL/6. If this is achieved, 
we could detect whether Cre-mediated inversion also works in vivo and furthermore, 
whether any CBP variants are actually formed by incorrect splicing.
3.7 Conclusions on generation of CBP mutant mice
Two constructs were generated to establish conditional CBP mutant mice, CBP^ °^ ^^  ^and 
çBpTyi658Aia Sections 3.5.1 and 3.6.1). Both constructs were electroporated
into ES cells, the correct homologous recombinants were obtained and then injected into 
blastocysts derived from C57BL/6 mice, which were then transferred into 
pseudopregnant mice. Several chimeras for both constructs were obtained. Construct 
Qgpstop523 sucgessfuUy transmitted in the germline, but CBP^^^^^^  ^ failed, possibly 
due to incorrect splicing resulting from the hairpin structure formed by the inverted 
sequences. Three mouse lines were generated from the construct CBP^ °^ ^^ .^ Firstly, 
CBD2^ ' has a general deletion of CBD exon 2 in all tissues. Preliminary results suggest 
that this mouse line shows severe developmental deficits. Secondly, CBD2.fioxed has the 
CBD exon 2 flanked by two loxP sites, and should behave like a wild-type mouse, but 
can be mated to different Cre-expressing mice to generate conditional mutant mice. 
Thirdly, CBD2.fioxed.neo is a mouse line in which the Neo gene is still present and can 
be used to test the possible interference of the PGK-Neo insertion on the cis-neighboring 
CBP gene, resulting in lower or null expression of CBP, i.e. hypomorph.
137
Chapter 4 Discussion
Chapter 4 
Discussion
One of the hallmarks of memory consolidation in both vertebrates and invertebrates is 
the requirement for new protein synthesis. Long-term but not short-term memory 
requires new mRNA expression and new protein synthesis and is reflected in an altered 
expression level of specific proteins regulated by the cAMP second messenger pathway.
Transcription factor CREB is proposed to be a key factor to mediate memory 
consolidation, as both mice homozygous for a hypomorphic allele of the CREB gene 
and Drosophila overexpressing a dominant-negative form of CREB showed a reduced 
ability to form long-term memory (Bourtchuladze et al., 1994; Yin et al., 1994 and 
1995). The switch from short- to long-term facilitation induced by behavioural 
sensitization in Aplysia involves CREB-like proteins, as the formation of long-term 
facilitation in Aplysia can be disrupted by drugs that interfere with transcription and 
translation, and by inhibiting cAMP-dependent gene expression (Dash et al., 1996). 
However, CREB itself is not sufficient for transcriptional induction of targeted genes, as 
phospho-CREB does not appear to associate directly with factors of the basal 
transcription machinery as examined by an affinity selection assay. CREB needs the 
transcriptional cofactor CBP to interact with the basal transcription machinery to further 
regulate gene transcription.
CBP is a large nuclear phosphoprotein that was originally characterized as a cofactor for 
CREB, and itself is directly regulated by nuclear Ca^”*" and Ca^Vcalmodulin kinase IV. 
Therefore, CBP is considered as an important site of regulation for Ca^^-induced gene 
expression (Chawla et ah, 1998). However, CBP does not bind directly to DNA. 
Furthermore, CBP serves also as a cofactor for many other transcription factors,
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transcriptional cofactors and kinases (for review see Janknecht and Hunter, 1996; 
Goodman and Smolik, 2000). To the present, very little knowledge has been gained on 
the function of CBP in memory consolidation. However, it has been found that CBP is 
mutated in the human Rubinstein-Taybi Syndrome (RTS) (Petrij et ah, 1995), a genetic 
disease characterized by multiple developmental defects and severe mental retardation. 
We therefore hypothesized that CBP might play a crucial role in the formation of long­
term memory.
4.1 Expression pattern of CBP in adult mouse brain
Although the physiological role of CBP in transcriptional mechanisms has been the 
focus of many studies, very little is known about the expression and function of CBP in 
adult mouse brain. Therefore, the expression patterns of CBP and its related protein 
p300 were examined in adult mouse brain by in situ hybridisation. This showed that 
both CBP and p300 are present in most neuronal populations in mouse forebrain (Fig. 
3.1), including the so-called limbic system, which is considered as central for many 
important brain functions, e.g. learning and memory, emotion, cognition and anxiety 
(Suzuki, 1996; Miller et al., 1998). “Enhanced” in situ hybridization with DIG-labelled 
riboprobes revealed that CBP is not expressed ubiquitously in many brain areas, 
including the forebrain region. For example, CBP-negative cells were found in the 
dentate gyrus, cortical layer IV and even hippocampal CAl and CA3 areas. 
Furthermore, it showed that there are differences in density of CBP expression between 
the two sides of the midaxis. This peculiar observation is in accordance with 
Stromberg’s report of CBP distribution in rat brain (Strdmberg et al., 1999).
Immunostaining showed that CBP protein was present in forebrain regions, e.g. intense 
signals were observed in hippocampal CAl, CA3, dentate gyrus and different layers of
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cortex. However, CBP protein was not ubiquitously present, consistent with the 
expression patterns of CBP at mRNA level.
These results indicate that CBP might be involved in the regulation of gene activity in 
the adult brain.
4.2 Genomic organization of CBP
So far, detailed information on the CBP gene is only available from the human genome. 
The human CBP gene, which encodes a 7.3 kb transcript, appears to cover 159 kb 
genomic sequence (Chrivia et al., 1993). The gene is localized on chromosome 16pl3.3, 
and is transcribed from centromere to telomere. At least 14 exons were identified by 
PCR amplification of human genomic DNA (Giles et al., 1997b). The genomic structure 
in CBD region is quite similar to mouse CBP characterized in this thesis. One splice 
donor site is located at nucleotide 798 shown to be near the site of one translocation 
breakpoint, and a deletion breakpoint in one RTS patient was found at this very same 
CBP splice donor site. Recently, more downstream exons of human CBP were well 
characterized by Petrij et al. (2000), showing that the CBP open reading frame is 
encoded by 31 exons in total that span 146 kb of genomic DNA from start (ATG) to 
stop (TAG).
Mouse CBP gene is located on chromosome 17 at the position of 11.0 cM from the
centromere. A full-length cDNA clone has been sequenced and comprises 7,326
nucleotides. CBP is a large nuclear protein of 265 kDa and 2,441 amino acid residues.
In order to generate CBP mutant mice, two independent phage clones were isolated,
which encompass about 28 kb of genomic CBP sequence, including the CREB-binding
domain (CBD). By comparing genomic and cDNA sequences (see Appendix II), 11
exons were characterized, covering about 2 kb of cDNA sequence. The CBD is encoded
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by 6 exons, named CBD exons 1 to 6. There is no coding sequence detected in about 7.5 
kb genomic sequence just upstream of the CBD exon 1. Comparing our results with the 
human genome sequence, and assuming that both mouse and human CBP genome share 
high similarity. This suggests that there may be two exons locating at least 7.5 kb 
upstream of CBD exon 1 (see Appendix II), which encode 1.3 kb of cDNA sequence. 
Furthermore, the downstream exons of mouse CBP encode another 4.0 kb of cDNA 
sequence could not be isolated from the phage libraries in this thesis.
The whole phage insert screened from one phage library was unable to be subcloned 
into plasmid vectors. It was first thought that the fragment was too big to be cloned. 
Actually that was not the case, as even the short fragment clone pBS-CBD.Nhe-Spe 
(Fig. 3.13) was difficult to be cloned. BLAST searches revealed 2.3 kb of highly 
repetitive sequences about 1 kb downstream of the CBD exon 5, which may be a reason 
for the failure to subclone the whole phage clone into the plasmid vector. This piece of 
sequence seems to cause problems in all bacterial strains used, always resulting in 
unstable clones or clones with deletions. The instability is probably due to repeats 
present in this piece of sequence, as it might allow ectopic recombination with similar 
sequences elsewhere in the genome, thus causing chromosomal rearrangements, 
indicating that this region might be involved in the breakpoints observed in RTS. 
However, all breakpoints reported so far are located in other regions of CBP gene (Petrij 
et al., 1995; Borrow et al., 1996; Sobulo et al., 1997). Moreover, because of the 
possibility of recombination with ectopic sites, this highly repetitive sequence had to be 
avoided in the homology arm of targeting constructs. Therefore, only 1.0 kb could be 
used for the right homology arm in the construct 0BpTyr658Aia tk cassette used in 
this construct as negative selection marker was aimed to increase the yield of clones 
with correct homologous recombination.
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Remarkably, several discrepancies, A ^ T  transversions, were found between the 
published cDNA sequence of CBP and the sequencing data that I obtained from clone 
pRc/RSV-mCBP.HA (see Appendix I). Thymidine (T) at nucleotide 2008, 2477, 2871 
and 2932 of the mouse cDNA clone were detected instead of adenosine (A) in the 
published mouse cDNA sequence. Interestingly, all these discrepancies in mouse cDNA 
were replacement of the corresponding human cDNA sequence of CBP gene.
4.3 Functional analysis of CBP in vitro
As PKA activity is reported to be increased upon differentiation of F9 cells, and the 
CREB phosphorylated at residue Ser^ ^^  is present in the nucleus only of differentiated 
F9 cells, but not in the nucleus of F9 embryonal carcinoma (EC) cells (Kingsley- 
Kallesen et ah, 1999), RA-induced, differentiated F9 cells were used for transfection 
experiments to investigate the properties of various CBP mutants. My results suggest 
that both CBD mutants (CBPAla658 and CBP.CBDAexon2-5) examined showed 
inhibitory effects on cAMP-mediated gene transcription. The repressive effects of 
CBPAla658 as compared to the wild-type CBP seem to be dose-dependent. As F9 cells 
are rather sensitive to small variations in cell culture conditions, transfection reagents 
and plasmid purity, the in vitro analysis of CBP mutants will have to be modified and 
extended to other cell lines, e.g. HEK293. Nevertheless, our results clearly indicate that 
both CBD mutants interfered with cAMP signalling pathway and that the inhibitory 
effects of CBPAla658 are dose-dependent.
I also measured the effects of the CBP mutants on dexamethasone-stimulated GRE- 
luciferase activity in transfection assays. Both CBPAla658 and CBP.CBDAexon2-5 
showed profound activation of nuclear receptor signal transduction, revealing that both
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mutants still retain other functions of CBP that are not related to the CBD, or at least the 
functions that require the N-terminal receptor interacting domain (RID).
All three RTS mutants showed strong inhibitory effects on the cAMP pathway. As 
major symptoms of RTS, such as developmental and mental retardation, may be related 
to CREB-mediated transcription, and RTS3 is similar to one of the knock-out mice 
(CBP^ °^^ ^^ )^, it is evident that the conditional mouse model for RTS might be a very 
useful tool to understand the complex mechanisms of the syndrome.
4.4 Cre-mediated inversion by using mutated Cre/loxP system
So far, inversion induced in a tissue-specific manner using a mutated Cre/loxP system 
(Albert et al., 1995) has not been reported. For the construct cgpTyrfissAia^  the inversion 
of the point mutated CBD exon 5 was tested in bacteria and ES cells. Both experiments 
showed that the targeted allele was inverted once. Cre recombinase efficiently 
recognized the lox66 and lox71 sites (forward reaction), and after inversion, the double 
mutant loxP and wild-type loxP sites were poorly recognized by Cre recombinase 
(reverse reaction). Cre-mediated recombination has been shown to be 4-fold to 7-fold 
more efficient between lox66 and lox71 than between double mutated loxP and wild- 
type loxP in tobacco protoplasts (Albert et al., 1995). In our result, restriction digestion 
did not detect any of the original construct when Cre recombinase-mediated inversion 
was tested in bacteria (Fig. 3.45), and positive bands for the inversion were observed in 
the ES cells by Southern blot (Fig. 3.46). These observations suggest that the difference 
in recombination efficiency between forward and reverse reactions is much higher in 
bacteria and ES cells than in plants. However, it was not possible to evaluate the 
efficiency of Cre-mediated inversion quantitatively with the methods applied.
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Nevertheless, our results suggest that the point mutation in CBD can be induced in mice 
using the mutated Cre/loxP system.
4.5 Generation of CBP knock-out mice
The functions of CBP and its closely related protein p300 have recently been 
investigated by gene targeting in mouse (Tanaka et a l, 1997; Yao et a l, 1998; Oike et 
al., 1999; Kung et al., 2000). Mice lacking both alleles of CBP die in utero between 
E8.5 to E l0.5, mice double-heterozygous for CBP and p300 have a comparable 
phenotype to that of CBP null mutants, and mice heterozygous for CBP display skeletal 
defects in the limbs similar to those observed in the human Rubinstein-Taybi syndrome 
(RTS) which is caused by mutations in the human CBP gene (Petrij et al., 1995).
CBP-defîcient mice will serve as a very useful tool to elucidate the physiological 
functions of CBP and to understand the complex mechanisms underlying RTS. The link 
between CBP and RTS symptoms was suggested by the interaction of CBP with 
multiple transcription factors. The molecular mechanisms of developmental and mental 
retardation of RTS still remain unclear. However, recruitment of CBP is sufficient for 
CREB-mediated gene activation (Cardinaux et al., 2000; Shaywitz et al., 2000), and 
CREB has been implicated in many forms of long-term synaptic plasticity and shown to 
be critical for memory consolidation. Thus, the mental retardation of RTS caused by 
mutations in CBP might be due to the impairment of CREB-mediated gene expression 
in central nervous system. It is evident that the conditional CBP knock-out mice will be 
a powerful tool to pinpoint the mechanisms underlying the multiple congenital 
malformations and mental retardation syndrome.
Cre-expressing mice are the other class of mouse lines used in the Cre/loxP system. Cre
recombinase is expressed under the control of different regulatory sequences that can
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drive Cre recombinase expression in specific tissues or cells and/or at specific 
developmental stage.
CBP is widely expressed in mouse forebrain areas, including the limbic system which is 
considered to be related with many central functions of brain, such as learning and 
memory. CaMKIIa-Cre mice can now be used to generate a CBP deficiency restricted 
mostly to the hippocampus, cortex and thalamus. This can be a good model to analyze 
the function of CBP on learning and memory.
4.5.1 knock-out mice
Qgpstop523 g deletion mutant derived from a construct in which the CBD exon 2 is 
flanked by two loxP sites. The exon 2 can be excised in the presence of Cre 
recombinase, and a new stop codon is then introduced at position 523, leading to a 
truncated N-terminal CBP. Similar deletion mutations of CBP have been reported in 
RTS. Another mouse model for RTS containing a truncated CBP has recently been 
generated by gene trapping (Oike et ah, 1999).
Three mouse lines were generated from the first targeting construct One is
the floxed mouse line containing the PGK-Neo cassette. Because of the possibility of
hypomorphic effects (Artelt et al., 1991; Tiering et al., 1993; Rijli et al., 1994; Meyers
et al., 1998), the interference of the Neo gene on CBP gene expression is being tested.
Secondly, the CBD2^ ' mouse line was obtained by mating of the germline mice
containing the targeted allele with a Cre deleter mouse line (Schwenk et al., 1995) to
excise the CBD exon 2. Because of the efficiency of Cre-mediated recombination, there
is a mosaic situation of excision and non-excision of the CBD exon 2 in Fl mice, and
the allele carrying the excision was transmitted to 4 of 24 F2 mice. Clearly, the
heterozygous mutant mice were under-represented among weaned pups according to the
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Mendelian inheritance rule. The result indicates that the general deletion of the CBD 
exon 2 surely causes severe developmental defects. It is also evident that the conditional 
Cre-mediated excision of the CBD exon 2 using tissue-specific expression of Cre 
recombinase should work in mouse as well. Furthermore, CBD2^ ' mice might serve as 
a model for RTS, and an useful tool for functional analysis of CBP in vitro, for 
example, overexpression of wild-type CBP into the cell lines from the mutant mice to 
see whether this can rescue some phenotypic changes. Thirdly, as floxed mouse line in 
Cre/loxP system should behave like the wild-type before crossing with Cre-expressing 
mouse lines, and as the Neo gene located in an intron of CBP may cause a hypomorphic 
allele of CBP, the PGK-Neo cassette had to be removed. The floxed mouse line was 
obtained by mating of the germline mice (CBD2.floxed.neo) with a Flp deleter mouse 
line (Dymecki, 1996). Finally, this mouse line can be mated with different Cre- 
expressing mouse lines to generate tissue-specific CBP deletions.
The floxed mouse line, which carries the CBP®‘°^ ^^  ^ allele and lacks the PGK-Neo 
cassette, is now in the process of being crossed to CaMKIIa Cre-mice, in which Cre 
expression is driven by the CaMKIIa promotor. Expression of Cre starts postnatally in 
most of the forebrain neurons, including the hippocampus, the brain region essential for 
learning and memory, in the first 3-4 weeks when many neural circuits have already 
been formed (Burgin et al., 1990). Therefore, recombination, and hence CBP 
deficiency, will occur in the forebrain neurons postnatally. This should avoid 
developmental defects caused during neurogenesis as observed in conventional knock­
outs (Tanaka et al., 1997; Oike et al., 1999a; Kung et al., 2000). Certainly, this 
conditional knock-out mouse will be a useful tool to understand the functions of CBP 
on learning and memory.
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4.5.2 knock-out mice
To elucidate the functions of CBP on CREB-mediated gene transcription, another CBP 
mutant mouse was proposed, in which a tyrosine to alanine substitution at amino acid 
residue 658 would be introduced by Cre-mediated inversion using the mutated Cre/loxP 
system (Albert et al., 1995). Our results showed that longer inverted repeats were more 
difficult to clone into E. coli’, a 300 bp repeat could be cloned, but a 780 bp repeat could 
not. After construction of the targeting vector and electroporation into the El 4 cells, the 
correct homologous recombinants were verified by Southern blot and PCR, and injected 
into blastocysts isolated from C57BL/6 mice. Eight chimeras with ES-derived cell 
percentages ranging from 30-85% were obtained and mated with wild-type C57BL/6 
mice for germline transmission at the age of about 8 weeks. Up to now, all pups (n = 
57) derived from four of the chimeras showed a black colour characteristic of the 
C57BL/6 host. This suggested that the construct is not being transmitted, possibly 
because of strong interference of the modified allele on CBP gene expression. Two 
possibilities can be put forward: Due to the insertion of the Neo gene in a CBP intron, a 
hypomorphic CBP allele might have been generated. Secondly, might hairpin structures 
formed by the exon 5 and inverted exon 5 with the point mutation, might lead to 
aberrant splicing and thus to a variant protein, or to lack of protein expression. The later 
explanation might be favored, as RT-PCR experiments showed that the splicing pattern 
of the inverted allele was incorrect.
4.6 Preliminary phenotypic analysis of CBD mouse line
Mouse line CBD 2^'' is a ubiquitous deletion mutant of CBD exon 2, obtained by 
crossing the targeted CBP®‘°^ ^^  ^mouse line with a Cre deleter mouse line (Schwenk et 
al., 1995). Two of 17 Fl offspring were confirmed as positive for Cre-mediated
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deletion. Neither showed any apparent phenotypes, and both had normal fertility. They 
were further mated with wild-type C57BL/6 to get heterozygous mice (CBD2^^‘). 
Among 24 F2 offspring, there were only 4 mice confirmed as heterozygous for the 
targeted allele (CBD Such a reduced number of pups suggested that CBD 2^'' may 
lead to embryonic lethality to some extent. This was confirmed by isolation of the 
embryos at E8.5 and E l0.5. Furthermore, one of the heterozygous F2 mice died at the 
age of two weeks postnatally, and another mouse did survive, but displayed a 
significantly smaller size in comparison to its wild-type littermates (Fig. 3.32). As this 
mouse appeared less and less healthy, it was committed at the age of two months to 
allow dissection of internal organs for further phenotypic analysis. Another two, up to 
now, do not show any health problem except for the obviously smaller size, but they 
were infertile, as they could not give birth to pups after mating for more than two 
months. So far, more F2 CBD2^ ' mice have been obtained when the Fl was mated to 
the CDl mouse strain than to the C57BL/6 strain. Interestingly, most F2 mice are 
female. The reason for this is not clear to the present. In conclusion, much stronger 
phenotypes were observed, compared to the phenotype of CBP mutant mice generated 
by others (Tanaka et a l, 1997; Oike et a l, 1999; Kung et al., 2000). This is possibly 
due to the presence of the N-terminal amino acid residues 1-522, which acts as in a 
dominant-negative manner. Further phenotypic analyses are required to characterize the 
mutant mice.
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Future perspectives
1) As the splicing pattern of the construct was found to be incorrect likely
owing to a hairpin structure formed by the inverted mutated CBD exon 5 and wild- 
type CBD exon 5, it is proposed that elimination of the hairpin structure by 
introduction of silent point mutations into the inverted mutated CBD exon 5 
sequence without interfering with the final protein product. This will be done by 
overlap PCR and confirmed by subsequent sequencing. This new construct will be 
introduced in to ES cells, to generate finally the mutant mice with the point 
mutation.
2) Further phenotypic analyses of CBD2^ ' mouse line at behavioral level, e.g. Morris 
water maze, fear conditioning experiments etc., and at cellular level, histological, 
immunohistological and in situ hybridization techniques to characterize expression 
differences and downstream targeted genes; primary neuronal cultures to analyze 
intracellular signal transduction pathways, will be performed.
3) Phenotypic analyses of forebrain-deficient mutant mice are also been 
performed at the behavioral and cellular level to underline the functions of CBP on 
learning and memory.
4) Phenotypic analyses of CBD2.floxed.neo mouse line are also considered to 
underline the possible hypomorphic effects caused by insertion of Neo gene into the 
intron.
5) Electrophysiological characteristics will be measured in slices from hippocampus 
and amygdala. The in vivo LTP/LTD recording from the dentate gyrus of freely 
moving mice is being established.
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Appendix I cDNA sequence of mouse CBP
1 ATGGCCGAGA ACTTGCTGGA CGGACCGCCC AACCCCAAAC GAGCCAAACT
51 CAGCTCGCCC GGCTTCTCCG CGAATGACAA CACAGATTTT GGATCATTGT
101 TTGACTTGGA AAATGACCTT CCTGATGAGC TGATCCCCAA TGGAGAATTA
151 AGCCTTTTAA ACAGTGGGAA CCTTGTTCCA GATGCTGCGT CCAAACATAA
201 ACAACTGTCA GAGCTTCTTA GAGGAGGCAG CGGCTCTAGC ATCAACCCAG
251 GGATAGGCAA TGTGAGTGCC AGCAGCCCTG TGCAACAGGG CCTTGGTGGC
301 CAGGCTCAGG GGCAGCCGAA CAGTACAAAC ATGGCCAGCT TAGGTGCCAT
351 GGGCAAGAGC CCTCTGAACC AAGGAGACTC ATCAACACCC AACCTGCCCA
401 AACAGGCAGC CAGCACCTCT GGGCCCACTC CCCCTGCCTC CCAAGCACTG
451 AATCCACAAG CACAAAAGCA AGTAGGGCTG GTGACCAGTA GTCCTGCCAC
501 ATCACAGACT GGACCTGGGA TCTGCATGAA TGCTAACTTC AACCAGACCC
551 ACCCAGGCCT TCTCAATAGT AACTCTGGCC ATAGCTTAAT GAATCAGGCT
601 CAACAAGGGC AAGCTCAAGT CATGAATGGA TCTCTTGGGG CTGCTGGAAG
651 AGGAAGGGGA GCTGGAATGC CCTACCCTGC TCCAGCCATG CAGGGGGCCA
701 CAAGCAGTGT GCTGGCGGAG ACCTTGACAC AGGTTTCCCC ACAAATGGCT
751 GGCCATGCTG GACTAAATAC AGCACAGGCA GGAGGCATGA CCAAGATGGG
801 AATGACTGGT ACCACAAGTC CATTTGGACA ACCCTTTAGT CAAACTGGAG
851 GGCAGCAGAT GGGAGCCACT GGAGTGAACC CCCAGTTAGC CAGCAAACAG
901 AGCATGGTCA ATAGTTTACC TGCTTTTCCT ACAGATATCA AGAATACTTC
951 AGTCACCACT GTGCCAAATA TGTCCCAGTT GCAAACATCA GTGGGAATTG
1001 TACCCACACA AGCAATTGCA ACAGGCCCCA CAGCAGACCC TGAAAAACGC
1051 AAACTGATAC AGCAGCAGCT GGTTCTACTG CTTCATGCCC ACAAATGTCA
1101 GAGACGAGAG CAAGCAAATG GAGAGGTTCG NGCCTGTTCT CTCCCACACT
1151 GTCGAACCAT GAAAAACGTT TTGAATCACA TGACACATTG TCAGGCTCCC
1201 AAAGCCTGCC AAGTTGCCCA TTGTGCATCT TCACGACAAA TCATCTCTCA
1251 TTGGAAGAAC TGCACACGAC ATGACTGTCC TGTTTGCCTC CCTTTGAAAA
** CBD e x o n  1 (CBD 1)
1301 ATGCCAGTGA CAAGCGAAAC CAACAAACCA TCCTGGGATC TCCAGCTAGT
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*** * E co R  I
1351 GGAATTCAAA ACACAATTGG TTCTGTTGGT GCAGGGCAAC AGAATGCCAC
1401 TTCCTTAAGT AACCCAAATC CCATAGACCC CAGTTCCATG CAGCGGGCCT
1451 ATGCTGCTCT AGGACTCCCC TACATGAACC AGCCTCAGAC GCAGCTGCAG
1501 CCTCAGGTTC CTGGCCAGCA ACCAGCACAG CCTCCAGCCC ACCAGCAGAT
A v r IICBD  2
1551 GAGGACTCTC AATGCCCTAG GAAACAACCC CATGAGTGTC CCAGCAGGAG
S a p
1601 GAATAACAAC AGATCAACAG CCACCAAACT TGATTTCAGA ATCAGCTCTT
I CBD 3
165 1 CCAACTTCCT TGGGGGCTAC CAATCCACTG ATGAATGATG GTTCAAACTC
170 1 TGGTAACATT GGAAGCCTCA GCACGATACC TACAGCAGCG CCTGCTTCCA
1751 GCACTGGTGT TCGAAAAGGC TGGCATGAAC ATGTGACTCA GGACCTACGG
CBD 4
1801 AGTCATCTAG TCCATAAACT CGTTCAAGCC ATCTTCCCAA CTCCAGACCC
1851 TGCAGCTCTG AAAGATCGCC GCATGGAGAA CCTGGTTGCC TATGCTAAGA
CBD 5
1901 AAGTGGAGGG AGACATGTAT GAGTCTGCTA ATAGCAGG GA TGAATACTAT
* * * a a 6 5 8
1951 CATTTATTAG CAGAGAAAAT CTATAAAATA CAAAAAGAAC TAGAAGAAAA
2 0 0 1 GCGGAGGACA CGTTTACATA AGCAAGGCAT CCTGGGTAAC CAGCCAGCTT
2 0 5 1 TACCAGCTTC TGGGGCTCAG CCCCCTGTGA TTCCACCAGC CCAGTCTGTA
CBD 6
21 0 1 AGACCTCCAA ATGGGCCCCT GCCTTTGCCA GTGAATCGCA TGCAGGTTTC
CBD 7
2 1 5 1 TCAAGGGATG AATTCATTTA ACCCAATGTC CCTGGGAAAC GTCCAGTTGC
2 2 0 1 CACAGGCACC CATGGGACCT CGTGCAGCCT CCCCTATGAA CCACTCTGTG
CBD 8
22 5 1 CAGATGAACA GCATGGCCTC AGTTCCGGGT ATGGCCATTT CTCCTTCACG
230 1 GATGCCTCAG CCTCCAAATA TGATGGGCAC TCATGCCAAC AACATTATGG
235 1 CCCAGGCACC TACTCAGAAC CAGTTTCTGC CACAGAACCA GTTTCCATCA
240 1 TCCAGTGGGG CAATGAGTGT GAACAGTGTG GGCATGGGGC AACCAGCAGC
CBD 9 *T
2 4 5 1 CCAGGCAGGT GTTTCACAGG GTCAGGAACC TGGAGCTGCT CTCCCTAACC
2 5 0 1 CTCTGAACAT GCTGGCACCC CAGGCCAGCC AGCTGCCTTG CCCACCAGTG
2 5 5 1 ACACAGTCAC CATTGCACCC GACTCCACCT CCTGCTTCCA CAGCTGCTGG
2 6 0 1 CATGCCCTCT CTCCAACATC CAACGGCACC AGGAATGACC CCTCCTCAGC
26 5 1 CAGCAGCTCC CACTCAGCCA TCTACTCCTG TGTCATCTGG GCAGACTCCT
2 7 0 1 ACCCCAACTC CTGGCTCAGT GCCCAGCGCT GCCCAAACAC AGAGTACCCC
2 7 5 1 TACAGTCCAG GCAGCAGCAC AGGCTCAGGT GACTCCACAG CCTCAGACCC
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2 8 0 1 CAGTGCAGCC ACCATCTGTG GCTACTCCTC AGTCATCACA 
CBD 10
GCAGCAACCA
2 8 5 1 ACGCCTGTGC ATACTCAGCC ACCTGGCACA CCGCTTTCTC AGGCAGCAGC
290 1 CAGCATTGAT AATAGAGTCC CTACTCCCTC CACTGTGACC AGTGCTGAAA
295 1 CCAGTTCCCA GCAGCCAGGA CCCGATGTGC CCATGCTGGA AATGAAGACA
3001 GAGGTGCAGA CAGATGATGC 
CBD 11
TGAGCCTGAA CCTACTGAAT CCAAGGGGGA
3 0 5 1 ACCTCGGTCT GAGATGATGG AAGAGGATTT ACAAGGTTCT TCCCAAGTAA
310 1 AAGAAGAGAC AGATACGACA GAGCAGAAGT CAGAGCCAAT GGAAGTAGAA
315 1 GAAAAGAAAC CTGAAGTAAA AGTGGAAGCT AAAGAGGAAG AAGAGAACAG
320 1 TTCGAACGAC ACAGCCTCAC AATCAACATC TCCTTCCCAG CCACGCAAAA 
X ba I
3 25 1 AAATCTTTAA ACCCGAGGAG CTACGCCAGG CACTTATGCC AACTCTAGAA
3301 GCACTCTATC GACAGGACCC 
A v r  I I
AGAGTCTTTG CCTTTTCGTC AGCCTGTAGA
3351 TCCTCAGCTC CTAGGAATCC CAGATTATTT TGATATAGTG AAGAATCCTA
3401 TGGACCTTTC TACCATCAAA CGAAAGCTGG ACACAGGGCA ATATCAAGAA
3451 CCCTGGCAGT ATGTGGATGA TGTCAGGCTT ATGTTCAACA ATGCGTGGCT
3501 ATATAATCGT AAAACGTCCC GTGTATATAA ATTTTGCAGT AAACTTGCAG
3551 AGGTCTTTGA ACAAGAAATT GACCCTGTCA TGCAGTCTCT TGGATATTGC
3601 TGTGGACGAA AGTATGAGTT CTCCCCACAG ACTTTGTGCT GTTACGGAAA
3651 GCAGCTGTGT ACAATTCCTC GTGATGCAGC CTACTACAGC TATCAGAATA
370 1 GGTATCATTT CTGTGGGAAG TGTTTCACAG AGATCCAGGG CGAGAATGTG
3751 ACCCTGGGTG ACGACCCTTC CCAACCTCAG ACGACAATTT CCAAGGATCA
3801 ATTTGAAAAG AAGAAAAATG ATACCTTAGA TCCTGAACCT TTTGTTGACT
3851 GCAAAGAGTG TGGCCGGAAG ATGCATCAGA TTTGTGTTCT ACACTATGAC
3901 ATCATTTGGC CTTCAGGTTT TGTGTGTGAC AACTGTTTGA AGAAAACTGG
3951 CAGACCTCGG AAAGAAAACA AATTCAGTGC TAAGAGGCTG CAGACCACAC
4001 GATTGGGAAA CCACTTAGAA GACAGAGTGA ATAAGTTTTT GCGGCGCCAG
4051 AATCACCCTG AAGCTGGGGA GGTTTTTGTC AGAGTGGTGG CCAGCTCAGA
4101 CAAGACTGTG GAGGTCAAGC CGGGAATGAA GTCAAGGTTT GTGGATTCTG
4151 GAGAGATGTC GGAATCTTTC CCATATCGTA CCAAAGCACT CTTTGCTTTT
4201 GAGGAGATCG ATGGAGTCGA TGTGTGCTTT TTTGGGATGC ATGTGCAAGA
4251 TACGGCTCTG ATTGCCCCCC ACCAAATACA AGGCTGTGTA TACATATCTT
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4301 ATCTGGACAG TATTCATTTC TTCCGGCCCC GCTGCCTCCG GACAGCTGTT
4351 TACCATGAGA TCCTCATCGG ATATCTCGAG TATGTGAAGA AATTGGTGTA
4401 TGTGACAGCA CATATTTGGG CCTGTCCCCC AAGTGAAGGA GATGACTATA
4451 TCTTTCATTG CCACCCCCCT GACCAGAAAA TCCCCAAACC AAAACGACTA
4501 CAGGAGTGGT ACAAGAAGAT GCTGGACAAG GCGTTTGCAG AGAGGATCAT
4551 TAACGACTAT AAGGACATCT TCAAACAAGC GAACGAAGAC AGGCTCACGA
4601 GTGCCAAGGA GTTGCCCTAT TTTGAAGGAG ATTTCTGGCC TAATGTGTTG
4651 GAAGAAAGCA TTAAGGAACT AGAACAAGAA GAAGAAGAAA GGAAAAAAGA
4701 AGAGAGTACT GCAGCGAGTG AGACTCCTGA GGGCAGTCAG GGTGACAGCA
4751 AAAATGCGAA GAAAAAGAAC AACAAGAAGA CCAACAAAAA CAAAAGCAGC
4801 ATTAGCCGCG CCAACAAGAA GAAGCCCAGC ATGCCCAATG TTTCCAACGA
4851 CCTGTCGCAG AAGCTGTATG CCACCATGGA GAAGCACAAG GAGGTATTCT
4901 TTGTGATTCA TCTGCATGCT GGGCCTGTTA TCAGCACTCA GCCCCCCATC
4951 GTGGACCCTG ATCCTCTGCT TAGCTGTGAC CTCATGGATG GGCGAGATGC
5001 CTTCCTCACC CTGGCCAGAG ACAAGCACTG GGAATTCTCT TCCTTACGCC
505 1 GCTCCAAATG GTCCACTCTG TGCATGCTGG TGGAGCTGCA CACACAGGGC
5101 CAGGACCGCT TTGTTTATAC CTGCAATGAG TGCAAACACC ATGTGGAAAC
5151 ACGCTGGCAC TGCACTGTGT GTGAGGACTA TGACCTTTGT ATCAATTGCT
520 1 ACAACACAAA GAGCCACACC CATAAGATGG TGAAGTGGGG GCTAGGCCTA
5251 GATGATGAGG GCAGCAGTCA GGGTGAGCCA CAGTCCAAGA GCCCCCAGGA
5301 ATCCCGGCGT CTCAGCATCC AGCGCTGCAT CCAGTCCCTG GTGCATGCCT
535 1 GCCAGTGTCG CAATGCCAAC TGCTCACTGC CGTCTTGCCA GAAGATGAAG
5401 CGAGTCGTGC AGCACACCAA GGGCTGCAAG CGCAAGACTA ATGGAGGATG
5451 CCCAGTGTGC AAGCAGCTCA TTGCTCTTTG CTGCTACCAC GCCAAACACT
5501 GCCAAGAAAA TAAATGCCCT GTGCCCTTCT GCCTCAACAT CAAACATAAC
5551 GTCCGCCAGC AGCAGATCCA GCACTGCCTG CAGCAGGCTC AGCTCATGCG
5601 CCGGCGAATG GCAACCATGA ACACCCGCAA TGTGCCTCAG CAGAGTTTGC
5651 CTTCTCCTAC CTCAGCACCA CCCGGGACTC CTACACAGCA GCCCAGCACA
5701 GCCCAAACAC CACAGCCCCC AGCCCAGCCT CAGCCTTCAC CTGTTAACAT
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5 7 5 1 GTCACCAGCA GGCTTCCCTA ATGTAGCCCG GACTCAGCCC CCAACAATAG
5801 TGTCTGCTGG GAAGCCTACC AACCAGGTGC CAGCTCCCCC ACCCCCTGCC
5851 CAGCCCCCAC CTGCAGCAGT AGAAGCAGCC CGGCAAATTG AACGTGAGGC
5 9 0 1 CCAGCAGCAG CAGCACCTAT ACCGAGCAAA CATCAACAAT GGCATGCCCC
595 1 CAGGACGTGA CGGTATGGGG ACCCCAGGAA GCCAAATGAC TCCTGTGGGC
6001 CTGAATGTGC CCCGTCCCAA CCAAGTCAGT GGGCCTGTCA TGTCTAGTAT
6051 GCCACCTGGG CAGTGGCAGC AGGCACCCAT CCCTCAGCAG CAGCCGATGC
6101 CAGGCATGCC CAGGCCTGTA ATGTCCATGC AGGCCCAGGC AGCAGTGGCT
6151 GGGCCACGGA TGCCCAATGT GCAGCCAAAC AGGAGCATCT CGCCAAGTGC
6201 CCTGCAAGAC CTGCTACGGA CCCTAAAGTC ACCCAGCTCT CCTCAGCAGC
6251 AGCAGCAGGT GCTGAACATC CTTAAATCAA ACCCACAGCT AATGGCAGCT
6301 TTCATCAAAC AGCGCACAGC CAAGTATGTG GCCAATCAGC CTGGCATGCA
6351 GCCCCAGCCC GGACTTCAAT CCCAGCCTGG TATGCAGCCC CAGCCTGGCA
6401 TGCACCAGCA GCCTAGTTTG CAAAACCTGA ACGCAATGCA AGCTGGTGTG
6451 CCACGGCCTG GTGTGCCTCC ACCACAACCA GCAATGGGAG GCCTGAATCC
6501 CCAGGGACAA GCTCTGAACA TCATGAACCC AGGACACAAC CCCAACATGA
6551 CAAACATGAA TCCACAGTAC CGAGAAATGG TGAGGAGACA GCTGCTACAG
6601 CACCAGCAGC AGCAGCAGCA ACAGCAGCAG CAGCAGCAGC AACAACAAAA
6651 TAGTGCCAGC TTGGCCGGGG GCATGGCGGG ACACAGCCAG TTCCAGCAGC
6701 CACAAGGACC TGGAGGTTAT GCCCCAGCCA TGCAGCAGCA ACGCATGCAA
6751 CAGCACCTCC CCATCCAGGG CAGCTCCATG GGCCAGATGG CTGCTCCAAT
6801 GGGACAACTT GGCCAGATGG GGCAGCCTGG GCTAGGGGCA GACAGCACCC
6851 CTAATATCCA GCAGGCCCTG CAGCAACGGA TTCTGCAGCA GCAGCAGATG
6901 AAGCAACAAA TTGGGTCACC AGGCCAGCCG AACCCCATGA GCCCCCAGCA
6951 GCACATGCTC TCAGGACAGC CACAGGCCTC ACATCTCCCT GGCCAGCAGA
7 0 0 1 TCGCCACATC CCTTAGTAAC CAGGTGCGAT CTCCAGCCCC TGTGCAGTCT
7 0 5 1 CCACGGCCCC AATCCCAACC TCCACATTCC AGCCCGTCAC CACGGATACA
7 1 0 1 ACCCCAGCCT TCACCACACC ATGTTTCACC CCAGACTGGA ACCCCTCACC
7 1 5 1 CTGGACTCGC AGTCACCATG GCCAGCTCCA TGGATCAGGG ACACCTGGGG
7 2 0 1 AACCCTGAAC AGAGTGCAAT GCTCCCCCAG CTGAATACCC CCAACAGGAG
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7 2 5 1  CGCACTGTCC AGTGAACTGT CCCTGGTTGG TGATACCACG GGAGACACAC 
730 1  TAGAAAAGTT TGTGGAGGGT TTGTAG
* I n s t e a d  o f  A ,  c o r r e s p o n d i n g  n u c l e o t i d e s  (T) i n  hum an cDNA a r e
d e t e c t e d  i n  t h e  o r i g i n a l  m o u se  cDNA c l o n e  pRC/RSV-mCBP.HA.
** S e q u e n c e s  m a rk e d  i n  b l u e  a n d  b l a c k  a r e  11 e x o n s  c h a r a c t e r i z e d  i n
t h e  i s o l a t e d  CBP genom e ( h e r e  nam ed  CBD e x o n  1 t o  1 1 ) .
*** C o d in g  s e q u e n c e s  f o r  t y r o s i n e  a t  a m in o  a c i d  6 5 8 .
****  U n d e r l i n e d  s e q u e n c e s  a r e  u s e f u l  r e s t r i c t i o n  s i t e s  f o r  c l o n i n g ,
a n d  m u t a g e n e s i s  o f  CBP f o r  i n  v i t r o  t r a n s f e c t i o n .
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Appendix II Genomic sequence of CBP in the region of the CBD exons
*BanM  I
1 GGATCCCTGC TGTTTTTAGG CATCAGAGCA TTAAGAAGAG ATATGAATGC
51 CTCTTCCCAG TTTTAAGAAC CTTTGCTGTC ATTTCAGAGG CTACATTGTG
101 GTCTTTAAAT ATGCCCCTCA TTTGCACATC TAGAAAATGC TCTTGGGTGG
151 GCATGCTCTA ATTGGAGGCA ATCCCTTTTT TAGTGATCTT TCAGGGTGAC
201 ACAGTCTTTC TCATCTTTCA CAATCTTACT TCTCCCCAGT GTTCTTGGTG
251 TTCTTAGAAC ATCTTCTTGA ATATCTTTAC CTGCCTGGTG AACATGTGCT
301 GCTTTCTTCC TGGCTGGCTG TACATGGCAA ATCACTCTAA TCTAAAAGTA
351 CTATGGAGTG CCATTGCTCT GTTCGATCTC TTATGAATCT AGCTTTTCTT
401 CCTGTGAGCT GATTCACACT GTATAGCATG CTTCATTGGA AAAAACAGGA
451 TGTTGGGGCT TGATGTCTTC TTCCCTTACA GATGTACCAC CACAATTAAG
501 TTTCTTTGAA AACTTAGTTT CTTGAATCTT TTTGTGTATA TGTATTGGAG
551 GTGCTTGTGT GTGTGTATGT GTGTGTGTGT ACGGTTACTC ATTTGCCACA
601 GCGTGTGGTA TAGGTCAGAA ATGTTGGTTC TTACCCTTTA CTTTGTTTTA
651 AGGCTAGGTC TTTGTTGTTT ATGTGTCCTG TATATATAAG CTGGGTAGCC
701 TGTGAGTATC TAGAGATTGC TCTATCTCCA CCTGGCATTT GAACTGGGAT
751 TACATGCATG TTGCCATGGC TGGTTTTACA CAGGCTATGG AAATTTAAAC
801 TCAGGTCCTT ACACTTGTCT GATAAGTACT TTAGCCTTCT TTGTAACTCC
851 TAAATTTTTA ATATATTAAT TTTTTTTGAC ATTTCTTACA TAAAGTTCTG
901 GAATAGTGGG TCTTATTAGC CATGAATAAT GAGCTAGGAT CTCACTTTTA
951 AGTTTTAATT TTGGGATGTG ACTGAGGGAG CTTTTGAGCT TCGTATGTNC
1001 AAACTGTTAT GAAGATTGTA AAGCTTTGCA ATTTCTCTTT TTAAGAAATA
1051 ATGTGGGTTT TGTTCAAGAG AGAGGAAAAA AAGAAACATG GTTTGTTTTT
1101 CTTAATGTCC TTATAACTGC CTAAATATGA AAATGGATTC AAAGCATGCt
1151 TTCTCAAGTG GTAAACCACA GTGTTTCTAT AACGTGAGCN GTTAGTGTGT
1201 GGGGGGGGGG GAGGGGGGAA TGTTTGTGAT GATGTAAAGT CACAGGTAGA
1251 GTTGAGATGA TCTCTGCACA ATTTGTTGTT GTTGTTGTTG TTGTTGTTTT
1301 TCGAGACAGG GTTTCTCTGT ATATCCCTGG CTGTCCTGGA ACTCACTGTA
1351 GATCAGGTTG ACCTCGAACT CAGAAATCCA CCTGCTTTTG TCTCCTGAGT
1401 GCTGGGATTA AAGGTGTGCG CCTCCATGCC CGGCTCCAAA AATTTTTAAT
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1451 GGGAAAAAAA. GCTAAAAAAT TTTAATGCTC CTTTTTAAAA TTTTAATTGT
1501 GTATGTTCCT ATAGGTGATT TTGCTCATAT GTGAGCCTGT GGAAGCTAGA
1551 GATCATCTGG TGTCTTGTTC TAATCACCCT CTACCTTAAT TTTTTTATTT
1601 GAGATAGTCT CTAATTGAAC CTGGATCTCA TAGTTTTAGA TAGATTGATG
1651 AGCAAGTGAT CCCCTGGAAT CTGCCTGTCT TTGCCTTCTC AGCACCAGGG
1701 TTGCAGACAC ATACTGTCAC CACAACAATG TGCTTTTTTT ATGTGAGTGT
1751 TGGAGACCTG AGCTCAACTT CTCATGGTGG TGCTACAAGC ACTTTCCTAA
1801 GCCATTTCTC CAGCCTAAAT GCTTCTTAAA TTACATTTCA GTTTTGAGTG
1851 TGGTCTTTTG GCTCTATACT TTTAGATGTG TGAGATAGAA TTTATTTTAT
1901 GTCATCAGGG GAGAATGTTT AGCAGTGCCC CTTTTCTCTA GAAAAATGTG
1951 TTTATGGTTT ATAATCCTAG ACTAAGAATT ATATATAGAA AAAAGTGAAT
200 1 CCAATCCTTC AGTGTGTTCA GGTTGAATTC TAAAGATTGA AATATTTATC
205 1 TTAAAAATTA GTGTGGTTGG TCATTCCAGT ACTCCAGAAG CTGAGGCAGG
210 1 AGGATTATGA ATTCTAGGCT ATCTTAAGTA TATATTGCTA GACCATGTCC
215 1 CCTCAAAAAC AAAACAACAA AACCCCCACT ATTGTTAATT TGTATTTGCT
220 1 TGATATTAAT TCAGTGAATT ATGAGCTTCA GTTTCATGCT TAACTTTTAA
225 1 TTTAGGGAGT GGCTTTTCTA GGATTCTGGG GGTTGCTGCT AGTCATATTT
230 1 TTAAAAGTAG TAATGGTCTC TCCTAAAGGA TCAGGAATAG GTGTGAGGTA
235 1 TTCTGTGTAG GCCTTACGGG GTGGAATGAG AACATGCCTA GACCTTCATA
240 1 GAGAAAAGTG 
A c c 6 5  I
TTGCTCATGA AACCCAAGAT CAATAAAATT ACAAGGGTAG
2 4 5 1 TAAGGTACCG GTACCAGGAG AACACATAGC CTAAGAATAA TGGGTATGGT
25 0 1 GAATTÂAATA AGAATGGCCC TCCATAGGCA CTTATATTTG CATGCTCAGT
2551 CATCATGGAG CAACACTGTT AGAAAGAATT AGGTGTGGCC TTGGAGGAAG
260 1 TATGTCACTG GGGTGTTTCA AAAGTCCAAG CCAGGCCCAG TGGCTCTCCT
2651 CCTGCTACCT GGGGGTCCAG ATTTAGAACT CTAGTCTACA TCTGCATATG
2701 TGCCTTCATG CTCTCTGCCA TGATGATAAT GGAGTAAACC TCCTAAACCT
2751 AACAAGCCTC CAGTTAATTG CCTTCCTTTA TAAGAGTTGC TGTGGTCTTG
280 1 GTGCTCCAAC GGTGACTAAA 
S a c  I
ACACTGGGCT TAGAGATAAC TGTGTTGAGG
2 8 5 1 CTCACTCTGT GGAGCTGCCA ACAGATATGT CAAAGCTCTA CCTTCTGAAC
2901 ATATTTCCTA CAGATATTGA CCAGTGTCCT CTTCTTGGTA GTTACATTTT
2951 CCATTCTCAA ACTTCTGTGT TTTCTACTGA CAGAATCTTG GGAAGTTTAC
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300 1 TAAGGCACTA TGATATTGCT TGAAAAGAAA CTCATACTGT TATTTTGGGG
3051 TCTGTTTGAT GTTTGTTTTT TAACTGTGAT GATGAGTTAT CCACCTATCA
3101 TAGAAATAGT TGTTCACTTA TCATCAGTCC TGTTCTGGTC AGACAATTTC
3151 TAGTAGATTC TGTGTGACAT GTGCTTGAGT TCCCATATTG GAACCCATGA
3 20 1 GTCTCTTGAT ACTCATAGTT AATATCCAGA CATGCTTTAT AAAAATGGGG
3251 AAATCTGGAC CCTATCTAGG TTTCTTGTAC TAAAACCTGT ATTTTTAACA
3 30 1 AATTTTCAGT ATTTGTTGGG TACATTAAAA TCTGAGCTGT AGTTTTTTGG
3351 GGTGACTACA AGTGCCAGGT TTGTGTCAGA GCTTCAAGGG AGAATAGACG
3 40 1 TATTCTATGA GGAAGACCCT GGCTTCTCTA TACCTGAACC CCACAGGGAT
3451 TTAGACCTGT GCTTCATGAA CAGCCCCAGG TCCAGCCCCA GACTTAGGCA
3501 GAATCACAGA ACAACAATCT CTAGTGACTA TGATAGCAGT CCTCTAGCTT
3551 GTTGCTCCAG TGTCCATATC ACCTTGGCCC TTAATTCACG GAGTGGCTCT
360 1 TTATCCCATT TCTAGGCACA TTTTGGATAG CTTAAAACAC CTTTCATCTA
365 1 TTATTATTAT TGTTGTTATT ATTATTGTTA TTGTTATTAT TATTATTATA
370 1 TTGAGTTAAA ATCAGCCTCA GATTTCACTT GAATAGAGCA CCTCCTGGCC
375 1 CCACCTGGTC AGGCTCTCAG TTCCACTTGG GAGCCCTGTG GTCTCCAGAT
3801 GCCTCTAGCA TACCAATAGA GATTGTGTTG GGAAGTAGGG CCTGAATAGC
3851 TTTACAGAGT AAGAGAGCCA TGAGCTCACT GTCCCTTCCT TGATCAGAAC
3901 AGTTGCTTCT TGCCCTCTGG TGTGTCTTAG CTTCTGAGGA AAGCCACCTT
3951 TGTGAACTTG GGCACTCCAG ACTTTCTGTT TGGGAGAGTC TATGTGGGAG
4001 TACCCTCTAC TTGCAGAGAT AGGTACAGAT TTGAATAAAC TTAACACTGT
4051 TTTTATTGTT GTTGTTTTAT GTAGCAATCT AAGAATGAAT AGAATAACTA
4101 CCTAGCTTGC ATTTTGATTT GTCTCCCACC ACTCTGACTG AGTTTGAAAT
4151 TTAATTTGTG TCAGTTTTTG TTGAACTTTC TTTTTTGTCT TTTCTTTTTC
4201 TTTTTTTGGT TTGGTTTTTT TTGTTTGTTT GTCTTTTTTT GTTTTTTTGA
425 1 GACAGGGTTT CTCTGTATAG CCCTGGCTGT CCTGGAACTC ACTTTGTAGA
N he  I
4301 CCAGGCTAGC CTCAAACTCA GAAATCCGCT TGCCTCTGCC TCCCGAGTGC
4351 TGGGATTAAA AGGCATGTGC CACCACGCCC AGCTTTTGTT GAATTTTCAA
4401 ATTGAGCCCA ATTTTATTGG AAATGATTAG AGCCTGATGG TGACTGGCTA
4451 ATAGAATGTT TAGCATTCTA TTAGCAACAT ATATATTTCA CAGGGGAAAG
4501 ACTGTCTTGC CCCTATTCAG AGATTGATAG TTAAGTCTTA TATAGAACCC
4551 TTAATGAATG TGGACTTTTG TTTCCTAAGC TATGATTTCT TACTTTAGCT
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4601 ACAACAGTGA GGCAGAAAAG GCACTGAGCA TACATTAGAA AAGGCAAACA
465 1 TATGTCAGAA ACCATGGCTC TTGCCTGCAA TCACTATACT CAGGAGCAGG
470 1 CCATGAACTT GAGCCCTCNT TGGGCTGCAT AGTGAGTTAC AGGCCAGCCA
4751 TAGCTATATA GTAAAACTCG GTCTCCCCTA CCCCCACCAA ACAGACCAAA
4801 ATAAAAACCA AAAAAACTCC TCAAAGATGT ATCTCGATTC AGATGTGATA
4851 AACTAGgCTA GAGTATTGGA ACTCCTCAGG GTATAATATG ACATTACAAC
4901 ATGAAACTTC AGAAGAGAAA AGACCAAGTA GAAAGTCTTC ATTAACATGT
4951 CCAGTTTATG AGTGCAGAAA GCTCTTTGTC AGGGATGCAA ATAGGTGAGC
5001 ATTGGcTGCC TTTAAGGCTC TGTTTATTCT TGTTCATCCT CAAGGTGCTT
5051 GGGGTGGGCA AGGAGCAGAT GGCTACAGAT CCCCTACACT AACTACATCC
510 1 TGTGGCACTT CACATAGCCC CATGTAGCAG GTGAAGAGTA AACTCTGGTA
5151 CTGAACCCTC CCAGCAATAG CATCCGTGTG TGACAAGAGT AGGTGAAGAG
5201 ACAGCTGGAT CATAGGAGTC CCAGTCTGCA GTGATGTCCA GGATGGGATG
5251 AACAGGCTTT TCTCTGATCC ATGTCTCAAG TTGTGGTTTG ATATGTGTTG
5301 GATAAATATT AGATTACTCT TGTTTTCCCC AGCAGGTCTA AGCTCAAGGA
5351 ATACATCGAC TGTGTGTTAG CCAGTGTTTC TGGGAGCCTA ATGTGAAAGT
5401 ATAAATGCCT AAAGATAAAC AGACCAGTGG GCCCTGTGGG AATTTAGAGA
5451 AGAATATGGA ATATGGTAGC TCCTTTTATA TGACTGATGT CAGTCCATCC
5501 TCCCACTATA AATTCTTATA ACCCTAGATG TTAGTGCTTT TCATACACTA
5551 GCATTGTTTG GAGCTCCTGT TGTTGTGTTT TAGTGTCAAA TCTCTTTGTG
5601 GTTTCTTCTT CTTGGTCTGG ATTGTTAAAT TGTCAAGTTC CTAAATTTCT
5651 ACATGTTTTC TGCTAGATGT GTTTTGTTTC AAAATGAAAA TAATATATTT
5701 AGAGAACATG TTTTTAACAT AAACACAAAG TAGAGTGACT GTGTCAGCAG
5751 CACCCATCAG AAGGTGTGGT GAGGGCTGGA GAGATGGCTC AGCGATTAAG
D ra
5801 AGCATTGTCT
I I I
GGTCTTCCAG AGGTCCTGAG TTCAATTCCC AGCAACCACA
5851 TGGTGGCTCA CAACCATCTG TAATGGGATC TGATGCCTTC TTCTGGTGTC
5901 TCTGAAGACC GCTACAGTGT ACTTGTCATA TATATAAAAA ATAAATAAAA
5951 TCTTTAAAAA AAAGAAGTTA AAAACATGCA TTTCCTAATA AGCAACTTAA
6001 AAAAAGATTT ATTTAAAAAA AAAAAAGGTG TGGTGAATGA GACTGTTTAC
6051 TGCATATGTG GTTCTGGATT TAGGAGTGGT ATTCATCCTG TGGTGCGCAT
6101 TTTATCTAAA TAGATGACAC TTCAGGATGT GCACGTGAAA GAGTAAAGCC
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6151 AGTACATCTT CACCTAGAGA GGGAGGGCCG GCTTATTCTT TCTTAGGCTG
6201 AAGGTAGTAG CAGGTAAACT GTCCTGGTCT GGGGTTGAAC ACTTGAGTAG
6251 CATTTGTGAG AAGATTGGgG GGGGACGGGG GACGGCTGAG GAAGGGAGAG
6301 AGAGAATGAG AATAAATATC TTGGTAATGA GTGAGGCCAG GGAATTTTGT
6351 CATACAAGGG AACACCAGAT AATTATTTTC TTCTATGTCT TTACTCTTTT
6401 TGAAAAATTA CCATGATGAC AGGGTACAAG CTTATATTTT CAAGTGCAAT
6451 CTTGATATTG TATACTTGAC TATTTCTTCT ATATTCTTGT TGAGATGTAT
6501 ATTGGGAATT GCATTTTATT TATAATGATG AGTTGTTGGC TGTGTTTAAG
6551 TGTATCTAAT GAGTGCTAAT GAGTTTGAGA TTTGACTGTC CTTATTAGAA
6601 AAGGTAATAA TATGGAATGG CTAATTACCA CAGTTTTATT TTTCTTTTTA
6651 TACATTTAAT TAAGTTAATC TGATAAGCAT TTCAGTTCTA TATTATTCTG
6701 GCATAGATTT TGGCTAGAAG AATATTACTA ACTAAAAAAT CCTTTGTGAC
6751 TGTTTTGTAT GTCAAAGTCA TATAATGTCA ACTTTATAAG CTTAATACAT
6801 AAAGCAGTGA TTTTACTTTT AACATAACTC TAAGCCTTCT GTAAGTTTTT
6851 TAAAAGACCT CTTTTTTAAG ATTTATGTAT TTATTTTATG TATGTGAGTA
6901 CACTATAGCT GTACAGGTGG TTATGAGCCT TCATCTGGTT GTTGAGAATT
6951 GAATTTAGGA CCTCTGCTCA GGTCAGGCTG ATTCAGACCC TGCTCGCTCC
700 1 AGCCCAAAGA TTTATGATAA ATAAGTATTC TGTAGCTGTC TTCAGATGCA
7051 CCAGAAGAGC AGTCAGTGCT CTTACCCGCT GAGCCATCTC ACCAGTCCCT
7101 GGACCTCTTT TAAAAAAAAT AAATAAAAAA TAGTGTGACA GAAAACCTCT
7151 GCCATACAGA AAACTCATCA AATGGATGGA TTATATGGGT GGGTGGATTG
7201 GTTAAACTTG AAATGACCAA AGAAGTCTGG ATGAGTTTAT TATGTGGACA
7251 CTGTTTTTTT CCTTCTAATT CCTGGGGTTA GACAGCCAGG TGGGACAGCT
7301 GTTCTGTGTG CTGCTTGTAG CTTTGGGTCA GCTACATGAG GCACATCTAC
7351 ATCCTGAATA TCAGTGATAC TGAGGTGACA CCTAAATTAA TTAAAGCTCA
7401 TTTGGGATCC TCAAGTCTCG c t t g t t c c a t CTGTTAATTT TGGGCAGATC
7451 TGTCAGTCAG TCAAATATAA TATAGTGTAG CCTAGGGCTC TTCTGGAAAA
7501 GAATTCCATG AAAGGGTTTT TTAAAAGAAA GGTCTGTTGC TAATGCTGCC
7551 ATTACACAAT TAAGTTTAGA GAAATGCCAT TTTGTAATTT AGANGATCAC
7601 CTCATAGATC TATASATTAA GAAGTGTCCA ACAGGTTCCC CTTTCCTATT
7651 TCTCTCAGTT TACAGAAGTG AATACTAAAA GCTANGTGGG GCAACAGCTT
S a l  I
7701 GTAGGAAGGC TCCTTCCTTC ACTGNGAGGT AGTTGTCGAC CCATTCATAA
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7 75 1 TTATGTACTT TGCATACATT TGACACTCCT TGTAACTGAC TTCCTAGTTA
7 80 1 TCTCTAGATT TTAATAAATA CTAATTTTTA CTAAGTGAAC TCTTTTTAAT
7 85 1 TTTTTTATGT TTTGTTGCTT TTAGACATAA AGGGTGGATT TGCTTTAGAT
7901 TTTTGTTCCT TAACTACTGC TAGACAAAAT AGATTCTGTG CTGCTTATTT
7 95 1 CTTGCTAGAT TTAATGCTTA CTCTTTGAAA AGCTTATTTG ACTCATTTAT
8001 CGTTTATTTG TGGGCCTCTC CCCTTTACTT ACCTTTTTCC TTATCTGTCT
CBD e x o n  1 (CBD 1) EcoR  I
8051 GTCTGTCTGT TGTTCTAGCC ATCCTGGGAT CTCCAGCTAG TGGAATTCAA
8101 AACACAATTG GTTCTGTTGG TGCAGGGCAA CAGAATGCCA CTTCCTTAAG
8151 TAACCCAAAT CCCATAGACC CCAGTTCCAT GCAGCGGGCC TATGCTGCTC
8201 TAGGACTCCC CTACATGAAC CAGCCTCAGA CGCAGCTGCA GCCTCAGGTT
8251 CCTGGCCAGC AACCAGCACA GCCTCCAGCC CACCAGCAGA TGAGGACTCT
8301 CAATGCCCTA GGTAAGTGAA GGAACACGCA AGAACTAACT ACCTCCAGGT
8351 ATATTGTAAA GATGGTGGTG CTTACTGGAG CCTTAGGCTG TTTCCAGTTT
8401 GTTCTGTCTT CAGATCCATT GCTTTTGATC AACGTCTTCC AGAGAAAACT
8451 GAGGTGTAAA TGTGCAGGGA AGATGGTGCA TGGTTGTAAC ATTTCAAGTG
8501 AGGTAGTGAT TCGCTCTGTG TGTGCCACTT TATCTAGACA GTTTATAAAG
8551 GACATTGTTG TGCCTCAGAA TGCAGAATCC AACTTGAGTG AGCTCTTTTT
8601 TGTTTGTTTT GTTTTGTTTT GTTTTGTTTT TCGAGACAGG GTTTCTCTGT
8651 GTAGCCCTGG CTGTCCTGGA ACTCACTCTG TAGACCAGGC TGGCCTCTAA
8701 CTCAGAAATC CACCTGCCTC TGCCTCCCGA ATGCTGGGGA TTAAAGGTGT
8751 GCGCCACCAC GCCTGGCTTT CAGTGAGCTC TTAAGTATGC CACTTATTGG
8801 TACGGTCCTG ACATGTCTTT GTATTTGTGG TCACTTTGGA GGTGACCGTG
8851 TAGAATCAGG CTGGTTAGCA GTGACATTCA GTAGCTGCTG TCACCTGCCT
8901 ATGGGTGTGT CAGTGCTTCC TCTGCTCACT GTAGCCCGTC ATTTGCCAGC
8951 TTAATCATTT GTTGTCTTAA TCATTTTGTT ACTTCTTTAA CATTTTTCCT
9001 CTGTCCTTTT TAACCTCAGA CTCTTCTAGT GTGAACACTG CTATCAATGA
9051 AGTTGTGACT GGTAGCACTA GCTTTTTTAG ATTAAAAATT GAGTCATTAT
9101 AAAATGACCA GTTAGTATTA GGGACATGAG TCAGTGATAG AGCACTTGTT
9151 TAGTGTGCAT GAAGGAAGCT CCAAGTTTGA TATACAGCAG TGCAGAGAGA
9201 GATAAAAAGA GGGGGAGATG GACCAATTAA AACCATCCCT GTTTTATTTT
9251 CTGGATAAAT ACCTAAATTA TTATCAGTAG TGTCCCAAAT TCAGTCTACT
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9301  CCCCTCCTGT ATTGATGGTA GTGTTTTGGA ATTATATTAT TCTGAGTTTG
9351  CATTTTTTTA AAACACCTAT TTCTTTTTCC CCTAAACTTA ACTTTTATAA
9401  GTTTACTCTC TGACATGTAA GAACAGCCCC AAACACAGGT ATGTGCCAGG
9 45 1  CAGGTCAGTG TAGTTGTTTG ACACTAAGGA AACAGAAAAG CTGAAGGCAT
S e a  I
9501  CAAATGGGCA GTGATCATTT TCTCAGTAGC CATAGAGTAC TGTCAAGACA
9551  CTCTGTAGCC TCCAGGGCAT ATTCTCTTTA GGCTGTAGAG TAAGAGTGGG
9601  AAGGAGCTGA CGATGGACTT GGCTGACTAA TGAGACTACA GCTTACACTA
9651  ATGAGAAATA CAGCTTTCAG AGCTTCTGTC CTACTGTGTT CTGCTATTCT
9701  TTATATACTC ACTTTTTCAC CTATTACAGG AACTTGAAGT GTTTATTGTG
CBD 2
975 1  TAGGAATTAA TTTCATTTTT CTTTGTCTTT AAAGGAAACA ACCCCATGAG
9801  TATCCCAGCA GGAGGAATAA CAACAGATCA ACAGCCACCA AACTTGATTT
9851  CAGAATCAGC TCTTCCAACT TCCTTGGGGG CTACCAAGTA AGACCAAAGT
9901  TTAGGTAACT CCTATCTGAA GCCTGGTCCT CTGAAGGAGA AACAAGCACT
9951  CTTAACAGTG GAGCTATCTC TTCAGCCTCT CTTTTTAAAG TGATAAGTGT
10 0 0 1  AAAACAGCCA ATGAAACACT TTGAATTTTG GTGGATATAC ATTACTTGCT
N de  I
1 0 0 5 1  TCTCTTAAAC TTTTTAAGTC ATAT6ATTGA AGAAGGTGGA GTACATTTGA
CBD 3
1 0 1 0 1  TTCACTTGAG TAGCTGCTTG AAGTATCCTT ATTTCTTCTT TAGTCCACTG
1 0 1 5 1  ATGAATGATG GTTCAAACTC TGGTAACATT GGAAGCCTCA GCACGATACC
1 0 2 0 1  TACAGCAGCG CCTCCTTCCA GCACTGGTGT TCGAAAAGGC TGGCATGAAC
1 0 2 5 1  ATGTGACTCA GGACCTACGG AGTCATCTAG TCCATAAACT GTATGTAACC
1 0 3 0 1  CTTGAGATCC AGAGTCACAT TTTGTGGCTG AGGAAACTGT TGAATCTTTG
1 0 3 5 1  TGGGTGTGTA GATGTTTGAT GTTGTTTTTT TATCTGCATG TTGAGCCACA
1 0 4 0 1  TTTTAACAGC TCAGAGCTGT GCAGGGTCCA TGCTTGTTTC AGAAAGCCAT
1 0 451  TCCCACTGCT AAGAGACCTA AGAAGGCTGA CTTTCTCGGA CTCTGTCCCC
1 0 5 0 1  ATTGTGTAGT GGCATCAGAG AGCATAGAAA TATGACCTGA AGCCATCCTC
1 0 551  TTTGGTTTTG AGCTCAAGGA TGTTCAATGA CTTGAAACTA GTTATAGAGC
1 0 6 0 1  TCCCTAAAAA TTGGGGAAAT TTTGGTCTGG TAAGTACAGA TAGCTTGACA
1 0 6 5 1  GTTATTTTAT GTACAGAAAG GTAATGTTTT CATACTATAT GTCCTGAGTT
1 0 7 0 1  GAAATGAAGT TAATCAACTA TTGATTCTTC TTACTTTGAT GTTTTTATAA
1 0 7 5 1  TGCATAGTTT CTAAATAGCA ATTTGGAATC ATACTGTTTC TTAAAATGGC
1 0 8 0 1  ATAGCACATA TTTATGTTTG GTATATAGAG TCTGGGTGTG TAGATGCAAG
1 0 8 5 1  GTTAGTATTG TTTCCCATGT CCATGACAAG AAATGAACAG TGAGATTTGG
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1 0 9 0 1 GCCTCTACAG GTAGCTAGCC ATTCCTGGTT TTATTTTTTt AGTTCCCTTG 
CBD 4
1 0 9 5 1 TGCCACCTTG AAAGCAATTT GATAGAATAC ATTGTTCTTT CAGCGTTCAA
1 1 0 0 1 GCCATCTTCC CAACTCCAGA CCCTGCAGCT CTGAAAGATC GCCGCATGGA
1 1 0 5 1 GAACCTGGTT GCCTATGCTA AGAAAGTGGA GGGAGACATG TATGAGTCTG
1 1101 CTAATAGCAG GGTATGTTGC TAAGCAGCTG TTGAAGCTAT AGGTGGGAAA
1 1 1 5 1 TGGTATTTGT CTAGTTAGTT ATCTAGAATT AGGAGAATCT GCATGGTCTA
1 1 2 0 1 GGAGACTCCT AACTTGAGTA CCCTGAACAG AGACATGTCC AAGTAAGAAT
1 1 2 5 1 GAGATTCCTG GACACCTCTC TTGTGAAGCA CAAGTGTCAT AGTTTAGGAA
1 1 3 0 1 GGAGTACAGA AGATCTATAA AATCAACGTG TATCTTTGGG ACATCTTTTT
1 1 3 5 1 TCACAGAGCG TGTTCTTTAA GATTCTTGTA TTTTTATTTA TTTTATTATA 
BsaH  I
11 4 0 1 TGTAAGTACA CTGTAGCTGT CTCCAGACAC TCCAGAAGAG GGCGTCAGAT
1 1 451 CTCATTAGGG ATGGTTGTAA GCCATCATGT GGTTGCTGGG ATTTGAACTC
11 5 0 1 GGGACCTTCA GAAGAGCAGT CAGTGCTCTT AACCACTGAA CCATCTCGCC
11551 AGCCTGGATT CTTGTATTAT TGGTAGTGTC AGTGAATACC AAAGAAAAAG
1 1 6 0 1 TTCAGTTGTG CAAAAAATAA
S p e
AAAAAGGCAG
I
TGTTTGTACC TTCAATTTGT
1 1 6 5 1 TATGTCTAGT AAAGTCACTA GTTCAATAAA GTGAAAACTA AAGGGTATGC
1 1 7 0 1 TGGTATCACT GGGAATTTAG GTAGAGCAGG GGGGGTGGGA TTTTGGTTTA
11751 TCAGATGTGT CAAACCTCTT TGTCAATGCA CTTAAAATGT GCTCAGTGGT
11 8 0 1 ATAGTACCTG CTTAGTGCAT CATGGCCAAG TTCAGTTCCC AACAGCAAAA
11 8 5 1 CGTGAGTGAC AAGTGAGTTT TTTAGTTAGA ACATGCAAAC TAAATGATGG
11 9 0 1  GCTCTCATAT 
CBD 5
TTTTCAGTAC CTTAATATTA ATTATTATTT CTTTTTAGGA
11 9 5 1 TGAATACTAT CATTTATTAG CAGAGAAAAT CTATAAAATA CAAAAAGAAC
12001 TAGAAGAAAA GCGGAGGTCA CGTTTACATA AGCAAGGCAT CCTGGGTAAC
12 051 CAGCCAGCTT TACCAGCTTC TGGGGCTCAG CCCCCTGTGA TTCCAGCAGC
1 2 1 0 1 CCAGTCTGTA AGACCTCCAA GTAAGAACTG CATTTCTCTC TTCCAGTCCT
1 2151 TAGCTTGTTT GCTTAGTGCT CTTTTAGTCT TTGGAGTATA TTTTTAAGAC
1 2201 TACAGAGTTC TGTTCTCCAA AATCTGCACT TTGAAAGCTC TTTGTATGAT
12251 CTTGCCTTAT GGGAAGAATC TTTTATTTTT GTTTGTTTTT TGGTGTCTCC
1 2 3 0 1 CAAGTTTTTC AAGACAGGCT TATTTCTCTG 
N he  I
TGCACCCCTG GCTAATCTGG
12 351 AGCTCACTCT GTAGACCAGG CTAGCTTCAA ATTCAGAGAT CCTCTGCCGC 
EcoR  V
1 2401 TGCCGCCGCC CACCTTCCCC TCACCACTGC CCAGCAGAGG GGAGATATCT
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1 2 4 5 1  TAAAAGGGTG TGCTGGCAAG TGTCTTTTAG ATTCAATGTG TTTGTGTGTG
CBD 6
1 2 5 0 1  TGTATGTGTA TTATATTTTT AATTACATTT TCCTCCTTAT AGATGGGCCC
1 2 5 5 1  CTGCCTTTGC CAGTGAATCG CATGCAGGTT TCTCAAGGTA TTTAACTATT
1 2 6 0 1  TATTGTCAGT CATATTTTAG TTTAACATTC AGCAGCAGCA AACATGTGCT
1 2 6 5 1  CCCTCCACCT AGCCCCTATT TTCCCTTTTG TATTATTTCT ATTCCTCTTT
1 2 7 0 1  CTGATGAAAA TGTAATCCAC CAAATAATGT GAGTCTCTTG TATTAAATTT
1 2 7 5 1  TGGAATTTAT TGCAGAGTTT TTTTTAAAGA GGTCAGAAAT AGGATTTTGT
1 2 8 0 1  ACTGACATAC AAACCCACCA CCAAAACAAT G G T G A C A A A A  CAATGGAGAT
1 2 8 5 1  TATGTAAAGG AAACATACTC TAGGAAGGAA AAGGCCTTTC TGAATACTCA
1 2 9 0 1  GCTGGGGAGT CTGTGAGCCA GTTTGTGGCA GGCACTTGTA GGGGACCAAG
1 2 9 5 1  AAGATACAGT GCTGCTCCAG GCCATCAGAA TTGAAGATGG TGAGTGGGTC
1 3 0 0 1  TCAACAACAG GAGGCTATGT GTAGAGCTCC ATTCTTTTTT TTGTTTTGGT
1 3 0 5 1  TTTTTGGTTT TTCGAGACAG GGTTTCTCTG TGTAGCCCTG GCTGTCCTGG
1 3 1 0 1  AACTCACTTT GTAGACCAGG CTGGCCTCGA ACTCAGAAAT CCACCTGCCT
1 3 1 5 1  CTGCCTCCTG AGTGCTGGAA TCAAAAGGTG TGCGCCACCA CACCCGGCTA
1 3 2 0 1  CAGAGCTCCA TTCTTGCCTG GAGTAGTGAT AGCTGTCTAA ACCATAGAAG
1 3 2 5 1  GCTCAATTCA AGGTTCTGTT GTTATTTGGG CTTCAGGGCT TGGGGCCATT
1 3 3 0 1  TGTGAGATTT TCAGCTCTTG ACACACTAAG ACCTGAACTG TAGGGTATTG
1 3 3 5 1  CTCCAGGTTG TGAAATAAAA TGGGAGCATT ATCCAGATAG TAAAGAAAGG
1 3 4 0 1  TGCTTGTATA TTCTTGGACC AGGGAGTGGC ACCATTTAGA GGTGTGGCCT
N de I
1 3 4 5 1  CGTTGGAATA GGTTTGTCAC TGTGGGTATG GGCATATGAT CCTCACCCTG
1 3 5 0 1  GTTGCCTGGA AATCAGTCTT CCACTAGCAG CCTTTGGATA AAGATGTAGA
1 3 5 5 1  ACTCTCAGCT CTGCCTGTGC CATGCCTTGA GCTGGATACT GCCATGCTCC
1 3 6 0 1  CACCTTGATG ATAATGGACT GAACCTCTGA ATCTGTAAGC CAGCCCCAAT
1 3 6 5 1  TAAATGYTTT TATAAAACTT GCCTTGGTCG TGGTGTCTGT TGACAAGAGT
1 3 7 0 1  AAAACCCTAA CTAAGACAGA AGTTGGTACT GGGAGTGGGG TATTGCTGTG
1 3 7 5 1  ATAGGCCTGA CCATGCTTTT CTTTGAAAGA ATGTGGATTT TTGGACTTTG
1 3 8 0 1  GATTTGGAAC ACAGTAGAAT GCTTTATATG TGGCTTAATG GGTCATCCTA
1 3 8 5 1  GTAGGAATAT AGAAGACTTT GTTGCTGGGA GTGATTTGAA CTGTGTTGAT
1 3 901  CTGGCCCAAG AGATTTCAAA GGAGAAGAAT TTCATAATGT GGCATAAAGA
1 3 9 5 1  CTGTTTTTGT GGTATTTTGG TGAAGAATGT GGCTACTTTT TGCCCCTGAC
1 4 0 0 1  TGAAAAGTTT GCCTGAGGCT AAGGTGAAGA GACTCAGATT AATTACATTG
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14 0 5 1 ACAAAGGAAG TTTCAAAAAA GGCCAGCAGA GACTTTGTTC TCTGGTTAAG
14 1 0 1 TCTTATGAAG AGAAGTTTGA ACAAGCATAG CAAGCTTAGA AAAGAAAAAT
A c c 6 5  I
14 1 5 1 ATAAAATATA TGGTTTGAGT ATTAAAGGGG TACCAGGAAG TGAAATTGAG
1 4 2 0 1 CAAAATCCTA TGTTCTAGGA GATAACAGAT TAAGAGAGTG GGACCTTGGG
1 4 2 5 1 GCAAGATCCT ACCCAGCTAA ATTTAGATCC AGGCATGGTG TTATACACCT
14 3 0 1 TTAATCCCAG GAGACAGGCA TGCTGATCTC TGTGTTCAAG GTCCAGGATA
1 4 3 5 1 GCCAAGCTTA GGCAGTGAAG GATTTGGAAA ACATAAAGCC AGTGATAATT
1 4401 TAATAGTACA AGGGGGGTCA TGTTCTAGTT CCTGCAAGCG GCAGAACTCG
1 4 4 5 1 ACAGCTTCAG CCATGTGGCT CTGGCTCTAG AGAATGGAAA GAACTACTGG
1 4 5 0 1 GACAATTGAA GCTGGTTAGC TGGAGCTAAG GAATTAGCAG TGATTAAGAA
1 4551 GAGACCAGCc ATCACTGAGG TGAAATCTTC TGGGAGCACA AAGAAGCTGT
1 4 601 GTTCCAGAGA TAGCCAAGGT TGTACCTTAG TCCTGCAGCT GGATTTGGTA
1 4 6 5 1 ACGTGTAAGA GTCACCCAGG TGATACTTGT TTTGAAGTCA TGAAGGTGTC
1 4 701 ATGAACAGCT GAGGCTTGGT ACTGTGAGAG GCCATGGAAG GCCATTGGTG
1 4 751 AAGGTGCAGC ATCAGTTTTA GTTGATGGCC CAGGACTGAA GGGGTCATGC
1 4 801 GAAGAATTTG AGGCTTGACA CCATGAAGAG AGCCTATGAG AGGCTATTGG
1 4 851 TGAAGCCTTG TTGTAGTGGA ACACCGCAGT GTTTTGGAGA TGTCAGTACC
1 4 901 ATGGGACGAT CACCAAGAAC AGAAGCCATA GTGGAGTGGA TCAATCTGAG
1 4 951 TTTAGAGTGC TACAGAGGGC AGAGCTGGAG AAGTGATGCC AGCCCTTAGG
15001 AGGAGTCCAA AAGATCAAGT GGAATCCCAG ACACTGAAAC AAGAAGCTGT
15 0 5 1 AACATTGAGA TTAAAGATGC CAGAGCTATG GGATACATGG TGAGAAAAGC
15101 TGCTAACAGG GAGTGGAACC AGCCCAGGAG AAAGCAGTTT GTTGCAGTCA
15151 ACAAAGATGA AAAAGGAGTG GAGATCTGAA GACCGCTTTG ACATCAGCCA
15 201 TGGAGATGTA GAGTTTGGAA TTTGCCCAGC TGGTTTCCTG TCTTTCTTTG
15251 AGGATTACAG TTCAGTAATT GGATGAATCT CAGAAGAGAC CTTGAATTTT
15 301 GAACTTTTAA CATTGTTGAG ACTGCTGTAG ACTATGAGGA CTTTAAAAGT
1 5351 TGGACTACAT GCATTTTGCT TTATGCTATG TTTTAAGTAT GGCTCCCCCA
1 5401 TAGACTCATG TGTTTGAACA AGCCTCTGGG GGCCAGGGAG TGGAATGTGA
15451 TGGTTTATAC ATTCTTGGAC CAAGGAGTGG CACCATTTGG AGGTGGCCTT
1 5501 GTTGGAATAG GTATGACATG GTGTGTCACT GTGGATGTGG GCTTAAGATC
15551 CTCACCCTAG TTGCTTGGAA GTCAGTCTTC CACTAGCAGC CTTTGGATGA
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1 5 6 0 1  AGATGTAGAA CTCTCAGCTC CTCCTGCGCC ATGCCTGCCT GGATACTGCC
1 5 6 5 1  ATGCTCCCAC CTTGATGATA ATGGACTGAA CCTCTGAATC TGTAAACCAG
1 5 7 0 1  CCCCAATTTA ATGTTGTTTT TATAAGACTT GCCTTGGTCA TGGTGTCTGA
1 5 7 5 1  TCACAGCAGT AAAACCCTAA CTAAGACAGT GTTGCAGTCT ACAGATCAGT
1 5 8 0 1  TTGAGAGGGA AGGGTACTTG ATTTAAAGTT GTGACTCTTG CTGCACACTG
1 5 8 5 1  AGATAGACAT TGGATAAACT GGCCAAGGAC TTGTTAGGAT GGACTGCATT
1 5 9 0 1  TGAGAGGGGA TTAAGTTAAG TGGTGGAGAA GTTGAGCCAG AGCAATGTTG
1 5 9 5 1  GGAACATGGG CATTGCTGCA TAGGGAGCCA TGCTGACTTG GGGTCTGACA
1 6 0 0 1  AGATAACTTG TAAGCTGCAG GTGATAAGAA GAGATGTTTT CTGGGTCATG
S e a  I
1 6 0 5 1  CTTACCAGCC CTTTTTGCTG GAAATATCAG TACTTGTGAA TGTGGATGAC
1 6 1 0 1  TTTCCATGCT CTTTTTTTAG TATGTGGACA AAATTGGTAT GGAGGAGAGA
1 6 1 5 1  CTTTTACATT TGTTATACAC TCCCTAGAAA GTCTTGTTGG GTCTTGTTGG
1 6 2 0 1  AGTTTGGTTT GGATAGTCGC TGAAAGTGTA AGAAGCCTCT CTTGCTTATG
1 6 2 5 1  GCAGTGGCAA GGCAGGCTTC TCAGAAACTT CAAGGTGTCA GATTGCAGCG
1 6 3 0 1  ATGGGCAGAA TGTTAACAGC TTGAACTGAG GTTTCATTTA GAGCCCACAG
1 6 3 5 1  TTTACATAGT TTCTGTAGAA AGTTCATGAG AACTAGCCTC TGTGGTCTGA
1 6 4 0 1  AAATACTTCC CAGCTAAGCC TTTGGCATTG GTGTGATATT TCTGCTAACT
1 6 4 5 1  ATTAAGTCTA AGGGTAGCCC TTGGGACTTT CTGCTAAAGA TATTTGCAAA
1 6 5 0 1  ATTGAGAAGG TTAGTCTTAG CACAGATTCT AACCATAGTA TCATCCTAGC
1 6 5 5 1  CAAGAAGCTT GGAAGCCTGG CTAGGGTCTT TAAGTGAAGG TGTGCTCAGA
1 6 6 0 1  TAGATGAGGT AGGCTCAGTG CTGCACAAGA CCTCCTTGTC TGTTTTGTCG
1 6 6 5 1  CTTCTGTGCT CTGTGCGCAT TAGTTCTGGT TAGTTCTACA CTGCCCTCGT
1 6 7 0 1  GTCCTCATCT AGCTCCCCTA GCCCTCCCAC TCACAGCCCC TGTCAGATAT
1 6 7 5 1  GGAAAGGCTA CTACAGTCTG CTCTGATTTG CTTGTGGGTT CGGTTCCTCT
1 6 8 0 1  CTGTTGTCTA TTTCCCTTGT CTTTGGTCTT AAGAGTTATT TGATGAGTGC
1 6 8 5 1  ATTTCTTTTC TTGTGAATGC TTTTGTTAAT GAACTATTGT AACTGTTTCT
CBD 7 E coR  I
1 6 9 0 1  AGGGATGAAT TCATTTAACC CAATGTCCCT GGGAAACGTC CAGTTGCCAC
1 6 9 5 1  AGGCACCCAT GGGACCTCGT GCAGCCTCCC CTATGAACCA CTCTGTGCAG
1 7 0 0 1  ATGAACAGCA TGGCCTCAGT TCCGGGTGTA AGTGCTCCTC CTCTCAGTCC
1 7 0 5 1  TTGCTCAGTA GAGTGTTCTC TAAGGAGGGA TACCCCATTG TTACCTGAGA
1 7 1 0 1  ATTTTAGGGG ACTTATTCAT TTAAATTTGA GCATTGTTTT ATTTCCTTGT
7 1 5 1  TTTCTTAAAC TAGCCAACAA ACAGGATTGT TGGTATAATG
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1 7 2 0 1 GAATGCTGAT TTTTTTTTTA AAATAATAAT TCTGTAAGTA TTTGCTGTCA
1 7 2 5 1 GTGAATTGGA ACAGGCAGCC AATGGCTTAT ATTGTTGGTG TCTGTTCACA
EcoR I
1 7 3 0 1 TCAGCAACTA ATTAAAGGCA TGATTGAATT CAAAATGACA GCATGTTATT
1 7 3 5 1 GATTGCCATT CTGAAGACAG TTCAGCATTG ACTTGAGAAA TTGTAGAAAG
1 7 4 0 1 TGCCTAGGAA CTGGGGAGTC CCTGGGAAGT AGTGGTCTTT AAAACCAAAG
1 7 4 5 1 TGTACTAGAT TTGTAAGGCT TTGGATCTCC ACTGTACTGT GATCTCTTGA
CBD 8
1 7 5 0 1 AGACTCTGAC CTAACACTTC TGATTCTTGT CTTATAGATG GCCATTTCTC
1 7 5 5 1 CTTCACGGAT GCCTGAGGCT CCAAATATGA TGGGCACTCA TGCCAACAAC
1 7601 ATTATGGCCC AGGCACCTAC TCAGAACCAG TTTCTGCCAC AGAACCAGTT
1 7 6 5 1 TCCATCATCC AGTGGGGCAA TGAGTGTGAA CAGTGTGGGC ATGGGGCAAC
1 7 7 0 1 CAGCAGCCCA GGCAGGTGTT TCACAGGTAC ATTCACTGAG GGAGCCTGGT
1 7 7 5 1 CAACCAGTAT TTATATAGCC CCAGCCTTTG TGACATGATC CTGTCTTAGT
EcoR  I
1 7 8 0 1 TGATGGAAAC TAGAATTCTA GAATATACAT CTTTCCATTT CCCGTTTGCC
1 7 8 5 1 CTATAATTTT TAATTTGTGT TTAATTTTTC TTGTTCCCTC TAGGTAAACT
1 7 9 0 1 TCACACATAA AGTAAAATGG ATTGTGGTTG TGGGGGTTTT GTTTGTTTGG
1 7 951 TTTTGGTTTT TGTTAGTTTG TTTTGTTACT CTTATATTTT TACCTTTGGA
1 8 001 TTTTGGTTGC TGTTTGTGTG CTTTAGAAAT CTAAGATTAA CGTCATTCTG
1 8 051 AGAAATACTG GAATTTTAAG AAGGGGTGAA TTTTCTTTTA GTGACTTGGT
1 8 101 TAGTTTTTTG TATCTTAACT ATGTGTTGGG GTGACAGAGC TGTCAGAATC
1 8 1 5 1 ATGGGAATAG CACTCTTCTC ATGAGCATGT TCCAGTTACT TAGTCATAGC
1 8201 CGAGTTCCCV CCAGTTTACT GCTTTCCCTC ACTTTGGTAG TGCATCAAGT
1 8251 GTCAGCTGCA TACAAAGTAT TTCAAATAGG CTAAATCTTT CTCAAAATAT
1 8301 AAAAGTCCTG TCCTTTTAAA CACTCAGCTG ATGCTGAATG CGTTGTTGAA
1 8351 TATATTAGGT TTACTCGGGG ATGATTAATT TTCCCTATCA TTTCATTTCT
1 8401 TTAGAACAGA GATAAGGAAA CCAACTCTAT TCCCTTTCCA GAGTCTCTCC
1 8 4 5 1 ATGTAGCCCA GGCTACACTC TTTATATCTC AGTCATTTGC CACAGTGACC
1 8 501 AGTAGTTTCA ACAGCCAGAT AGTAAATATG TTCTCTTTCC AGAGTCATAC
1 8 5 5 1 TCCTAGTCGT TCGTAACTGT TTAGCTCTGC TCTTAACCGT GTACAAGTAG
1 8 601 TTACAGACAA TGTGTAATCT CCTTGTGGTT GTCATCCTAT AAAACTGTTG
1 8 6 5 1 GTGGTACCTA GGTCAAATTT CTCTCTGGAA CAGCCATTGT GATTCTTTTT
1 8 701 TTAAAGTTAG GGGTCTCCCA GTGCTCTATG TTCTACTGTC TCAACTTATT
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1 8 7 5 1  TAAAAAACAA AACAAAACTC CTTTTTCTGT GGTCTAAGTT AAAAGTAGAT
1 8 8 0 1  GTGGCAAAAC ATGAAGTTAG TAAACTAAGT AAATATGTGC CTAAGCCATG
1 8 8 5 1  ACTATTGTAA CCTGATATTG AAGTTCTATA AGTCAAAGTA TGAGAAGGAT
1 8 9 0 1  TTTAGTGCTA ATTTTATTAC ATGGTGTGGT GCATGCTATA AATGGTTAGT
S p e  I
1 8 9 5 1  CTGAAGTTTT ACAAATGCAA TATCCTCCTG AAACTAGCAG AACTAGTTAA
1 9 0 0 1  GAAACTAGTA TAATTTTTTT TTTCTACAAG TCCCTCATGG TTTCAATTGG
CBD 9
1 9 0 5 1  GTAAAATAGT TTTTATATAT TCTTACTATC TCTTTTAGGG TCAGGTACCT
1 9 1 0 1  GGAGCTGCTC TCCCTAACCC TCTGAACATG CTGGCACCCC AGGCCAGCCA
1 9 1 5 1  GCTGCCTTGC CCACCAGTGA CACAGTCACC ATTGCACCCG ACTCCACCTC
1 9 2 0 1  CTGCTTCCAC AGCTGCTGGC ATGCCCTCTC TCCAACATCC AACGGCACCA
1 9 2 5 1  GGAATGACCC CTCCTCAGCC AGCAGCTCCC ACTCAGCCAT CTACTCCTGT
1 9 3 0 1  GTCATCTGGG CAGACTCCTA CCCCAACTCC TGGCTCAGTG CCCAGCGCTG
1 9 3 5 1  CCCAAACACA GAGTACCCCT ACAGTCCAGG CAGCAGCACA GGCTCAGGTG
1 9 4 0 1  ACTCCACAGC CTCAGACCCC AGTGCAGCCA CCATCTGTGG CTACTCCTCA
1 9 4 5 1  GTCATCACAG CAGCAACCAA CGCCTGTGCA TACTCAGCCT CCTGGCACAC
1 9 5 0 1  CGGTGAGCCT CTTTGTCCTT ATCAAGTCAC ACTTGTACAG AGTCCCTTAA
19 5 5 1  GAATGGTCTG TCGGGCACTC AAAGCACTGG CAGGCTTATC TTGTGAGCTT
19 6 0 1  GAAGCCAGCC AGAGCTAGGA AGTAAGACTC TTATCTATAA ATATAAAATA
19 6 5 1  AAAGACTATT CTGTCTGTcA GGNTGCtATA GCAAATBGCT CTGGBGCGAA
1 9 7 0 1  AAACTCGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT
19 7 5 1  GTGTGTGTGT GTGAAATTGT AGTAAACTGA TTTGTTCCCA CTATTATTGG
19801  CCCTAAAGGT ATGGCTTACA GTTTCCCTTG GTCAGAGTGG TTTATAGAAG
19 8 5 1  TCAGTAATCA TCAGTATGTC ACAGCATGGA CAGAACTATT GAACTGTGTG
19 9 0 1  TGCTGCCATT CTTTTACCTG GTTTTTGTTC TAGAGTAATA CTGTCGAGGT
1 9 9 5 1  TTGACTGCTT TTGTGCTTAG TTCTGTGGGT TTAGTTATCA TGCTTCGCTC
2 0 0 0 1  CAGACTATAA AGGTCCAGGC TAATCAGCCT TCTTTCAGAA TACATGACTT
2 0 0 5 1  TTTTTTTTTA TTTATAATGA AACAACAGAT CCCCTCCTGT CAGGTTTGCA
2 0 1 0 1  TTAATTCTGT TCTTAGATAC TTAGGATATT TGTAGAATAA CAAAATCATT
2 0 1 5 1  CAACAGTTGC AAAGATGACA TTACTAATTT GCTTTCTCTA TAAGGGCATA
2 0 2 0 1  TACTTACTCT GTTTGTTTTT GTCTCCAATT ATTTATGTTT CCTGACTTCA
2 0 2 5 1  AACCAGGCCT TTGTAAACAC TAGGCAAGCA CTTTGCCACT GGCTGCATCC
2 0 3 0 1  TATGCCCTCT AAGATACTTG TATTTAATTT TTCAATCTTC CTTTATTAAT
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2 0 3 5 1 TTATGTACTG CTTAGAGCCT GTTACATGGT AGTGGAGTGT TTGCTTACTA
2 0 4 0 1 CACCACCATC ACTACCCTGT GATAGATGCT TCATATGGGC CATTATTTCA
2 0 4 5 1 TGACCTCTCT GTAAATACTT TTTTTAATAG TTTATAATTT GCCTTTCTCC
2 0 5 0 1 ATAAATAGGA ATGTTAGTGA AGAAAAATAA TGGTAAAATA ATCCAGTCTG
2 0 5 5 1 AAAGCAGAGA GAAAATAATT TTATGTCAGA ATTTAGAAAA CTCTGTTTGT
2 0 6 0 1 CCAGCTCTTC ATTTTTGGTA AGAAGTCAGT CATTGTGTTT CTGACACTCA
2 0 6 5 1 GTGACTGACT GTTAAGCTTC CTCAGGGAGC CTCTGCCCTT CAGTGTCACA
2 0 7 0 1 CTAAGTACTT AGGCTGTAAA GAAGAATAAT GAGCAGACTG CGGTGGGAGG
2 0 7 5 1 ACATGTATGG 
CBD 10
CTCTCCTTTA CAGAGGTGAA TGACTGTGAT TTCTTTGCAG
2 0 8 0 1 CTTTCTCAGG CAGCAGCCAG CATTGATAAT AGAGTCCCTA CTCCCTCCTC
2 0 8 5 1 TGTGACCAGT GCTGAAACCA GTTCCCAGCA GCCAGGACCC GATGTGCCCA
2 0 9 0 1 TGCTGGAAAT GAAGACAGAG GTGCAGACAG ATGATGCTGA GCCTGAACCT
2 0 9 5 1 ACTGAATCCA AGGGGGAACC TCGGTCTGAG GTAGATGCTC CCTCAGCCTT
2 1 0 0 1 AGTCCATAGC TATGTATGGC AGCTTTACCA TATATCCTCA GGACCTAACG
2 1 0 5 1 TGGTGTTGGA TATTCATTTT AACTGTTCCA GTTTTCCACA AATCTTTTTG
2 1 1 0 1 TTAATGTTCT TCTTTCATTT TTAGTTCTGC AGAAGGGGTG GTAGATTCAT
21 1 5 1 TTACTGACTT AGAGCAGAAG TTGAAATCAG TAGGCCAAGA GCCAAATCCA
21 2 0 1 GCCTGGGAAT GTGTTTTGTT TTTGTGGGGG TTTTTGTTTT GTTTTGTTTT
21 2 5 1 GGTTTTTGGT TTTTGGTCTG TGTTCAGTGT TTTAAAAATC ATGAAGTTAT
2 1 3 0 1 AAATAAAACT TTAGATAGTC TGCTTTTTCT CAAAAGTTGA GCAACTCTGT
21 3 5 1 CATCAGTACC CTTATACTCC TTTATGGCAG CCAGTGTCAT ACGTGATGTG
21 4 0 1 GGTGCCACAT GGTAGTGGCA TGGGCTTCCC AGTTGGTCCA AGTCTCATAT
2 1 4 5 1 CACACTCTTC ATCTCAGAGC ACAGGGTCTT GATCCTTATT TTGATTTTTC
2 1 5 0 1 AAGGTACCCT TATTTTCAAA CTAGATGTAC CAATATTTTA CTGAGCATGT
2 1 5 5 1 AAACATACTT TTATATTAAA AAAATTAAAT TAGAATTATG ATTGTACTGA
2 1 6 0 1 TGCTGTATAA AGTAACTAAG TAGACATCAG ACATTTTGTT CCTTTTCCTA
2 1 6 5 1 GTGGGAAACT AAAAAGAATA TTTACAGTGT CTTTGACTAA GGGAGCACTC
2 1 7 0 1 AGCAAGCTTG TGTGCTGCAG TCGTCAAGGG GAAGCTGGCC TGGGTTACAA 
CBD 11
2 1 7 5 1 AGGTCTCATA GACACCTGTT CTCTGTGACT CTGTCTTTCT CAAGATGATG
2 1 8 0 1 GAAGAGGATT TACAAGGTTC TTCCCAAGAA AAAGAAGAGA CAGATACGAC
2 1 8 5 1 AGAGCAGAAG TCAGAGCCAA TGGAAGTAGA AGAAAAGAAA CCTGAAGTAA
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2 1 9 0 1 AAGTGGAAGC TAAAGAGGAA GAAGAGAACA GTTCGAACGA CACAGCCTCA
2 1 9 5 1 CAATCAACAT CTCCTTCCCA GCCACGCAAA AAAAGTAGGT CACGTTTTCT
2 2 0 5 1 GTAATGTTAG ACTAAGCTGT GCTTCCACAC CAAAGATTAA AAGCTGAGGC
2 2 1 0 1 AGGAAAATAA TTACAAATTC CTTTTCATGT TCCTTGTCTC TCATTCTCTA
22 1 5 1 AGCTTTACCT TTGGAAATGG AGACAGCAGG GTGGCAGAGA TTGCTGGGCA
2 2 2 0 1 AACATGAAGC CCGGGGTTTG GATTCTAGCA CTCGTGTAAA AGGTTGGGTG
22 2 5 1 TGGCTATGCA CACGTCTCTC TAACTCCAGC ACCGGAGGAG TGGGGCTGAC
2 2 3 0 1 ACAGGAAGTT GTAACTTGCT TGCCACCAGT CTAACTCCAG ACTCAGTAAG
2 2 3 5 1 ACCTAAAGGA ATAAGGCAGG GAACCAGTTG TACACTAGCA TCCATGAATG
2 2 4 0 1 CATGCAAAGG TGTGTATACC TGTACACACT CAAGTACCAT AGACAGCCTT
2 2 4 5 1 CCCCACATCC ACACATTCAC AGAGAGAAAA GTAACAGTAA CAGACTGCGG
2 2 5 0 1 CTAGGGAGCC AGCCCTCAGA TGAGATGTCA CTGACTAGAG AGGCAGACTT
2 2 5 5 1 GGAATGCTTC TGGGTCTCTG AGCAGGGTAA GCAGTGTAGG TTCTGCAGAG
2 2 6 0 1 CCAGGGAAAA GGTGATGAAG GAGTCAGGAT GGAAAATGAG CAAAAATGCT
2 2 6 5 1 GTAGTTTGAG ACAAA
Sequences marked in red are useful restriction sites for cloning, construction of 
the targeting vectors and diagnosis of correct homologous recombinants.
Sequences marked in green encode part of exons of CBP, here named CBD exon 
I t o l l .
Sequences marked in blue are overlapped by two CBP fragments isolated from 
two phage libraries.
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